0000950170-23-041575.txt : 20230811 0000950170-23-041575.hdr.sgml : 20230811 20230811063117 ACCESSION NUMBER: 0000950170-23-041575 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Finch Therapeutics Group, Inc. CENTRAL INDEX KEY: 0001733257 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823433558 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40227 FILM NUMBER: 231161437 BUSINESS ADDRESS: STREET 1: 75 STATE STREET STREET 2: SUITE 100 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 617-229-6499 MAIL ADDRESS: STREET 1: 75 STATE STREET STREET 2: SUITE 100 CITY: BOSTON STATE: MA ZIP: 02109 10-Q/A 1 fnch-20230630.htm 10-Q/A 10-Q/A
0001733257--12-31trueQ20001733257us-gaap:EmployeeStockOptionMember2022-12-310001733257us-gaap:AdditionalPaidInCapitalMember2022-03-310001733257us-gaap:EmployeeStockOptionMember2023-06-300001733257us-gaap:AdditionalPaidInCapitalMember2021-12-310001733257us-gaap:AdditionalPaidInCapitalMember2023-06-3000017332572023-08-040001733257us-gaap:FurnitureAndFixturesMember2023-06-3000017332572022-01-012022-03-310001733257us-gaap:ComputerEquipmentMember2023-06-300001733257us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001733257fnch:HoodParkDriveMember2023-01-012023-06-300001733257us-gaap:AdditionalPaidInCapitalMember2022-12-310001733257us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001733257us-gaap:CommonStockMember2023-06-300001733257us-gaap:CommonStockMember2021-02-180001733257us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001733257us-gaap:RetainedEarningsMember2023-01-012023-03-310001733257us-gaap:RestrictedStockUnitsRSUMemberfnch:TwoThousandTwentyOneEquityIncentivePlanMember2023-06-300001733257fnch:HoodParkDriveMember2021-08-032021-08-0300017332572022-04-012022-06-300001733257us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-3100017332572023-06-300001733257us-gaap:CommonStockMember2022-12-310001733257us-gaap:FairValueMeasurementsRecurringMember2023-06-300001733257fnch:HoodParkDriveMember2021-08-030001733257us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300001733257fnch:InnerBeltRoadLeaseMember2023-01-012023-06-300001733257us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001733257us-gaap:FurnitureAndFixturesMember2022-12-310001733257us-gaap:RetainedEarningsMember2022-12-310001733257us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001733257us-gaap:EmployeeSeveranceMember2023-06-300001733257fnch:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-01-010001733257fnch:TwoThousandTwentyOneEquityIncentivePlanMemberfnch:IncentiveStockOptionsMember2023-06-300001733257fnch:LabEquipmentMember2023-06-300001733257fnch:InnerBeltRoadLeaseMember2015-12-012015-12-310001733257fnch:LoanAndSecurityAgreementMember2023-01-252023-01-250001733257us-gaap:EmployeeStockMember2022-01-012022-06-300001733257us-gaap:ConstructionInProgressMember2022-12-310001733257srt:ScenarioPreviouslyReportedMember2023-04-012023-06-300001733257us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001733257us-gaap:EmployeeSeveranceMember2023-01-012023-06-3000017332572022-03-310001733257fnch:TwoThousandTwentyOneEquityIncentivePlanMember2023-06-300001733257us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001733257srt:RestatementAdjustmentMember2023-04-012023-06-300001733257fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember2022-12-310001733257fnch:TwoThousandTwentyOneEquityIncentivePlanMember2023-01-012023-06-300001733257us-gaap:ConstructionInProgressMember2023-06-300001733257fnch:UnvestedRestrictedStockUnitsMember2022-12-310001733257us-gaap:ComputerEquipmentMember2022-12-310001733257us-gaap:RetainedEarningsMember2023-04-012023-06-300001733257fnch:HoodParkDriveMember2022-12-310001733257us-gaap:LeaseholdImprovementsMember2023-06-300001733257us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001733257fnch:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-01-012023-06-300001733257us-gaap:RetainedEarningsMember2021-12-310001733257us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001733257fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember2023-01-012023-06-300001733257us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001733257fnch:LabEquipmentMember2022-12-3100017332572023-03-310001733257us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001733257srt:MaximumMemberus-gaap:CommonStockMember2021-02-180001733257us-gaap:RetainedEarningsMember2022-06-300001733257fnch:HoodParkDriveMember2022-01-012022-06-300001733257fnch:UndesignatedPreferredStockMember2021-02-180001733257us-gaap:EmployeeStockMember2023-01-012023-06-300001733257us-gaap:RetainedEarningsMember2023-06-300001733257us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001733257us-gaap:RetainedEarningsMember2022-03-310001733257us-gaap:RetainedEarningsMember2022-04-012022-06-3000017332572015-12-310001733257fnch:OpenBiomeMember2023-01-012023-06-300001733257us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001733257us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001733257us-gaap:EmployeeSeveranceMember2022-12-310001733257us-gaap:LetterOfCreditMember2021-08-032021-08-030001733257us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001733257fnch:LoanAndSecurityAgreementMember2022-05-110001733257us-gaap:RestrictedStockUnitsRSUMemberfnch:TwoThousandTwentyOneEquityIncentivePlanMember2023-01-012023-06-300001733257fnch:OptionsToPurchaseCommonStockMember2022-12-310001733257us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100017332572023-04-012023-06-300001733257us-gaap:AdditionalPaidInCapitalMember2023-03-3100017332572022-06-300001733257us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-3000017332572021-12-310001733257us-gaap:CommonStockMember2022-06-300001733257us-gaap:AdditionalPaidInCapitalMember2022-06-300001733257us-gaap:CommonStockMember2021-12-310001733257fnch:TwoThousandTwentyOneEquityIncentivePlanMember2023-01-010001733257us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001733257fnch:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-06-3000017332572022-12-3100017332572022-01-012022-06-300001733257us-gaap:CommonStockMember2022-03-310001733257us-gaap:CommonStockMember2023-03-310001733257us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001733257fnch:UnvestedRestrictedStockUnitsMember2023-06-300001733257fnch:OptionsToPurchaseCommonStockMember2023-06-300001733257us-gaap:CommonStockMember2023-01-012023-03-310001733257fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember2023-06-300001733257fnch:InnerBeltRoadLeaseMember2015-12-3100017332572023-01-012023-03-310001733257fnch:InnerBeltRoadLeaseMember2022-01-012022-06-300001733257fnch:HoodParkDriveMember2022-09-3000017332572023-01-012023-06-300001733257us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001733257fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember2022-01-012022-12-310001733257us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001733257fnch:TwoThousandSeventeenEquityIncentivePlanMember2023-01-012023-06-300001733257us-gaap:LeaseholdImprovementsMember2022-12-310001733257us-gaap:RetainedEarningsMember2023-03-310001733257us-gaap:CommonStockMember2022-01-012022-03-310001733257us-gaap:CommonStockMember2022-04-012022-06-300001733257us-gaap:RetainedEarningsMember2022-01-012022-03-310001733257fnch:TwoThousandTwentyOneEquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-12-310001733257us-gaap:StockOptionMember2023-01-012023-06-300001733257srt:MaximumMemberfnch:UndesignatedPreferredStockMember2021-02-18iso4217:USDxbrli:sharesxbrli:pureutr:sqftxbrli:sharesiso4217:USD

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission File Number: 001-40227

 

FINCH THERAPEUTICS GROUP, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

82-3433558

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

 

 

75 State Street, Suite 100

Boston, Massachusetts

02109

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 229-6499

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

FNCH

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

As of August 4, 2023 there were 1,604,761 outstanding shares of the registrant’s common stock, par value $0.001 per share.

 

 

 


 

 

 

EXPLANATORY NOTE

Finch Therapeutics Group, Inc. (the “Company”) filed its Form 10-Q for the quarterly period ended June 30, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission on August 10, 2023. The Company is filing this Amendment No. 1 on Form 10-Q/A (i) to correct the Section 302 and Section 906 Certifications (collectively, the “Certifications”) filed in the Form 10-Q as Exhibits 31.1, 31.2, and 32.1, respectively, which inadvertently set forth incorrect names and signatures on the Certifications and (ii) to correct the filing of an amendment to a material contract that was designated as filed in the Exhibit Index of the Form 10-Q but was inadvertently omitted in the filing.

Except as expressly set forth herein, this Form 10-Q/A does not reflect events occurring after the date of the Form 10-Q filing or modify or update any of the other disclosures contained therein in any way other than as required to reflect the amendments discussed above. Other than the changes in exhibits referred to above, all other information in the Form 10-Q remains unchanged.

 

i


 

 

 

 

FINCH THERAPEUTICS, INC.

FORM 10-Q

For the quarterly period ended June 30, 2023

 

Table of Contents

 

Page

 

 

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

iii

 

SPECIAL NOTE REGARDING COMPANY REFERENCES

iv

 

SPECIAL NOTE REGARDING TRADEMARKS

iv

 

 

 

PART I.

FINANCIAL INFORMATION

1

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

1

Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022

1

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022

2

Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2023 and 2022

3

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022

4

Notes to Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

25

Item 4.

Controls and Procedures

26

PART II.

OTHER INFORMATION

27

Item 1.

Legal Proceedings

27

Item 1A.

Risk Factors

27

Item 5.

Other Information

28

Item 6.

Exhibits

28

 

Signatures

30

 

 

 

 

 

 

ii


 

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

our expectations with respect to our microbiome technology and related portfolio of intellectual property and microbiome assets, and our objectives to realize the value of our intellectual property estate through licensing our technology to collaboration partners and enforcing our patent rights against infringing technologies;
the initiation, timing, progress and results of any current or future preclinical studies and clinical trials and related preparatory work of product candidates developed using our microbiome technology, including through academic collaborations;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
our expectations and projections regarding the sufficiency of our cash on hand to fund our operating expenses and capital expenditure requirements;
the ability of our current or future partners or collaborators to obtain regulatory approval of product candidates developed using our microbiome technology;
the ability of our current or future partners or collaborators to advance product candidates into, and successfully complete, preclinical studies and clinical trials;
the ability of our current or future partners or collaborators to contract with contract research organizations, contract manufacturing organizations, third-party suppliers and manufacturers and other third parties with which they do business and their ability to perform adequately;
our expectations regarding the potential market size and the rate and degree of market acceptance for any product candidates developed using our microbiome technology;
our ability to fund our working capital requirements and to service any debt obligations we may incur;
our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering product candidates developed using our microbiome technology;
our financial performance; and
our ability to obtain additional funding for our operations.

These forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions and are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and in any other reports we file with the Securities and Exchange Commission, including this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

 

 

iii


 

 

 

You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in our forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law. We qualify all of our forward-looking statements by these cautionary statements.

 

SPECIAL NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to “FTG,” the “Company,” “we,” “us” and “our” refer to Finch Therapeutics Group, Inc., and its subsidiaries.

SPECIAL NOTE REGARDING TRADEMARKS

All trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

iv


 

 

 

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements.

FINCH THERAPEUTICS GROUP, INC.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share data)

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

ASSETS

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

 

$

34,051

 

 

$

71,038

 

Accounts receivable

 

 

 

 

 

144

 

Prepaid expenses and other current assets

 

 

2,448

 

 

 

3,369

 

Total current assets

 

 

36,499

 

 

 

74,551

 

Property and equipment, net

 

 

732

 

 

 

15,936

 

Operating right-of-use assets

 

 

27,308

 

 

 

32,752

 

In-process research and development

 

 

 

 

 

32,900

 

Restricted cash, non-current

 

 

2,318

 

 

 

2,568

 

Other assets

 

 

 

 

 

4,232

 

TOTAL ASSETS

 

$

66,857

 

 

$

162,939

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Accounts payable

 

$

432

 

 

$

1,097

 

Accrued expenses and other current liabilities

 

 

7,487

 

 

 

10,161

 

Operating lease liabilities, current

 

 

1,656

 

 

 

3,431

 

Total current liabilities

 

 

9,575

 

 

 

14,689

 

Deferred tax liability

 

 

 

 

 

3,461

 

Loan payable, non-current

 

 

 

 

 

14,653

 

Operating lease liabilities, non-current

 

 

29,388

 

 

 

34,255

 

Other liabilities

 

 

 

 

 

170

 

Total liabilities

 

 

38,963

 

 

 

67,228

 

COMMITMENTS AND CONTINGENCIES (Note 11)

 

 

 

 

 

 

Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no 
  shares issued and outstanding as of June 30, 2023 and December 31, 2022

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY:

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2023 and
    December 31, 2022;
1,604,761 and 1,601,717* shares issued and outstanding as of
    June 30, 2023 and December 31, 2022, respectively

 

 

2

 

 

 

2

 

Additional paid-in capital

 

 

372,830

 

 

 

371,350

 

Accumulated deficit

 

 

(344,938

)

 

 

(275,641

)

Total stockholders’ equity

 

 

27,894

 

 

 

95,711

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

66,857

 

 

$

162,939

 

* Adjusted for the 1-for-30 reverse stock split

 

See notes to unaudited condensed consolidated financial statements.

1


 

 

 

FINCH THERAPEUTICS GROUP, INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

 

 

 

THREE MONTHS ENDED
JUNE 30,

 

 

SIX MONTHS ENDED
JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

REVENUE:

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration revenue

 

$

 

 

$

361

 

 

$

107

 

 

$

715

 

Total revenue

 

 

 

 

 

361

 

 

 

107

 

 

 

715

 

OPERATING EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

203

 

 

 

13,923

 

 

 

7,199

 

 

 

29,453

 

General and administrative

 

 

8,877

 

 

 

8,164

 

 

 

18,494

 

 

 

17,568

 

Impairment of in-process research and development

 

 

 

 

 

 

 

 

32,900

 

 

 

 

Impairment of long-lived assets

 

 

 

 

 

 

 

 

13,141

 

 

 

 

Restructuring

 

 

801

 

 

 

903

 

 

 

4,037

 

 

 

903

 

Total operating expenses

 

 

9,881

 

 

 

22,990

 

 

 

75,771

 

 

 

47,924

 

Net loss from operations

 

 

(9,881

)

 

 

(22,629

)

 

 

(75,664

)

 

 

(47,209

)

OTHER INCOME (EXPENSE), NET:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

420

 

 

 

(65

)

 

 

845

 

 

 

(52

)

Gain on lease termination

 

 

752

 

 

 

 

 

 

752

 

 

 

 

Loss on loan extinguishment

 

 

 

 

 

 

 

 

(1,366

)

 

 

 

Gain (loss) on sale and disposal of fixed assets, net

 

 

754

 

 

 

(6

)

 

 

617

 

 

 

(6

)

Sublease and other income

 

 

1,005

 

 

 

 

 

 

2,058

 

 

 

 

Total other income (expense), net

 

 

2,931

 

 

 

(71

)

 

 

2,906

 

 

 

(58

)

Loss before income taxes

 

 

(6,950

)

 

 

(22,700

)

 

 

(72,758

)

 

 

(47,267

)

Income tax benefit

 

 

 

 

 

 

 

 

3,461

 

 

 

 

Net loss

 

$

(6,950

)

 

$

(22,700

)

 

$

(69,297

)

 

$

(47,267

)

Net loss attributable to common stockholders—basic and diluted (Note 15)

 

$

(6,950

)

 

$

(22,700

)

 

$

(69,297

)

 

$

(47,267

)

Net loss per share attributable to common stockholders—basic and diluted

 

$

(4.33

)

 

$

(14.31

)

 

$

(43.21

)

 

$

(29.82

)

Weighted-average common stock outstanding—basic and diluted *

 

 

1,604,795

 

 

 

1,585,978

 

 

 

1,603,811

 

 

 

1,585,093

 

* Adjusted for the 1-for-30 reverse stock split

See notes to unaudited condensed consolidated financial statements.

2


 

 

 

FINCH THERAPEUTICS GROUP, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited, in thousands, except share and per share data)

 

 

COMMON STOCK
$0.001 PAR VALUE

 

ADDITIONAL
PAID-IN

 

ACCUMULATED

 

TOTAL
STOCKHOLDERS’

 

 

 

SHARES*

 

AMOUNT

 

CAPITAL

 

DEFICIT

 

EQUITY

 

BALANCE, January 1, 2022

 

 

1,583,669

 

$

2

 

$

363,217

 

$

(160,995

)

$

202,224

 

Exercise of common stock options

 

 

680

 

 

 

 

14

 

 

 

 

14

 

Stock-based compensation

 

 

 

 

 

 

2,120

 

 

 

 

2,120

 

Net loss

 

 

 

 

 

 

 

 

(24,567

)

 

(24,567

)

BALANCE, March 31, 2022

 

 

1,584,349

 

$

2

 

$

365,351

 

$

(185,562

)

$

179,791

 

Exercise of common stock options

 

 

3,279

 

 

 

 

61

 

 

 

 

61

 

Issuance of common stock under employee stock purchase plan

 

 

1,825

 

 

 

 

110

 

 

 

 

110

 

Stock-based compensation

 

 

 

 

 

 

1,830

 

 

 

 

1,830

 

Net loss

 

 

 

 

 

 

 

 

(22,700

)

 

(22,700

)

BALANCE, June 30, 2022

 

 

1,589,453

 

$

2

 

$

367,352

 

$

(208,262

)

$

159,092

 

 

 

 

COMMON STOCK
$0.001 PAR VALUE

 

ADDITIONAL
PAID-IN

 

ACCUMULATED

 

TOTAL
STOCKHOLDERS’

 

 

 

SHARES*

 

AMOUNT

 

CAPITAL

 

DEFICIT

 

EQUITY

 

BALANCE, January 1, 2023

 

 

1,601,717

 

$

2

 

$

371,350

 

$

(275,641

)

$

95,711

 

Vesting of restricted stock units

 

 

3,044

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

1,180

 

 

 

 

1,180

 

Net loss

 

 

 

 

 

 

 

 

(62,347

)

 

(62,347

)

BALANCE, March 31, 2023

 

 

1,604,761

 

$

2

 

$

372,530

 

$

(337,988

)

$

34,544

 

Stock-based compensation

 

 

 

 

 

 

300

 

 

 

 

300

 

Net loss

 

 

 

 

 

 

 

 

(6,950

)

 

(6,950

)

BALANCE, June 30, 2023

 

 

1,604,761

 

$

2

 

$

372,830

 

$

(344,938

)

$

27,894

 

* Adjusted for the 1-for-30 reverse stock split

See notes to unaudited condensed consolidated financial statements.

3


 

 

 

FINCH THERAPEUTICS GROUP, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited, in thousands)

 

 

SIX MONTHS ENDED
JUNE 30,

 

 

 

2023

 

 

2022

 

CASH FLOWS USED IN OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(69,297

)

 

$

(47,267

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization expense

 

 

1,424

 

 

 

2,694

 

Stock-based compensation expense

 

 

1,480

 

 

 

3,950

 

Impairment of in-process research and development

 

 

32,900

 

 

 

 

Loss on loan extinguishment

 

 

1,366

 

 

 

 

Impairment of long-lived assets

 

 

13,141

 

 

 

 

Gain on lease termination

 

 

(752

)

 

 

 

(Gain) loss on sale and disposal of property and equipment

 

 

(617

)

 

 

6

 

Non-cash operating lease and interest cost

 

 

1,939

 

 

 

1,003

 

Benefit for deferred income taxes

 

 

(3,461

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

144

 

 

 

320

 

Prepaid expenses and other current assets

 

 

921

 

 

 

(4,858

)

Other non-current assets

 

 

4,033

 

 

 

308

 

Accounts payable

 

 

(664

)

 

 

(2,431

)

Accrued expenses and other current liabilities

 

 

(2,676

)

 

 

(506

)

Other non-current liabilities

 

 

(50

)

 

 

50

 

Operating lease liabilities

 

 

(2,369

)

 

 

5,246

 

Net cash used in operating activities

 

 

(22,538

)

 

 

(41,485

)

CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:

 

 

 

 

 

 

Proceeds on sale of property and equipment

 

 

1,270

 

 

 

 

Purchases of property and equipment

 

 

(14

)

 

 

(1,803

)

Net cash provided by (used in) investing activities

 

 

1,256

 

 

 

(1,803

)

CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from exercise of stock options, net

 

 

 

 

 

185

 

Proceeds from borrowings under loan agreement, net

 

 

 

 

 

14,738

 

Repayment of loan

 

 

(15,000

)

 

 

 

Payment of loan terminal fee obligation and prepayment fee

 

 

(1,155

)

 

 

 

Principal payments on finance lease obligation

 

 

 

 

 

(11

)

Payment of deferred offering costs

 

 

 

 

 

(132

)

Net cash (used in) provided by financing activities

 

 

(16,155

)

 

 

14,780

 

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

(37,437

)

 

 

(28,508

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

73,805

 

 

 

135,965

 

Cash, cash equivalents and restricted cash at end of period

 

$

36,369

 

 

$

107,457

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

Property and equipment in accounts payable and accrued liabilities

 

$

 

 

$

88

 

Right-of-use assets obtained in exchange for new operating lease liability

 

$

 

 

$

37,094

 

Prepaid rent reclassified to right-of-use assets

 

$

 

 

$

7,736

 

The following table provides a reconciliation of the cash, cash equivalents and restricted cash as of each of the periods shown above:

 

 

AS OF JUNE 30,

 

 

 

2023

 

 

2022

 

Cash and cash equivalents

 

$

34,051

 

 

$

104,673

 

Restricted cash

 

 

2,318

 

 

 

2,784

 

Total cash, cash equivalents and restricted cash

 

$

36,369

 

 

$

107,457

 

 

See notes to unaudited condensed consolidated financial statements.

4


 

 

 

FINCH THERAPEUTICS GROUP, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Business

Finch Therapeutics Group, Inc. (the “Company” or “FTG”) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (“Finch”) and Crestovo Holdings LLC (“Crestovo”) in September 2017 (the “Merger”), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (“Finch Holdings”). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.

The Company is a microbiome technology company with a portfolio of intellectual property and microbiome assets. In January 2023, the Company announced the decision to wind down its development efforts and focus on realizing the value of its intellectual property estate and other assets.

Liquidity and Capital Resources

Management believes that the Company’s cash and cash equivalents of $34.1 million as of June 30, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of these condensed consolidated financial statements. However, due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company does not currently expect to progress any product candidate through clinical trials or commercial approval and it does not currently expect to generate any revenue from product sales. The Company may never succeed in realizing the value of its intellectual property estate and other assets and, even if it does, it may never generate revenue that is significant or large enough to achieve profitability.

The Company has significantly scaled back its expenses by winding down its development efforts, including by liquidating certain of its assets, terminating vendor contracts and reducing headcount. The Company may need additional funding to support its operating activities as it seeks to realize value from its intellectual property estate and other assets. Until such time, if ever, that the Company can generate substantial revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If the Company is unable to obtain funding as needed, it may decide to pursue a dissolution and liquidation.

Reverse Stock Split

On June 9, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001, at a ratio of 1-for-30 (the “Reverse Stock Split”). The Reverse Stock Split was reflected on the Nasdaq Global Select Market beginning with the opening of trading on June 12, 2023. Pursuant to the Reverse Stock Split, every 30 shares of the Company's issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. The Reverse Stock Split did not change the total number of shares the Company is authorized to issue. The Reverse Stock Split affected all issued and outstanding shares of the Company's common stock, and the respective numbers of shares of common stock underlying the Company’s outstanding stock options, outstanding restricted stock units (“RSU”) and the Company's equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying financial statements have been retrospectively adjusted to give effect to the Reverse Stock Split for all periods presented.

 

5


 

 

 

Reclassifications

Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of Article 10 of Regulation S-X of the Securities Act of 1933, as amended, published by the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes the disclosures are adequate. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2023.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary for a fair presentation of the Company’s condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, condensed consolidated statements of stockholders’ equity (deficit) for the three and six months ended June 30, 2023 and 2022, and condensed consolidated cash flows for the six months ended June 30, 2023 and 2022. Such adjustments are of a normal and recurring nature. The results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023. The consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements of the Company but does not include all disclosures required by U.S. GAAP.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.

The significant accounting policies and estimates used in preparation of the unaudited interim condensed consolidated financial statements are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2023.

Goodwill and Acquired In-Process Research and Development

Goodwill and in-process research and development (“IPR&D”) are evaluated annually for impairment on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. To conduct impairment tests of goodwill, the fair value of the Company’s single reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value.

 

To conduct impairment tests of IPR&D, the fair value of the IPR&D asset is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&D asset exceeds its fair value. We estimate the fair value for our IPR&D asset using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates.

 

 

6


 

 

 

In January 2023, the Company made the decision to wind down its development efforts, which management concluded was an impairment indicator requiring the Company to perform an interim impairment test of IPR&D. Management's assessment for the impairment of IPR&D indicated that there are no future cash flow projections associated with its IPR&D asset and the fair value of the IPR&D asset was zero. This resulted in an impairment charge of $32.9 million during the six months ended June 30, 2023.

Recently Issued Accounting Pronouncements

On January 1, 2023, the Company adopted Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the Financial Accounting Standards Board (“FASB”) issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.

3. ADJUSTMENT TO PRIOR INTERIM UNAUDITED FINANCIAL STATEMENTS

During the preparation of the second quarter financial statements of fiscal year 2023, the Company identified an error in the accrual of certain costs for the fiscal quarter ended March 31, 2023, which resulted in an overstatement of accounts payable and research and development expenses for that quarter. The correction of this error impacted the unaudited condensed consolidated financial statements for the first quarter of fiscal year 2023. The Company assessed the applicable guidance issued by the SEC and the FASB and concluded this misstatement was not material, individually or in the aggregate, to its unaudited condensed consolidated financial statements for the aforementioned interim period. In the table below, the Company adjusted its previously issued first quarter unaudited condensed consolidated financial information to correct the error by decreasing accounts payable and research and development expenses by $1.6 million for the quarter ended March 31, 2023. The financial statements will be adjusted in subsequent filings with the Securities and Exchange Commission that include such statements, including when the first quarter Form 10-Q is filed for fiscal year 2024.

Accumulated deficit as of March 31, 2023 in the accompanying statement of stockholders’ equity for the quarter ended June 30, 2023 was made smaller by $1.6 million due to the effects of the decreased expense accruals for the first quarter of fiscal year 2023. The following are selected line items from the financial statements also impacted by the $1.6 million, or $1,592 thousand, illustrating the effect of the error correction for the quarter ended March 31, 2023 (in thousands):

 

 

As Previously Reported

 

 

As Revised

 

Research and development

 

$

8,588

 

 

$

6,996

 

Total operating expenses

 

 

(67,482

)

 

 

(65,890

)

Net loss from operations

 

 

(67,375

)

 

 

(65,783

)

Loss before income taxes

 

 

(67,400

)

 

 

(65,808

)

Net loss

 

 

(63,939

)

 

 

(62,347

)

Net loss per share attributable to common stockholders—basic and diluted

 

$

(39.89

)

 

$

(39.19

)

 

 

7


 

 

 

4. FAIR VALUE MEASUREMENTS

The Company has no financial liabilities measured at fair value on a recurring basis. The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):

 

DESCRIPTION

 

JUNE 30,
2023

 

 

QUOTED
PRICES
IN ACTIVE
MARKETS FOR
IDENTICAL
ASSETS
(LEVEL 1)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 2)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 3)

 

Money market funds

 

$

5,349

 

 

$

5,349

 

 

$

 

 

$

 

 

DESCRIPTION

 

DECEMBER 31,
2022

 

 

QUOTED
PRICES
IN ACTIVE
MARKETS FOR
IDENTICAL
ASSETS
(LEVEL 1)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 2)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 3)

 

Money market funds

 

$

69,991

 

 

$

69,991

 

 

$

 

 

$

 

 

There were no transfers between fair value levels during the six months ended June 30, 2023 and the year ended December 31, 2022. The carrying values of accounts receivable, prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.

5. PROPERTY AND EQUIPMENT, NET

Property and equipment, net consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Lab equipment

 

$

 

 

$

4,146

 

Office furniture and fixtures

 

 

869

 

 

 

1,406

 

Leasehold improvements

 

 

 

 

 

13,972

 

Construction work-in-progress

 

 

 

 

 

316

 

Software

 

 

 

 

 

4,883

 

Computer equipment

 

 

109

 

 

 

499

 

Total

 

 

978

 

 

 

25,222

 

Less: Accumulated depreciation

 

 

(246

)

 

 

(9,286

)

Property and equipment, net

 

$

732

 

 

$

15,936

 

 

Depreciation expense was $1.4 million and $2.7 million for the six months ended June 30, 2023 and 2022, respectively. During the quarter ended March 31, 2023, the Company recorded an impairment charge of $13.1 million to its long-lived assets, as it was determined that certain equipment, leasehold improvements, and software associated with program development would no longer be used following the discontinuation of the Company's Phase 3 clinical trial in CP101 and significant reduction in the Company's workforce, as announced in January 2023. In addition, during the quarter ended June 30, 2023, the Company sold its lab equipment, which resulted in a gain of $0.8 million included in other income (expense) on the condensed consolidated statement of operations.

 

8


 

 

 

6. LEASES

Inner Belt Road Lease

In December 2015, the Company entered into a 10-year lease agreement (the "Inner Belt Road Lease") for approximately 25,785 square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The monthly rental payments under the Inner Belt Road Lease, which include base rent charges of $0.1 million, are subject to periodic rent increases through September 2026.

The Inner Belt Road Lease terminated and the Company’s rent obligations ended on June 30, 2023. The landlord agreed to refund the Company for the full amount of the Company’s security deposit, which is included in prepaid expenses and other current assets on the condensed consolidated balance sheet.

The Company's lease expense under the Inner Belt Road Lease was $0.6 million for each of the six months ended June 30, 2023 and 2022.

Hood Lease

On August 3, 2021, Finch entered into a 10-year lease agreement (the “Hood Lease”) with Hood Park LLC, pursuant to which Finch leased approximately 61,139 square feet of office and laboratory space (the “Premises”). The Hood Lease provides Finch with an option to extend the lease for one additional five-year term. Finch’s annual base rent for the Premises started at approximately $4.5 million, and the lease contains annual rent escalations. Finch commenced business operations in the Premises in the second quarter of 2022, which triggered recognition of the lease for accounting purposes. The Company recorded lease expense related to the Hood Lease of $2.7 million and $0.9 million for the six months ended June 30, 2023 and 2022, respectively.

Finch posted a customary letter of credit in the amount of approximately $2.3 million, subject to decrease on a set schedule, as a security deposit pursuant to the Hood Lease. This is included in restricted cash, non-current on the condensed consolidated balance sheet as of June 30, 2023 and December 31, 2022.

In the third quarter of 2022, Finch entered into a sublease agreement to sublet approximately one third of its leased space under the Hood Lease, which commenced on August 10, 2022, for an initial term of two years, with an option for Finch to extend the sublease for up to one additional year, which Finch exercised in the fourth quarter of 2022. Additionally, in the fourth quarter of 2022, Finch entered into a second sublease agreement to sublet the remainder of its leased space under the Hood Lease for a three-year term, which commenced on December 15, 2022. For the six months ended June 30, 2023, Finch recognized sublease income of $1.9 million, which is presented as other income in the condensed consolidated statements of operations. No sublease income was recognized for the six months ended June 30, 2022, as the subleases had not commenced.

The following table presents the classification of right-of-use assets and operating lease liabilities as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

BALANCE SHEET CLASSIFICATION

 

JUNE 30, 2023

 

 

DECEMBER 31, 2022

 

ASSETS:

 

 

 

 

 

 

 

Operating lease assets

Operating right-of-use assets

 

$

27,308

 

 

$

32,752

 

LIABILITIES:

 

 

 

 

 

 

 

    Operating lease liabilities

 

 

 

 

 

 

 

Current

Operating lease liabilities, current

 

$

1,656

 

 

$

3,431

 

Noncurrent

Operating lease liabilities, non-current

 

 

29,388

 

 

 

34,255

 

Total lease liabilities

 

 

$

31,044

 

 

$

37,686

 

 

 

9


 

 

 

The following table represents the components of operating lease cost, which are included in general and administrative and research and development expense, and sublease income, which is included in other income on the statement of operations for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

 

 

THREE MONTHS ENDED JUNE 30,

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating lease cost

 

$

1,678

 

 

$

1,311

 

 

$

3,405

 

 

$

1,650

 

Short-term lease cost

 

 

4

 

 

 

31

 

 

 

17

 

 

 

139

 

Variable lease cost

 

 

87

 

 

 

469

 

 

 

532

 

 

 

964

 

Sublease income

 

 

(959

)

 

 

 

 

 

(1,919

)

 

 

 

Total lease cost, net

 

$

810

 

 

$

1,811

 

 

$

2,035

 

 

$

2,753

 

 

The weighted-average remaining operating lease term and discount rate as of June 30, 2023 and December 31, 2022 were as follows (in thousands):

 

 

 

JUNE 30, 2023

 

 

DECEMBER 31, 2022

 

Weighted-average remaining lease term (years)

 

 

8.5

 

 

 

8.5

 

Weighted-average discount rate

 

 

8.5

%

 

 

8.3

%

 

Supplemental disclosure of cash flow information related to operating leases for the six months ended June 30, 2023 and 2022 was as follows (in thousands):

 

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

Cash paid (received) for amounts included in measurement of lease liabilities

 

$

2,369

 

 

$

(5,246

)

The following table represents a summary of the Company’s future operating lease payments required as of June 30, 2023 (in thousands):

 

2023

 

$

1,825

 

2024

 

 

4,795

 

2025

 

 

4,930

 

2026

 

 

5,071

 

2027

 

 

5,215

 

Thereafter

 

 

22,391

 

Total future minimum lease payments

 

 

44,227

 

Less: amount representing interest

 

 

(13,183

)

Present value of future minimum lease payments

 

$

31,044

 

 

7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Accrued research and development

 

$

99

 

 

$

1,967

 

Accrued legal and professional fees

 

 

4,945

 

 

 

5,852

 

Accrued compensation and benefits

 

 

1,482

 

 

 

880

 

Accrued other

 

 

961

 

 

 

1,462

 

Total accrued expenses and other current liabilities

 

$

7,487

 

 

$

10,161

 

 

10


 

 

 

8. LOAN PAYABLE

Hercules Loan and Security Agreement

On May 11, 2022, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., providing for a term loan with aggregate maximum borrowings of up to $55.0 million. Under the Loan Agreement, the Company borrowed an initial amount of $15.0 million, and on January 25, 2023 (the “Payoff Date”), the Company voluntarily paid off all outstanding principal, accrued and unpaid interest, fees, costs and expenses under the Loan Agreement, equal to $16.2 million in the aggregate, recording a loss on extinguishment of $1.4 million. Following the Payoff Date, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement and all other documents entered into in connection with the Loan Agreement were terminated.

 

 

9. RESTRUCTURING

 

During the three and six months ended June 30, 2023, the Company recognized restructuring charges of $0.8 million and $4.0 million, respectively, primarily consisting of one-time severance payments, healthcare coverage, outplacement services and related expenses in connection with the Company's January 2023 restructuring action (the “January 2023 Restructuring”). All severance payments will be completed by the second quarter of 2024. The accrued restructuring liability is included in accrued compensation and benefits as of June 30, 2023.

 

The following table summarizes the restructuring accrual activity for the six months ended June 30, 2023 (in thousands):

 

 

 

 

 

Accrued restructuring liability as of December 31, 2022

 

$

201

 

Restructuring charges

 

 

4,037

 

Cash payments

 

 

(2,776

)

Accrued restructuring liability as of June 30, 2023

 

$

1,462

 

 

10. INCOME TAXES

During the six months ended June 30, 2023 and the year ended December 31, 2022, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. There were no material changes in the Company’s tax position in the six months ended June 30, 2023 as compared to the year ended December 31, 2022. The benefit for the six months ended June 30, 2023 reflects the full removal of the deferred tax liability on the IPR&D that was written off during the first quarter of 2023 and treated as a discrete item in the tax provision.

 

11


 

 

 

11. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

 

On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, “Rebiotix”) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the “Court”). The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the “’309 Patent”); 10,463,702 (the “’702 Patent”); 10,328,107 (the “’107 Patent”); 10,064,899; 10,022,406 (the “’406 Patent”); 9,962,413 (the “’413 Patent”); and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the ’107, ’702, and ’309 Patents. In June 2022, Finch alleged infringement of the ’406 and ’413 Patents by Rebiotix. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota (“UMN”), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012, (collectively, the “UMN Patents”). On April 4, 2022, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the UMN Patents. On May 2, 2022, the Company and UMN responded, denying such counterclaims. The Court set a trial date for a five-day trial beginning on May 20, 2024. On January 23, 2023, the Company filed a second amended answer and counterclaims, in which the Company alleged infringement by Rebiotix of two additional U.S. Patents owned by Finch: U.S. Patent Nos. 11,541,080 (the “’080 Patent”) and 11,491,193 (the “’193 Patent”). On February 7, 2023, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the ’080 and ’193 patents. The Court issued a claim construction order on February 28, 2023. On July 6, 2023, Rebiotix filed a motion to dismiss certain counts of our second amended answer and counterclaims based on the assertion that Finch lacks standing to sue as to ’107 Patent, ’702 Patent, ’309 Patent, ’406 Patent, ’413 Patent, ’193 Patent, and ’080 Patent. Rebiotix specifically alleges that the sole named inventor on these patents, Thomas J. Borody, did not assign his rights in those patents to Finch, and as a result, Finch does not own them and therefore does not have standing to assert them. Briefing on this motion is complete.

 

The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined that there is no probable or estimable loss contingency that is required to be recorded as of June 30, 2023.

License and Royalty Payments

The Company is party to license and other agreements under which it is obligated to make milestone and royalty payments and incur annual maintenance fees. The Company owes a nominal annual maintenance fee under its license agreement with UMN, (the “UMN Agreement”), as well as escalating minimum royalty amounts. The minimum payments continue in perpetuity for the University of Minnesota until the agreement is terminated. On April 12, 2023, the Company amended its agreement with UMN to, among other things, allow the Company to satisfy certain performance milestones through sublicensing agreements.

 

The Company is party to an agreement with OpenBiome requiring the Company to pay certain milestones of up to $26.0 million upon the occurrence of certain R&D events, regulatory approvals, and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.

 

12


 

 

 

12. STOCKHOLDERS’ EQUITY

On February 24, 2021, the board of directors of the Company (the “Board”) and the Company’s stockholders approved the Company’s Amended and Restated Certificate of Incorporation. The certificate authorized the issuance of up to 200,000,000 shares of $0.001 par value common stock and up to 10,000,000 shares of $0.001 par value undesignated preferred stock. The Board may designate the rights, preferences, privileges, and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and number of shares constituting any series or the designation of any series. The issuance of preferred stock could have the effect of restricting dividends on the Company's common stock, diluting the voting power of the Company's common stock, impairing the liquidation rights of the Company's common stock, or delaying or preventing a change in control. As of June 30, 2023, no shares of preferred stock were outstanding.

Each share of common stock entitles the holder to one vote, together with the holders of any preferred stock outstanding, on all matters submitted to the stockholders for a vote. Common stockholders are also entitled to receive dividends. As of June 30, 2023, no cash dividends have been declared or paid.

As of June 30, 2023 and December 31, 2022 the Company has reserved the following shares of common stock for the exercise of stock options, common stock warrants, vesting of restricted stock and shares issuable under the employee stock purchase plan:

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Options to purchase common stock

 

 

72,586

 

 

 

109,522

 

Unvested restricted stock units

 

 

 

 

 

9,039

 

Shares issuable under employee stock purchase plan

 

 

 

 

 

3

 

 

 

 

72,586

 

 

 

118,564

 

 

13. STOCK-BASED COMPENSATION

2021 Equity Incentive Plan
 

In March 2021, the Board adopted, and the stockholders approved, the 2021 Equity Incentive Plan (the “2021 Plan”).The 2021 Plan was amended and restated as of June 8, 2023 to reflect the stock split. The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates.

The number of shares of common stock reserved for issuance under the Company's 2021 Plan automatically increases on January 1 of each calendar year through January 1, 2031, in an amount equal to (i) 5.0% of the total number of shares of common stock outstanding on December 31 of the year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the applicable January 1. The maximum number of shares of common stock that may be issued on the exercise of incentive stock options under the 2021 Plan is 470,000 shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under the 2021 Plan.

 

On January 1, 2023, the number of shares of common stock reserved and available for issuance under the 2021 Plan automatically increased by 80,089 shares and as of June 30, 2023, there were 72,586 shares of common stock issuable upon the exercise of outstanding options and there were 263,753 shares available for future issuance under the 2021 Plan.

 

13


 

 

 

2021 Employee Stock Purchase Plan

In March 2021, the Board adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The 2021 ESPP was amended and restated as of June 8, 2023 to reflect the stock split. The 2021 ESPP is administered by the Board or by a committee appointed by the Board. The 2021 ESPP provides participating employees with the opportunity to purchase shares of common stock. The occurrence and duration of offering periods under the 2021 ESPP are subject to the determinations of the compensation committee of the Board. Annually the common stock reserved and available for issuance under the 2021 ESPP automatically increases and on January 1, 2023, increased by 16,018. As of June 30, 2023, 3,354 shares have been issued under the 2021 ESPP and 45,167 shares are available for future issuance.

Stock Options

The following table summarizes the activity of the Company’s stock options under the 2017 Plan and 2021 Plan for the six months ended June 30, 2023:

 

 

SHARES

 

 

WEIGHTED-
AVERAGE
EXERCISE
PRICE

 

 

WEIGHTED-
AVERAGE
REMAINING
CONTRACTUAL
TERM (in years)

 

 

AGGREGATE
INTRINSIC
VALUE
(in thousands)

 

Outstanding as of December 31, 2022

 

 

109,522

 

 

$

293.81

 

 

 

6.9

 

 

$

 

Granted

 

 

34,094

 

 

$

8.15

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(48,146

)

 

$

327.08

 

 

 

 

 

 

 

Expired

 

 

(22,884

)

 

$

291.79

 

 

 

 

 

 

 

Outstanding as of June 30, 2023

 

 

72,586

 

 

$

138.21

 

 

 

6.0

 

 

$

13

 

Options exercisable as of June 30, 2023

 

 

36,785

 

 

$

249.63

 

 

 

2.6

 

 

$

 

Options vested or expected to vest as of June 30, 2023

 

 

72,586

 

 

$

138.21

 

 

 

6.0

 

 

$

13

 

 

As of June 30, 2023, there was approximately $0.3 million of unrecognized compensation expense related to the stock-based compensation arrangements granted under the 2021 Plan remaining to be recognized. The Company expects to recognize this cost over a weighted average period of 3.7 years.

 

Restricted Stock Unit Awards

In June 2022, the Company issued RSU awards with time-based vesting conditions to employees. The fair value of an RSU award is equal to the fair market value of the Company's ordinary shares on the date of grant and the expense is recognized on a straight-line basis over the requisite service period. The RSUs primarily vest over one year from the grant date.

The following table summarizes the activity of the Company’s RSUs under the 2021 Plan for the six months ended June 30, 2023:

 

 

 

RSUs

 

 

WEIGHTED-
AVERAGE
GRANT DATE FAIR VALUE

 

 

AGGREGATE
INTRINSIC
VALUE
(in thousands)

 

Outstanding as of December 31, 2022

 

 

9,039

 

 

$

83.88

 

 

$

131

 

Vested and distributed

 

 

(3,317

)

 

$

83.80

 

 

 

 

Forfeited

 

 

(5,722

)

 

$

83.93

 

 

 

 

Unvested as of June 30, 2023

 

 

 

 

$

 

 

$

 

 

14


 

 

 

Stock-Based Compensation Expense

Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the periods presented is as follows (in thousands):

 

 

THREE MONTHS ENDED JUNE 30,

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

 

 

$

760

 

 

$

231

 

 

$

1,769

 

General and administrative

 

 

300

 

 

 

1,070

 

 

 

1,249

 

 

 

2,181

 

Total

 

$

300

 

 

$

1,830

 

 

$

1,480

 

 

$

3,950

 

 

14. RETIREMENT PLAN

The Company has adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. All employees are eligible to become participants of the plan at their hire date. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right to make additional contributions to this plan. The Company made contributions to the plan of $0.1 million and $0.4 million in the six months ended June 30, 2023 and 2022, respectively.

15. LOSS PER SHARE

Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):

 

 

 

FOR THE THREE MONTHS
ENDED JUNE 30,

 

 

FOR THE SIX MONTHS
ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(6,950

)

 

$

(22,700

)

 

$

(69,297

)

 

$

(47,267

)

Net loss attributable to
   common stockholders—basic and diluted

 

 

(6,950

)

 

 

(22,700

)

 

 

(69,297

)

 

 

(47,267

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common
   stock outstanding—basic and diluted

 

 

1,604,795

 

 

 

1,585,978

 

 

 

1,603,811

 

 

 

1,585,093

 

Net loss per share attributable
   to common stockholders—basic and diluted

 

$

(4.33

)

 

$

(14.31

)

 

$

(43.21

)

 

$

(29.82

)

 

The Company’s potentially dilutive securities, which include stock options, warrants, RSU awards and shares issuable under the employee stock purchase plan have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at June 30, 2023 and 2022 because including them would have had an anti-dilutive effect:

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

 

2022

 

Options to purchase common stock

 

 

72,586

 

 

 

 

109,522

 

Unvested restricted stock units

 

 

 

 

 

 

9,039

 

Shares issuable under employee stock purchase plan

 

 

 

 

 

 

3

 

 

 

 

72,586

 

 

 

 

118,564

 

 

15


 

 

 

16. SUBSEQUENT EVENTS

Except as discussed in Note 11, there have no subsequent events through the date of these financial statements.

16


 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with (1) our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and (2) the audited consolidated financial statements and the related notes and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2022 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 23, 2023, which we refer to as the 2022 10-K.

Overview

 

We are a microbiome technology company with a portfolio of intellectual property and microbiome assets. We have significantly scaled back our expenses by winding down our development efforts, including liquidating certain of our assets, terminating vendor contracts and reducing headcount, and we now focus on realizing the value of our intellectual property and other assets (the “Recent Business Initiatives”). This decision came after an assessment by our management team and board of directors of multiple factors, including our outlook for identifying a commercial partner, slower than anticipated enrollment in the PRISM4 trial, the harmful impact of what we believe is the ongoing unauthorized use of our intellectual property, and broader sector trends in the biotechnology industry.

 

We were previously developing CP101 as an orally administered complete microbiome therapeutic designed for the prevention of recurrent C. difficile infection, or CDI. Although we announced our decision to discontinue our Phase 3 clinical trial of CP101 for the prevention of recurrent CDI, or the PRISM4 trial, we believe that CP101 has therapeutic potential in both CDI and other indications.

 

We do not currently expect to be able to progress any product candidate through clinical trials or commercial approval, and we do not currently expect to generate any revenue from product sales. In April 2023, we announced the termination of employment, without cause, of our former chief executive officer and chief operating officer and the appointment of Matthew Blischak and Lance Thibault as our new chief executive officer and chief financial officer, respectively, effective May 16, 2023.

Since our inception, we have funded our operations primarily with proceeds from our March 2021 initial public offering (the ”IPO”), the sale of convertible preferred stock, our loan agreement with Hercules Capital and from collaboration revenue. Although we believe strongly in the value of our pioneering intellectual property portfolio and the merits of our current litigation activities relating to those assets, we may never succeed in realizing the value of our intellectual property estate and other assets and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability.

 

As a result, we may need additional funding to support our operating activities as we seek to realize value from our intellectual property estate and other assets. Until such time, if ever, that we can generate substantial revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If we are unable to obtain funding as needed, we may decide to pursue a dissolution and liquidation.

We believe that our existing cash and cash equivalents of $34.1 million as of June 30, 2023 will be sufficient to fund our operations into 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and Capital Resources.”

On June 9, 2023, we completed a reverse stock split of our outstanding shares of common stock at a ratio of one-for-thirty. All share and per share amounts of the common stock included in this Quarterly Report on Form 10-Q, including in the accompanying financial statements, have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.

 

17


 

 

 

Components of Our Results of Operations

Revenue

We have no products approved for commercial sale. We have not generated any revenue from product sales for the three months ended June 30, 2023 and do not expect to generate any revenue from the sale of licensed products for the foreseeable future. Our revenue to date has been generated primarily through collaboration and license agreements. We recognized revenue over our expected performance period under each agreement. We expect that our revenue for the next several years, if any, will be derived from enforcement and out-licensing of our intellectual property estate.

Takeda Agreement

In January 2017, we entered into a research collaboration and exclusive license agreement with Takeda, or as amended and restated, (“the Takeda Agreement”), pursuant to which we granted Takeda a worldwide, exclusive license, with the right to grant sublicenses, under our rights in certain patents, patent applications and know-how to develop, have developed, manufacture, have manufactured, make, have made, use, have used, offer for sale, sell, have sold, commercialize, have commercialized and import our microbiome therapeutic candidate FIN-524, for the prevention, diagnosis, theragnosis or treatment of diseases in humans.

In August 2022, we received written notice from Takeda that, following a review of its pipeline, Takeda had elected to exercise its right to terminate the Takeda Agreement. In accordance with the terms of the Takeda Agreement, the termination became effective on November 17, 2022. Pursuant to a further amendment to the Takeda Agreement, dated October 19, 2022, we transitioned activities under the Takeda Agreement. As of November 17, 2022, the license rights granted to Takeda terminated and Takeda ceased to accrue any financial obligations to us. Revenue earned under the Takeda Agreement was recorded as collaboration revenue on our consolidated statement of operations.

OpenBiome Agreement

On November 19, 2020, we entered into a License Agreement with OpenBiome (“the LMIC Agreement”) pursuant to which we granted OpenBiome a non-exclusive royalty-bearing license, with the right to grant sublicenses, under certain patents, patent applications, and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from stool from a stool donor source without the use of culturing or replication, or certain natural products. The only consideration from the LMIC Agreement is in the form of future royalties on certain net sales. We are entitled to receive tiered royalties on net sales of certain products, ranging from mid-single digit to low second decile digits on a product-by-product and country-by-country basis. We did not recognize any revenue related to the LMIC Agreement for the six months ended June 30, 2023 and 2022, as there are currently no products available for sale.

We entered into an Asset Purchase Agreement with Microbiome Health Research Institute, Inc (“OpenBiome”), also dated November 19, 2020 (“ the OpenBiome Agreement”). Under this agreement we will continue to earn royalties based on sales of fecal microbiota transplantation, or FMT, materials, which we receive as reimbursement for the payment of third-party license fees. The OpenBiome Agreement effectively terminated certain existing agreements with OpenBiome and internalized certain functions for which we previously relied on OpenBiome. Pursuant to the OpenBiome Agreement, we acquired certain biological samples and obtained a license to certain OpenBiome technology, and, upon closing of the transaction, which occurred on March 1, 2021, we acquired certain additional assets, including biological samples, a commercial lease, intellectual property, capital equipment and contracts. In accordance with the OpenBiome Agreement we have made payments of $5.0 million, which is the full amount agreed upon. We are also required to pay certain milestones up to $26.0 million upon the occurrence of certain research and development events, regulatory approvals, and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.

 

18


 

 

 

Operating Expenses

Research and Development Expenses

Until January 2023, research and development activities were central to our business model. As a result of our Recent Business Initiatives, we do not currently expect to be able to progress any product candidate through clinical trials or commercial approval.

Research and development expenses have primarily consisted of costs incurred for research activities, including discovery and development efforts. We expense research and development costs as incurred, which include:

salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;
upfront, milestone and maintenance fees incurred under license, acquisition and other third-party agreements;
costs of laboratory supplies and acquiring, developing and manufacturing study materials;
facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs; and
costs of outside consultants engaged in research and development functions, including their fees and related travel expenses

Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed. We do not allocate certain employee-related costs, external costs directly related to our Human First Discovery platform, and other indirect costs to specific research and development programs because these costs are deployed across multiple product programs and, as such, are classified as costs of our platform research.

General and Administrative Expenses

We expect that our general and administrative expenses will continue to decrease primarily due to our reduced headcount. We expect to continue to incur expenses associated with being a public company, including costs related to consulting, accounting, audit, legal, regulatory and tax compliance services, and director and officer insurance costs.

General and administrative expenses have primarily consisted of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

Impairment of Goodwill and IPR&D

Goodwill and IPR&D intangibles were evaluated for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors we consider important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in our use of the acquired asset or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.

To conduct impairment tests of goodwill, the fair value of the Company’s single reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value.

 

 

19


 

 

 

To conduct impairment tests of IPR&D intangible assets, the fair value of the asset is compared to its carrying value. If the carrying value exceeds its fair value, the excess is recorded an impairment loss. We estimated the fair value for our IPR&D asset using discounted cash flow valuation models, which required the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates.

 

Impairment of Long-Lived Assets

Impairment of long-lived assets consists of costs attributable to the cease of use of laboratory equipment, leasehold improvements, and software associated with program development, as it was determined that certain long-lived assets would no longer be used due to our Recent Business Initiatives, which discontinued the Company's Phase 3 clinical trial in CP101.

Restructuring Expense

 

Restructuring expense consists of costs directly incurred as a result of restructuring initiatives, and includes one-time severance payments, healthcare coverage, outplacement services and related expenses as well as contract cancellation costs.

Total Other Income (Expense), Net

Total other income (expense), net primarily consists of sublease income, gain on lease termination, gain (loss) on disposal of fixed assets, interest income (expense) and loss on loan extinguishment.

 

Income Tax Benefit

The income tax benefit reflects the full removal of the deferred tax liability associated with the IPR&D that was written off during the first fiscal quarter of 2023 and treated as a discrete item in the tax provision.

Results of Operations

Comparison of the Three Months Ended June 30, 2023 and 2022

The following table summarizes our results of operations for the three months ended June 30, 2023 and 2022 (in thousands):

 

 

THREE MONTHS ENDED
JUNE 30,

 

 

 

2023

 

 

2022

 

REVENUE:

 

 

 

 

 

 

Collaboration revenue

 

$

 

 

$

361

 

Total revenue

 

 

 

 

 

361

 

OPERATING EXPENSES:

 

 

 

 

 

 

Research and development

 

 

203

 

 

 

13,923

 

General and administrative

 

 

8,877

 

 

 

8,164

 

Restructuring expense

 

 

801

 

 

 

903

 

Total operating expenses

 

 

9,881

 

 

 

22,990

 

      Net operating loss

 

 

(9,881

)

 

 

(22,629

)

OTHER INCOME (EXPENSE), NET:

 

 

 

 

 

 

Interest income (expense), net

 

 

420

 

 

 

(65

)

Gain on lease termination

 

 

752

 

 

 

 

Gain (loss) on sale and disposal of fixed assets, net

 

 

754

 

 

 

(6

)

Sublease and other income

 

 

1,005

 

 

 

 

     Total other income (expense), net

 

 

2,931

 

 

 

(71

)

Net loss

 

$

(6,950

)

 

$

(22,700

)

 

20


 

 

 

Revenue

There was no revenue for the three months ended June 30, 2023 . Revenue of $0.4 million for the three months ended June 30, 2022 primarily consisted of collaboration revenue earned under the Takeda Agreement. Collaboration revenue decreased due to Takeda terminating our collaboration agreement in November 2022.

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended June 30, 2023 and 2022 (in thousands):

 

 

 

THREE MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

Increase
(Decrease)

 

CDI

 

$

 

 

$

4,066

 

 

$

(4,066

)

Autism Spectrum Disorder (ASD)

 

 

 

 

 

1,409

 

 

 

(1,409

)

Platform

 

 

 

 

 

7,002

 

 

 

(7,002

)

Other

 

 

203

 

 

 

1,446

 

 

 

(1,243

)

 

$

203

 

 

$

13,923

 

 

$

(13,720

)

 

Research and development expenses for the three months ended June 30, 2023 were $0.2 million, compared to $13.9 million for the three months ended June 30, 2022. The decrease was driven by our decision to significantly scale back our expenses by winding down our development efforts, including by liquidating certain of our assets, terminating vendor contracts and reducing headcount and now focus on realizing the value of our intellectual property and other assets.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the three months ended June 30, 2023 and 2022 (in thousands):

 

 

 

THREE MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

Increase (Decrease)

 

Personnel expenses (including stock-based compensation)

 

$

780

 

 

$

3,233

 

 

$

(2,453

)

Facilities and supplies

 

 

1,796

 

 

 

443

 

 

 

1,353

 

Professional fees

 

 

5,476

 

 

 

3,032

 

 

 

2,444

 

Other expenses

 

 

825

 

 

 

1,456

 

 

 

(631

)

 

$

8,877

 

 

$

8,164

 

 

$

713

 

 

General and administrative expenses were $8.9 million for the three months ended June 30, 2023, compared to $8.2 million for the three months ended June 30, 2022. The increase of $0.7 million was partially due to a $2.4 million increase in professional fees primarily related to legal expenses. There was also a $1.4 million increase in facilities and supplies primarily due to the increase in rent expense related to the commencement of the 10-year lease agreement with Hood Park LLC in May of 2022. These increases were partially offset by a $2.6 million decrease in personnel expenses due to the significant reduction of personnel.

Restructuring Expense

Restructuring expense for the three months ended June 30, 2023 was $0.4 million, compared to $0.9 million for the three months ended June 30, 2022. The decrease is primarily due to more costs associated with the first implementation of certain expense reduction measures, which occurred in the second quarter of 2022 compared to the expense reductions in the second quarter of 2023.

 

Other Income (Expense), Net

Total other income, net for the three months ended June 30, 2023 was $2.9 million compared to nominal expense for the three months ended June 30, 2022. The change to other income (expense) was primarily driven by the 2023 sublease income of $1.0 million, $0.8 million gain on the termination of our Inner Belt Road Lease, $0.8 million gain on the sale of fixed assets and interest income of $0.4 million earned on our cash equivalents due to higher interest rates.

 

 

21


 

 

 

Comparison of the Six Months Ended June 30, 2023 and 2022

 

The following table summarizes our results of operations for the six months ended June 30, 2023 and 2022 (in thousands):

 

 

 

SIX MONTHS ENDED
JUNE 30,

 

 

 

2023

 

 

2022

 

REVENUE:

 

 

 

 

 

 

Collaboration revenue

 

$

107

 

 

$

715

 

Total revenue

 

 

107

 

 

 

715

 

OPERATING EXPENSES:

 

 

 

 

 

 

Research and development

 

 

7,199

 

 

 

29,453

 

General and administrative

 

 

18,494

 

 

 

17,568

 

Impairment of IPR&D

 

 

32,900

 

 

 

 

Impairment of long-lived assets

 

 

13,141

 

 

 

 

Restructuring expense

 

 

4,037

 

 

 

903

 

Total operating expenses

 

 

75,771

 

 

 

47,924

 

Net operating loss

 

 

(75,664

)

 

 

(47,209

)

OTHER INCOME (EXPENSE), NET:

 

 

 

 

 

 

Interest (expense) income, net

 

 

845

 

 

 

(52

)

Gain on lease termination

 

 

752

 

 

 

 

Loss on loan extinguishment

 

 

(1,366

)

 

 

 

Gain (loss) on sale and disposal of fixed assets, net

 

 

617

 

 

 

(6

)

Sublease and other income

 

 

2,058

 

 

 

 

Total other income (expense), net

 

 

2,906

 

 

 

(58

)

Loss before income taxes

 

 

(72,758

)

 

 

(47,267

)

Income tax bebefit

 

 

3,461

 

 

 

-

 

Net loss

 

$

(69,297

)

 

$

(47,267

)

Revenue

Revenue of $0.1 million and $0.7 million for the six months ended June 30, 2023 and 2022, respectively, primarily consisted of collaboration revenue earned under the Takeda Agreement. Our collaboration revenue decreased by $0.6 million due to Takeda terminating our collaberation agreement in November 2022.

Research and Development Expenses

The following table summarizes our research and development expenses for six months ended June 30, 2023 and 2022 (in thousands):

 

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

Increase
(Decrease)

 

CDI

 

$

3,972

 

 

$

7,596

 

 

$

(3,624

)

Autism Spectrum Disorder (ASD)

 

 

71

 

 

 

3,275

 

 

 

(3,204

)

Platform

 

 

489

 

 

 

15,146

 

 

 

(14,657

)

Other

 

 

2,667

 

 

 

3,436

 

 

 

(769

)

 

$

7,199

 

 

$

29,453

 

 

$

(22,254

)

 

Research and development expenses for the six months ended June 30, 2023 were $7.2 million compared to $29.5 million for the six months ended June 30, 2022. The $22.3 million decrease was driven by our decision to significantly scale back our expenses by winding down our development efforts, including by liquidating certain of our assets, terminating vendor contracts and reducing headcount and now focus on realizing the value of our intellectual property and other assets.

22


 

 

 

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the six months ended June 30, 2023 and 2022 (in thousands):

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

Increase

 

Personnel expenses (including stock-based compensation)

 

$

2,868

 

 

$

6,891

 

 

$

(4,023

)

Facilities and supplies

 

 

3,636

 

 

 

661

 

 

 

2,975

 

Professional fees

 

 

9,874

 

 

 

6,286

 

 

 

3,588

 

Other expenses

 

 

2,116

 

 

 

3,730

 

 

 

(1,614

)

 

$

18,494

 

 

$

17,568

 

 

$

926

 

 

General and administrative expenses were $18.4 million for the six months ended June 30, 2023, compared to $17.6 million for the six months ended June 30, 2022. The increase of $0.8 million was partially due to a $3.6 million increase in professional fees primarily related to legal expenses. There was also a $3.0 million increase in facilities and supplies primarily due to the increase in rent expense related to the commencement of the 10-year lease agreement with Hood Park LLC in May of 2022. These increases were partially offset by a $4.2 million decrease in personnel expenses due to the significant reduction of personnel as well as a $1.6 million decrease in other expenses.

Impairment of IPR&D

There was no IPR&D impairment charge for the six months ended June 30, 2022. We recognized an IPR&D impairment charge of $32.9 million for the six months ended June 30, 2023 as the IPR&D asset was deemed to have no value.

Impairment of Long-Lived Assets

There was no impairment long-lived assets for the six months ended June 30, 2022. We recognized an impairment charge to long-lived assets of $13.1 million for the six months ended June 30, 2023, as it was determined that certain equipment, leasehold improvements, and software associated with program development would no longer be used.

Restructuring Expense

Restructuring expense for the six months ended June 30, 2023 was $3.6 million, compared to $0.9 million for the six months ended June 30, 2022. The increase is due to the costs associated with the implementation of certain expense reduction measures in January 2023 being higher than expenses associated with expense reduction measures, which occurred in the second quarter of 2022. Refer to Note 9 within the condensed consolidated financial statements for further information.

 

Other Income (Expense), Net

Total other income (expense), net for the six months ended June 30, 2023 was income of $2.9 million compared to a nominal loss for the six months ended June 30, 2022. The change to other income (expense) was driven by the 2023 sublease income of $2.1 million, interest income of $0.8 million earned on our cash equivalents due to higher interest rates, $0.8 million gain on the termination of our Inner Belt Road Lease, and $0.6 million gain on the sale of fixed assets. These increases were partially offset by realized loss on loan extinguishment of $1.4 million.

Income Tax Benefit

The income tax benefit for the six months ended June 30, 2023 reflects the full removal of the deferred tax liability associated with the IPR&D that was written off and treated as a discrete item in the tax provision. No income tax benefit was recorded for the six months ended June 30, 2022.

 

 

23


 

 

 

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, we have not recognized any product revenue and have incurred operating losses and negative cash flows from our operations. We do not currently expect to progress any product candidate through clinical trials or commercial approval and we do not currently expect to generate any revenue from product sales. We expect that our revenue for the next several years, if any, will be derived from enforcement and out-licensing of our intellectual property estate. We have funded our operations primarily through equity financings, the Loan Agreement, and from collaboration revenue. We have raised an aggregate of $118.8 million in net proceeds from our IPO, approximately $177.0 million from the sale of convertible preferred stock and $14.0 million in collaboration revenue from the upfront payment and milestone payments received under our collaboration agreement with Takeda, which was terminated in 2022. In May 2022, we borrowed $15.0 million under the Loan Agreement, and subsequently, in January 2023, we voluntarily paid off all outstanding amounts under the Loan Agreement.

Cash Flows

The following table summarizes our cash flows for the six months ended June 30, 2023 and 2022 (in thousands):

 

 

SIX MONTHS ENDED
JUNE 30,

 

 

 

2023

 

 

2022

 

Net cash used in operating activities

 

$

(22,538

)

 

$

(41,485

)

Net cash provided by (used in) investing activities

 

 

1,256

 

 

 

(1,803

)

Net cash (used in) provided by financing activities

 

 

(16,155

)

 

 

14,780

 

Net decrease in cash and cash equivalents, and restricted cash

 

$

(37,437

)

 

$

(28,508

)

 

Operating Activities

During the six months ended June 30, 2023, cash used in operating activities was $22.5 million compared to $41.5 million in 2022. The decrease in cash used in operating activities is primarily due to significantly scaling back our expenses by winding down our development efforts, terminating vendor contracts and reducing headcount. During the six months ended June 30, 2022, cash used in operating activities was primarily related to employee compensation expenses, utilizing consultants as well as legal and other professional services. During the six months ended June 30, 2023, significantly less cash was used for employee compensation expenses as well as other research and development expenses compared to the 2022 period.

Investing Activities

During the six months ended June 30, 2023, net cash provided by investing activities of $1.3 million was primarily due to selling certain property and equipment as a result of winding down our development efforts and reducing headcount. In contrast, during the six months ended June 30, 2022, we used $1.8 million as we were purchasing property and equipment.

Financing Activities

During the six months ended June 30, 2023, net cash used in financing activities of $16.2 million was primarily due to repaying the outstanding balance borrowed under the the Loan Agreement as well as related prepayment fees. Obtaining this financing during the six months ended June 30, 2022 resulted in the $14.8 million of net cash provided by financing activities in the previous year.

Funding Requirements

As of June 30, 2023, our cash and cash equivalents were $34.1 million. We believe that our existing cash on hand will enable us to fund our operating expenses and capital expenditure requirements into 2025. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. We expect to continue to incur significant losses for the foreseeable future as we attempt to realize the value of our intellectual property estate and other assets.

24


 

 

 

Material Cash Requirements

During the six months ended June 30, 2023, there were no other material changes to our material cash requirements from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” discussed in the 2022 10-K.

Critical Accounting Policies and Significant Judgments and Estimates

Our unaudited interim condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our unaudited interim condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis, and our actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the 2022 10-K.

Recently Issued Accounting Pronouncements

See Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.

Emerging Growth Company Status and Smaller Reporting Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. We expect to use the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

We will remain an emerging growth company until December 31, 2026 or, if earlier, (i) the last day of our first fiscal year in which we have total annual gross revenues of at least $1.235 billion, (ii) the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of interest rate sensitivities.

Interest Rate Sensitivity

As of June 30, 2023 and December 31, 2022, we had cash and cash equivalents of $34.1 million and $71.0 million, respectively. Our exposure to interest rate sensitivity is impacted by changes in the underlying U.S. bank interest rates. Our surplus cash has been invested in money market fund accounts as well as interest-bearing savings accounts from time to time. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our portfolio, and therefore, we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates.

25


 

 

 

We have been affected by market risk exposure primarily through the effect of changes in interest rates on amounts payable under the Loan Agreement. On January 25, 2023, we voluntarily prepaid all outstanding principal, accrued and unpaid interest, fees, costs and expenses under the Loan Agreement.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2023. Our disclosure controls and procedures are designed to ensure that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures, and is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Based on the evaluation of our disclosure controls and procedures as of June 30, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

 

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the six months ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations on Effectiveness of Controls

Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

 

26


 

 

 

PART II—OTHER INFORMATION

On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc., or, collectively, Rebiotix, filed a complaint against us in the U.S. District Court for the District of Delaware (the “Court”). The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by us: U.S. Patent Nos. 10,675,309, or the ’309 Patent; 10,463,702, or the ’702 Patent; 10,328,107, or the ’107 Patent; 10,064,899; 10,022,406, or the ’406 Patent; 9,962,413, or the ’413 Patent; and 9,308,226. On February 7, 2022, we filed an answer and counterclaims against Rebiotix for infringement of the ’107 Patent, the ’702 Patent, and the ’309 Patent. In June 2022, we alleged infringement of the ’406 Patent and ’413 Patent by Rebiotix. On March 7, 2022, we filed an amended answer and counterclaims, in which we, together with the Regents of the University of Minnesota, or UMN, alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to us: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012, or, collectively, the UMN Patents. On April 4, 2022, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the UMN Patents. On May 2, 2022, we and UMN responded, denying such counterclaims. The Court set a trial date for a five-day trial beginning on May 20, 2024. On January 23, 2023, we filed a second amended answer and counterclaims, in which we alleged infringement by Rebiotix of two additional U.S. Patents owned by us: U.S. Patent Nos. 11,541,080, or the ’080 Patent, and 11,491,193, or the ’193 Patent. On February 7, 2023 Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the ’080 and ’193 patents. The Court issued a claim construction order on February 28, 2023. On July 6, 2023, Rebiotix filed a motion to dismiss certain counts of our second amended answer and counterclaims based on the assertion that Finch lacks standing to sue as to ’107 Patent, ’702 Patent, ’309 Patent, ’406 Patent, ’413 Patent, ’193 Patent, and ’080 Patent. Rebiotix specifically alleges that the sole named inventor on these patents, Thomas J. Borody, did not assign his rights in those patents to Finch, and as a result, Finch does not own them and therefore does not have standing to assert them. Briefing on this motion is complete.

 

The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty.

 

We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.


There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 23, 2023, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.


 

27


 

 

 

Item 5. Other Information

None.

Item 6. Exhibits

 

 

 

 

Incorporated by Reference

Exhibit

Number

 

Description

 

Schedule

Form

 

File Number

 

Exhibit

 

Filing Date

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of Finch Therapeutics Group, Inc.

 

8-K

 

001-40227

 

3.1

 

March 23, 2021

3.2

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation.

 

8-K

 

001-40227

 

3.1

 

June 9, 2023

3.3

 

Amended and Restated Bylaws of Finch Therapeutics Group, Inc.

 

8-K

 

001-40227

 

3.2

 

March 23, 2021

10.1*#

 

Amendment to the Amended and Restated Exclusive License Agreement, dated as of April 12, 2023, between Finch Therapeutics Holdings LLC and Regents of the University of Minnesota.

 

 

 

 

 

 

 

 

10.2

 

Consulting Agreement, dated as of April 21, 2023, between Finch Therapeutics, Inc. and Matthew Blischak.

 

8-K

 

001-40227

 

10.1

 

April 25, 2023

10.3

 

Executive Employment Agreement, effective as of April 21, 2023, between Finch Therapeutics Group, Inc. and Matthew Blischak.

 

8-K

 

001-40227

 

10.2

 

April 23, 2023

10.4

 

Lease Termination Agreement, dated as of May 12, 2023, by and between the Company and NRL WCS 200 Inner Belt Prop, LLC.

 

8-K

 

001-40227

 

10.1

 

May18, 2023

10.5*†

 

2017 Equity Incentive Plan, as amended, and the forms of agreements thereunder.

 

 

 

 

 

 

 

 

10.6*†

 

2021 Equity Incentive Plan, as amended, and the forms of agreements thereunder.

 

 

 

 

 

 

 

 

10.7*†

 

2021 Employee Stock Purchase Plan, as amended.

 

 

 

 

 

 

 

 

31.1*

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

31.2*

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

32.1+

 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

101.INS*

 

Inline XBRL Instance Document

 

 

 

 

 

 

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

28


 

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

 

 

* Filed herewith.

# Certain confidential portions of this exhibit were omitted by means of marking such portions with brackets [***] because the identified confidential portions (i) are not material and (ii) is the type of information the Registrant treats as private or confidential.

† Indicates management contract or compensatory plan.

+ This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

29


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

FINCH THERAPEUTICS GROUP, INC.

Date: August 11, 2023

By:

/s/ Matthew P. Blischak

Matthew P. Blischak

President and Chief Executive Officer

(Principal Executive Officer)

 

Date: August 11, 2023

By:

/s/ Lance Thibault

Lance Thibault

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

30


EX-10.1 2 fnch-ex10_1.htm EX-10.1 EX-10.1

 

DocuSign Envelope ID: C23403EF-A3D5-465F-8315-7AD59052E3C4

Agreement #: A20120373

EXHIBIT 10.1

 

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions.

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

 

THIS FIRST AMENDMENT (this “Amendment”) to the EXCLUSIVE LICENSE AGREEMENT effective as of January 28, 2022 (the “Agreement”) is made as of the date of last signature below (“Amendment Date”) by and between Finch Therapeutics Holdings LLC, a Delaware limited liability company (“Licensee”), and the Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota (“University”).

 

WHEREAS, the parties desire to make certain amendments to the Agreement as set forth herein.

 

NOW THEREFORE, in consideration of the mutual covenants and promises contained in this Amendment, the parties hereby agree as follows:

 

1.
Defined Terms. Capitalized terms used in this Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.

 

2.
Amendments to Agreement. The Agreement is hereby amended as of the Amendment Date as follows:

 

a.
Amendment to Section 9 of Business Terms. Section 9 (Performance Milestones) of the Business Terms of the Agreement is hereby amended to read in full as follows:

 

Provided that a Regulatory Authority does not recommend or require unanticipated studies or prerequisites, including, without limitation, detailed characterization of control material for clinical trial use, as part of the regulatory approval process for obtaining a Licensed Product, Licensee (directly or indirectly by way of sublicense) shall achieve the following milestones. If the Regulatory Authority does recommend or require such unanticipated studies or prerequisites, the parties will negotiate in good faith extensions to the milestones to reflect additional time that may be needed to achieve the following:

 

(a)
[***];
(b)
[***]; and
(c)
[***].

 

 

1


 

DocuSign Envelope ID: C23403EF-A3D5-465F-8315-7AD59052E3C4

Agreement #: A20120373

[***].

 

b.
Amendment to Add Definition for Regulatory Authority. Subsection 1.1 (Definitions) of the General Terms of the Agreement is hereby amended to add the following definition:

 

Regulatory Authority” means, with respect to a Licensed Product, any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in the Territory, with authority over (a) the distribution, importation, exportation, manufacture, production, use, storage, transport, clinical testing or sale of the Licensed Product, including the United States Food and Drug Administration (“FDA”), European Medicines Agency, Therapeutic Goods Administration (Australia), Health Canada, and National Medical Products Administration (China), or (b) setting the price and/or reimbursement for the Licensed Product.

 

c.
Amendment to Subsection 10.1 of General Terms. Paragraph (b) of subsection

10.1 (University’s Right to Terminate for Breach) of the General Terms of the Agreement is hereby amended to replace “FDA” with “Regulatory Authority”.

 

3.
Ratification. Except to the extent expressly amended by this Amendment, all or the terms, provisions and conditions of the Agreement are hereby ratified and confirmed and shall remain in full force and effect. The term “Agreement”, as used in the License Agreement, shall henceforth be deemed to be a reference to the Exclusive License Agreement as novated and amended by this Amendment.

 

4.
Governing Law. For the avoidance of doubt, this Amendment (including any claim or controversy arising out of or relating to this Agreement) shall be governed by the law of Minnesota and subject to Section 14.1 of the Agreement.

 

5.
Further Assurances. Each of the parties agrees to perform (or procure the performance of) all further acts and things, and execute and deliver (or procure the execution and delivery of) such further documents, as may be required by law or as may be necessary or reasonably desirable to implement and/or give effect to this Amendment.

 

 

2


 

DocuSign Envelope ID: C23403EF-A3D5-465F-8315-7AD59052E3C4

Agreement #: A20120373

6.
Counterparts. This Amendment may be executed manually or by facsimile by the parties, in any number of counterparts, each of which shall be considered one and the same agreement and shall become effective when a counterpart hereof shall have been signed by each of the parties and delivered to each of the other parties.

 

 

 

 

THE PARTIES HEREBY EXECUTE THIS AMENDMENT

 

 

Regents of the University of Minnesota

Finch Therapeutics Holdings LLC

 

 

By:

/s/ Rick Heubsch

By:

/s/ Mark Smith

Name:

Rich Huebsch

Name:

Mark Smith

Title:

Executive Director

Title:

CEO

Date:

April 11, 2023

 

Date:

April 12, 2023

 

 

 

3


EX-10.5 3 fnch-ex10_5.htm EX-10.5 EX-10.5

 

EXHIBIT 10.5

 

FINCH THERAPEUTICS GROUP, INC.

2017 EQUITY INCENTIVE PLAN

 

AMENDED AND RESTATED AS OF: JUNE 8, 2023

 

1.
Definitions

 

As used in this 2017 Equity Incentive Plan, the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise:

1.1.
Accelerate,” “Accelerated,” and “Acceleration,” when used with respect to an Option, means that as of the time of reference such Option will become exercisable with respect to some or all of the shares of Common Stock for which it was not then otherwise exercisable by its term, and, when used with respect to Restricted Stock or Restricted Stock Units, means that as of the time of reference the Risk of Forfeiture otherwise still applicable to such shares of Restricted Stock or Restricted Stock Units shall expire or lapse.

 

1.2.
Acquiring Person” means, with respect to any Transaction or any acquisition described in clause (ii) of the definition of Change of Control, the surviving or acquiring person or entity in connection with such Transaction or acquisition, as the case may be, provided that if such surviving or acquiring person or entity is controlled, directly or indirectly, by an Ultimate Parent Entity, the term “Acquiring Person” shall mean such Ultimate Parent Entity.

 

1.3.
Affiliate” means, with respect to any person or entity, any other person or entity controlling, controlled by or under common control with the first person or entity.

 

1.4.
Ancillary Agreements” (i) that certain Voting Agreement, dated as of September 21, 2017, as amended, restated or modified from time to time, by and among the Company and the Company’s stockholders party thereto (the “Voting Agreement”), (ii) that certain Stockholders Agreement, dated as of September 21, 2017, as amended, restated or modified from time to time, by and among the Company and the Company’s stockholders party thereto, and (iii) that certain Right of First Refusal and Co-Sale Agreement, dated as of September 21, 2017, as amended, restated or modified from time to time, by and among the Company and the Company’s stockholders party thereto.

 

1.5.
Applicable Voting Control Percentage” means (i) at any time prior to the initial public offering of the Company, a percentage greater than fifty percent (50%) and (ii) at any time from and after the initial public offering of the Company, a percentage equal to or greater than twenty percent (20%).

 

1.6.
Award” means any grant or sale pursuant to the Plan of Options, Restricted Stock, Stock Grants or Restricted Stock Units.

 

1.7.
Award Agreement” means an agreement between the Company and the recipient of an Award, setting forth the terms and conditions of the Award.

 

1.8.
Beneficial Ownership” has the meaning ascribed to such term in Rule 13d-3, or any successor rule thereto, promulgated by the Securities and Exchange Commission pursuant to the Exchange Act.

 

1.9.
Board” means the Company’s board of directors.

 

1.10.
Change of Control” means (i) the closing of any Sale of the Company Transaction or (ii) the direct or indirect acquisition, in a single transaction or a series of related transactions, by any person or Group (other than the Company or a Controlled Affiliate of the Company) of Beneficial Ownership of

 


 

previously outstanding shares of capital stock of the Company if (A) immediately after such acquisition, such person or Group, together with their respective Affiliates, shall own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage of the total combined voting power of all outstanding classes and/or series of capital stock of the Company and (B) immediately prior to such acquisition, such person or Group, together with their respective Affiliates, did not own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage of the total combined voting power of all outstanding classes and/or series of capital stock of the Company. Notwithstanding anything expressed or implied in the foregoing provisions of this definition to the contrary, any direct or indirect acquisition referred to in clause (ii) above in this definition shall not be treated as a Change of Control if, at any time prior to or after such direct or indirect acquisition, a majority of the members of the Board as constituted immediately prior to such direct or indirect acquisition consent in writing to exclude such direct or indirect acquisition from the scope of this definition.

 

1.11.
Code” means the Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto, and any regulations issued from time to time thereunder.

 

1.12.
Controlled Affiliate” means, with respect to any person or entity, any other person or entity that is controlled by such person or entity.

 

1.13.
Committee” means any committee of the Board delegated responsibility by the Board for the administration of the Plan, as provided in Section 5 of the Plan, and which shall include at least one Board member designated by the Former Crestovo Holders (as defined in the Voting Agreement) and one Board member designated by the Former Finch Holders (as defined in the Voting Agreement). For any period during which no such committee is in existence, the term “Committee” shall mean the Board and all authority and responsibility assigned the Committee under the Plan shall be exercised, if at all, by the Board, and any action of the Board acting as the Committee shall require the affirmative vote at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders.

 

1.14.
Common Stock” means common stock, par value $0.001 per share, of the Company.

 

1.15.
Company” means Finch Therapeutics Group, Inc., a corporation organized under the laws of the State of Delaware.

 

1.16.
Grant Date” means the date as of which an Option is granted, as determined under Section 7.1(a).

 

1.17.
Exchange Act” means the Securities and Exchange Act of 1934, as amended.

 

1.18.
Group” has the meaning ascribed to such term in Section 13(d)(3) of the Exchange Act or any successor section thereto.

 

1.19.
Incentive Option” means an Option that by its terms is to be treated as an “incentive stock option” within the meaning of Section 422 of the Code.

 

1.20.
Market Value” means the fair market value of a share of Common Stock on a particular date as determined by the Committee.

 

1.21.
Non-statutory Option” means any Option that is not an Incentive Option.

 

1.22.
Option” means an option granted under the Plan to purchase shares of Common Stock.

 

 


 

1.23.
Optionee” means an employee, consultant, officer or director of the Company or any of its Affiliates to whom an Option shall have been granted under the Plan.

 

1.24.
Participant” means any holder of an outstanding Award under the Plan.

 

1.25.
Plan” means this 2017 Equity Incentive Plan of the Company, as amended and in effect from time to time.

 

1.26.
Restricted Stock” means a grant or sale of shares of Common Stock pursuant to the Plan to an employee, consultant, officer or director of the Company or any of its Affiliates if and to the extent that such grant or sale of such shares of Common Stock is made subject to a Risk of Forfeiture.

 

1.27.
Restricted Stock Unit” means a restricted stock unit granted under the Plan entitling the Participant to receive shares of Common Stock (or cash payment based on the value thereof).

 

1.27.
Restriction Period” means the period of time, established by the Committee in connection with an Award of Restricted Stock or Restricted Stock Units, during which such Restricted Stock or Restricted Stock Units are subject to a Risk of Forfeiture described in the applicable Award Agreement.

 

1.28.
Risk of Forfeiture” means a limitation on the right of a Participant to retain an Award of Restricted Stock or Restricted Stock Units arising because of the occurrence or non-occurrence of specified events or conditions described in the applicable Award Agreement, including, but not limited to, a limitation on the right of a Participant to retain an Award of Restricted Stock by virtue of any right granted or retained by the Company to reacquire all or any portion of such Restricted Stock at a purchase price less than the Market Value of the Restricted Stock at the time of such reacquisition arising by reason of the occurrence or non-occurrence of specified events or conditions.

 

1.29.
Sale of the Company Transaction” means any Transaction in which the stockholders of the Company immediately prior to such Transaction, together with any and all of such stockholders’ Affiliates, do not own or hold, immediately after consummation of such Transaction, shares of capital stock of the Acquiring Person in connection with such Transaction possessing at least a majority of the total voting power of the outstanding capital stock of such Acquiring Person.

 

1.30.
Securities Act” means the Securities Act of 1933, as amended.

 

1.31.
Stock Grant” a grant or sale of shares of Common Stock pursuant to the Plan to an employee, consultant, officer or director of the Company or any of its Affiliates if and to the extent that such grant or sale of such shares of Common Stock is made free from any Risk of Forfeiture.

 

1.32.
Stockholder Agreement” means one agreement, or, collectively, two or more agreements, as may be amended from time to time, by and among the Company and one or more stockholders of the Company (including, without limitation, any Participant or prospective Participant that became a stockholder of the Company as a result of the receipt, transfer, exercise or settlement of any Award) setting forth, among other provisions, restrictions on transfer, rights of first refusal, lock-up arrangements, bring-along rights, drag-along rights, voting agreements or the granting of certain proxies or powers of attorney with respect to shares of capital stock. Any and all provisions of this Plan that apply to any Stockholder Agreement shall be deemed to be applicable to any such agreement or agreements referred to in this definition even if such agreement or agreements are called or titled something other than Stockholder Agreement or Stockholders Agreement.

 

1.33.
Ten Percent Owner” means a person who owns, or is deemed within the meaning of Section 422(b)(6) of the Code to own, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (or any parent or subsidiary corporations of the Company, as defined in Section 424(e) and (f), respectively, of the Code). Whether a person is a Ten Percent Owner shall be determined

 


 

with respect to each Option based on the facts existing immediately prior to the Grant Date of such Option.

 

1.34.
Transaction” means any merger or consolidation of the Company with or into another person or entity or the sale or transfer of all or substantially all of the assets of the Company, in each case in a single transaction or in a series of related transactions.

 

1.35.
Ultimate Parent Entity” shall mean, with respect to any Person that is not an individual, any other Person that (i) directly or indirectly controls such Person and (ii) is not itself controlled, directly or indirectly, by one or more Persons that are not individuals.

 

2.
Purpose

 

This Plan is intended to encourage ownership of Common Stock by employees, consultants, officers and directors of the Company and its Affiliates and to provide additional incentive for them to promote the success of the Company’s business. The Plan is intended to be an incentive stock option plan within the meaning of Section 422 of the Code but not all Awards granted hereunder are required to be Incentive Options.

 

3.
Term of the Plan

 

Unless the Plan shall have been earlier terminated by the Board, Awards may be granted under this Plan at any time in the period commencing upon the date of approval of the Plan by the Board and ending immediately prior to the tenth anniversary of the earlier of the adoption of the Plan by the Board and the approval of the Plan by the Company’s stockholders. Awards granted pursuant to the Plan within such period shall not expire solely by reason of the termination of the Plan. Awards of Incentive Options granted prior to stockholder approval of the Plan are hereby expressly conditioned upon such approval, but in the event of the failure of the stockholders to approve the Plan shall thereafter and for all purposes be deemed to constitute Non-statutory Options.

 

4.
Stock Subject to the Plan

 

Subject to adjustment as provided in Section 8.1, at no time shall the number of shares of Common Stock issued pursuant to or subject to outstanding Awards under the Plan exceed Seven Hundred Fifty-Two Thousand Two Hundred Ninety (752,290) shares of Common Stock. For purposes of applying the foregoing limitation, (a) if any Option expires, terminates, or is cancelled for any reason without having been exercised in full, or if any Award of Restricted Stock or Restricted Stock Units is forfeited by a Participant, the shares of Common Stock not purchased upon exercise of such Option and/or any such Award of Restricted Stock or Restricted Stock Units so forfeited shall again be available for Awards thereafter to be granted under the Plan, and (b) if any Option is exercised by delivering previously owned shares of Common Stock in payment of the exercise price therefor, only the net number of shares, that is, the number of shares issued minus the number received by the Company in payment of the exercise price, shall be considered to have been issued pursuant to an Award granted under the Plan. Shares of Common Stock issued pursuant to the Plan may be either authorized but unissued shares or shares held by the Company in its treasury.

 

Subject to adjustment as provided in Section 8.1, the maximum number of shares of Common Stock which may be issued pursuant to Incentive Options under the Plan shall not exceed Seven Hundred Fifty Two Thousand Two Hundred Ninety (752,290) shares.

 

5.
Administration

 

The Plan shall be administered by the Committee by action thereof which shall require the affirmative vote at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders; provided, however, that at any time and on any one or more occasions the Board may itself exercise any of the powers and responsibilities assigned the Committee under the Plan and when so acting shall have the benefit of all of the provisions of the Plan pertaining to the Committee’s exercise of its authorities

 


 

hereunder; and provided further that the Committee may delegate to an executive officer or officers the authority to grant Awards hereunder to employees who are not officers, and to consultants, in accordance with such guidelines as the Committee shall set forth at any time or from time to time. Subject to the provisions of the Plan and the Ancillary Agreements, the Committee shall have complete authority, in its discretion, to make or to select the manner of making all determinations with respect to each Award to be granted by the Company under the Plan in addition to any other determination allowed the Committee under the Plan including, without limitation: (a) the employee, consultant, officer or director to receive the Award; (b) the form of Award; (c) whether an Option (if granted to an employee) will be an Incentive Option or a Non-statutory Option; (d) the time of granting an Award; (e) the number of shares subject to an Award; (f) the exercise price of an Option or purchase price, if any, for shares of Restricted Stock or for a Stock Grant and the method of payment of such exercise price or such purchase price; (g) the term of an Option; (h) the Restricted Period and the Risk of Forfeiture applicable to any Award of Restricted Stock or Restricted Stock Units as well as the Acceleration, if any, of such Restricted Period and Risk of Forfeiture; (i) the exercise date or dates of an Option as well as the Acceleration, if any, of such exercise date or dates; and (j) the effect of termination of any employment, consulting, officership or Board member relationship with the Company or any of its Affiliates on the subsequent exercisability of an Option or on the Risk of Forfeiture of Restricted Stock or Restricted Stock Units. In making such determinations, the Committee may take into account the nature of the services rendered by the respective employees, consultants, officers and directors, their present and potential contributions to the success of the Company and its Affiliates, and such other factors as the Committee in its discretion shall deem relevant. Subject to the provisions of the Plan and the Ancillary Agreements, the Committee shall also have complete authority to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it, to determine the terms and provisions of the respective Award Agreements (which need not be identical), and to make all other determinations necessary or advisable for the administration of the Plan. The Committee’s determinations made in good faith on matters referred to in this Plan shall be final, binding and conclusive on all persons having or claiming any interest under the Plan or an Award made pursuant hereto.

 

6.
Authorization and Eligibility

 

The Committee may grant from time to time and at any time prior to the termination of the Plan one or more Awards, either alone or in combination with any other Awards, to any employee of, or consultant to, one or more of the Company and its Affiliates or to any non-employee officer or member of the Board or of any board of directors (or similar governing authority) of any Affiliate. However, only employees of the Company or of any parent or subsidiary corporations of the Company, as defined in Sections 424(e) and (f), respectively, of the Code, shall be eligible for the grant of an Incentive Option.

 

Each grant of an Award shall be subject to all applicable terms and conditions of the Plan (including but not limited to any specific terms and conditions applicable to that type of Award set out in Section 7 below), and such other terms and conditions, not inconsistent with the terms of the Plan, as the Committee may prescribe. Except with respect to Options received pursuant to the Merger Agreement, no prospective Participant shall have any rights with respect to an Award, unless and until such Participant has executed an agreement evidencing the Award (or the transfer thereof to such Participant), delivered a fully executed copy thereof to the Company, and otherwise complied with the applicable terms and conditions of such Award.

 

7.
Specific Terms of Awards

 

7.1.
Options.

 

(a)
Date of Grant. The granting of an Option shall take place at the time specified in the Award Agreement. Only if expressly so provided in the applicable Award Agreement shall the Grant Date be the date on which the Award Agreement shall have been duly executed and delivered by the Company and the Optionee.

 

(b)
Exercise Price. The price at which shares of Common Stock may be acquired under each Option shall be not less than 100% of the Market Value of Common Stock on the Grant Date, or not less than 110%

 


 

of the Market Value of Common Stock on the Grant Date of an Incentive Option if the Optionee is a Ten Percent Owner.

 

(c)
Option Period. No Incentive Option may be exercised on or after the tenth anniversary of the Grant Date, or on or after the fifth anniversary of the Grant Date if the Optionee is a Ten Percent Owner. The Option period under each Non-statutory Option shall not be so limited solely by reason of this Section.

 

(d)
Exercisability. An Option may be immediately exercisable or become exercisable in such installments, cumulative or non-cumulative, as the Committee may determine. In the case of an Option not otherwise immediately exercisable in full, the Committee may Accelerate such Option in whole or in part at any time; provided, however, that in the case of an Incentive Option, any such Acceleration of such Incentive Option would not cause such Incentive Option to fail to comply with the provisions of Section 422 of the Code or the Optionee consents to such Acceleration.

 

(e)
Effect of Termination of Employment, Consulting, Officer or Board Member Relationship. Unless the Committee shall provide otherwise with respect to any Option, if the applicable Optionee’s association with the Company or any of its Affiliates as an employee, consultant, officer or director ends for any reason or no reason, regardless of whether the end of such association is effected by the Company, any such Affiliate or such Optionee (whether voluntarily or involuntarily, including because an entity with which such Optionee has any such association ceases to be an Affiliate of the Company), and immediately following the end of any such association, such Optionee is not associated with the Company or any of its Affiliates as an employee, consultant, officer or director, or if such Optionee dies (collectively, “Termination of Service”), then any outstanding Option initially granted to such Optionee, whether then held by such Optionee or any other Participant, shall cease to be exercisable in any respect and shall terminate on the ninetieth (90th) day following the end of such association or such death and, for the period it remains exercisable following the end of such association or such death, shall be exercisable only to the extent exercisable on the date of the end of such association or such death. Military or sick leave or other bona fide leave shall not be deemed a Termination of Service, provided that it does not exceed the longer of ninety (90) days or the period during which the absent Optionee’s reemployment rights, if any, are guaranteed by statute or by contract.

 

(f)
Transferability. Except as otherwise provided in this subsection (f), Options shall not be transferable, and no Option or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution (subject always to the provisions of subsection (e) above). Except as otherwise provided in this subsection (f), all of a Participant’s rights in any Option may be exercised during the life of such Participant only by such Participant or such Participant’s legal representative. The Committee may (at or after the grant of a Non-statutory Option) provide that a Non-statutory Option may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration whatsoever and that no transfer of a Non-statutory Option shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, “family member” means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant’s household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of Non-statutory Options to third parties pursuant to this subsection (f), which authorization shall be exercised by such officer or officers in accordance with guidelines established by any Committee at any time and from time to time.

 

 


 

(g)
Method of Exercise. An Option may be exercised by a Participant giving written notice, in the manner provided in Section 15, specifying the number of shares of Common Stock with respect to which the Option is then being exercised. The notice shall be accompanied by payment in the form of cash or check payable to the order of the Company in an amount equal to the exercise price of the shares of Common Stock to be purchased or, subject in each instance to the Committee’s approval, acting in its sole discretion and subject to such conditions, if any, as the Committee may deem necessary to comply with applicable laws, rules and regulations or to avoid adverse accounting effects to the Company, (i) by delivery to the Company of shares of Common Stock having a Market Value equal to the exercise price of the shares to be purchased, (ii) by delivery to the Company of the Participant’s executed promissory note in the principal amount equal to the exercise price of the shares to be purchased and otherwise in such form as the Committee shall have approved, (iii) by having the Company withhold a number of shares of Common Stock otherwise deliverable pursuant to exercise of the Option with such withheld shares having a Market Value equal to the exercise price of the shares to be purchased, or (iv) after the Common Stock is traded on an established market, through a cashless exercise program with a brokerage firm as authorized by the Company. Receipt by the Company of such notice and payment in any authorized or combination of authorized means shall constitute the exercise of the Option. Within thirty (30) days thereafter but subject to the remaining provisions of the Plan, the Company shall deliver or cause to be delivered to the Participant or his agent a certificate or certificates for the number of shares then being purchased. Such shares shall be fully paid and nonassessable. Notwithstanding any of the foregoing provisions in this subsection (g) to the contrary, (A) no Option shall be considered to have been exercised unless and until all of the provisions governing such exercise specified in the Plan and in the relevant Award Agreement shall have been duly complied with; and (B) the obligation of the Company to issue any shares upon exercise of an Option is subject to all of the applicable provisions of Section 9 hereof and to compliance by the applicable Optionee and the applicable Participant that is the then holder of such Option with all of the provisions of the Plan and the relevant Award Agreement.

 

(h)
Limit on Incentive Option Characterization. An Incentive Option shall be considered to be an Incentive Option only to the extent that the number of shares of Common Stock for which the Option first becomes exercisable in a calendar year do not have an aggregate Market Value (as of the date of the grant of the Option) in excess of the “current limit”. Except to the extent otherwise provided under applicable law or regulation, the current limit for any Optionee for any calendar year shall be $100,000 minus the aggregate Market Value at the date of grant of the number of shares of Common Stock available for purchase for the first time in the same year under each other Incentive Option previously granted to the Optionee under the Plan, and under each other incentive stock option previously granted to the Optionee under any other incentive stock option plan of the Company and its parent and subsidiary corporations (as defined in Sections 424(e) and (f) of the Code). Any shares of Common Stock which would cause the foregoing limit to be violated shall be deemed to have been granted under a separate Non-statutory Option, otherwise identical in its terms to those of the Incentive Option.

 

(i)
Notification of Disposition. Each person exercising any Incentive Option granted under the Plan shall be deemed to have covenanted with the Company to report to the Company any disposition of such shares prior to the expiration of the holding periods specified by Section 422(a)(1) of the Code and, if and to the extent that the realization of income in such a disposition imposes upon the Company federal, state, local or other withholding tax requirements, or any such withholding is required to secure for the Company an otherwise available tax deduction, to remit to the Company an amount in cash sufficient to satisfy those requirements.

 

(j)
Rights Pending Exercise. No person holding an Option shall be deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common Stock issuable pursuant to such Option, except to the extent that such Option shall have been exercised with respect thereto and, in addition, a certificate shall have been issued therefor and delivered to such person or his agent.

 

7.2.
Restricted Stock.

 

 


 

(a)
Purchase Price. Shares of Restricted Stock shall be issued under the Plan for such consideration, in cash, other property or services, or any combination thereof, as is determined by the Committee.

 

(b)
Issuance of Certificates. Subject to subsection (c) below, each Participant receiving an Award of Restricted Stock shall be issued a stock certificate in respect of such shares of Restricted Stock. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award substantially in the following form:

 

The transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Finch Therapeutics Group, Inc. Equity Incentive Plan and an Award Agreement entered into by the record owner of such shares and Finch Therapeutics Group, Inc., in each case as the same may be amended. Copies of such Plan and Award Agreement are on file in the offices of Finch Therapeutics Group, Inc.

 

(c)
Escrow of Shares. The Committee may require that the stock certificates evidencing shares of Restricted Stock be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock power, endorsed in blank, relating to the Common Stock covered by such Award.

 

(d)
Restrictions and Restriction Period. During the Restriction Period applicable to shares of Restricted Stock, such shares shall be subject to limitations on transferability and a Risk of Forfeiture arising on the basis of such conditions related to the performance of services, Company or Affiliate performance or otherwise as the Committee may determine and provide for in the applicable Award Agreement. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems appropriate.

 

(e)
Rights Pending Lapse of Risk of Forfeiture or Forfeiture of Award. Except as otherwise provided in the Plan or the applicable Award Agreement, at all times prior to lapse of any Risk of Forfeiture applicable to, or forfeiture of, an Award of Restricted Stock, the applicable Participant shall have all of the rights of a stockholder of the Company, including the right to vote the shares of Restricted Stock.

 

(f)
Effect of Termination of Employment, Consulting, Officer or Board Member Relationship. Unless otherwise determined by the Committee at or after an Award of Restricted Stock is made by the Company to any Participant and subject to the applicable provisions of the Award Agreement, if such Participant’s association with the Company or any of its Affiliates as an employee, consultant, officer or director ends for any reason or no reason during the Restriction Period, regardless of whether the end of such association is effected by the Company, any such Affiliate or such Participant (whether voluntarily or involuntarily, including because an entity with which such Participant has any such association ceases to be an Affiliate of the Company), and immediately following the end of any such association, such Participant is not associated with the Company or any of its Affiliates as an employee, consultant, officer or director, or if such Participant dies, then all outstanding shares of Restricted Stock initially awarded or sold to such Participant that are still subject to Risk of Forfeiture, whether then held by such Participant or any other Participant that is the direct or indirect transferee of such Participant, shall be forfeited or otherwise subject to return to or repurchase by the Company if and to the extent so provided by, and subject to and in accordance with, the terms of the applicable Award Agreement; provided, however, that military or sick leave or other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety (90) days or the period during which the absent Participant’s rights, if any, are guaranteed by statute or by contract.

 

(g)
Lapse of Restrictions. If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock, the certificates for such shares shall be delivered to the Participant promptly if not theretofore so delivered.

 

 


 

(h)
Transferability. Except as otherwise provided in this subsection (h), shares of Restricted Stock shall not be transferable during the applicable Restriction Period, and no share of Restricted Stock or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated during the applicable Restriction Period, other than by will or by the laws of descent and distribution (subject always to the provisions of subsection (f) above). The applicable Award Agreement or the Committee (at or after the grant of a share of Restricted Stock) may provide that such share of Restricted Stock may be transferred by the applicable Participant to a family member during the applicable Restriction Period; provided, however, that any such transfer is without payment of any consideration whatsoever and that no transfer of a share of Restricted Stock during the applicable Restriction Period shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, “family member” means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant’s household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of shares of Restricted Stock during the applicable Restriction Period to third parties pursuant to this subsection (h), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time.

 

7.3.
Stock Grants.

 

(a)
In General. Stock Grants shall be issued for such consideration, in cash, other property or services, or any combination thereof, as is determined by the Committee. Without limiting the generality of the foregoing, Stock Grants may be awarded in such circumstances as the Committee deems appropriate, including without limitation in recognition of significant contributions to the success of the Company or its Affiliates or in lieu of compensation otherwise already due. Stock Grants shall be made without forfeiture conditions of any kind.

 

(b)
Issuance of Certificates. Each Participant receiving a Stock Grant shall be issued a stock certificate in respect of such Stock Grant. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award substantially in the following form:

 

The transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Finch Therapeutics Group, Inc. 2017 Equity Incentive Plan, as the same may be amended. A copy of such Plan is on file in the offices of Finch Therapeutics Group, Inc.

 

7.4.
Restricted Stock Units.

 

(a)
In General. Each Restricted Stock Unit shall entitle the Participant to receive shares of Common Stock (or a cash payment based on the value of the shares) at the close of such Restriction Period (or such later period) as the Committee may establish and subject to a Risk of Forfeiture arising on the basis of such conditions relating to the performance of services, Company or Affiliate performance or otherwise as the Committee may determine and provide for in the applicable Award Agreement. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems appropriate.

 

(b)
Payment. Payment with respect to Restricted Stock Units may be made in shares of Common Stock, cash or in a combination thereof, as determined by the Committee.

 

 


 

(c)
Transferability. An Award of Restricted Stock Units (and shares of Common Stock subject to the Award) shall not be assignable or transferable prior to expiration of the Restriction Period applicable to the Award.

 

(d)
Stockholder Rights. The Participant shall not have any stockholder rights with respect to the shares of Common Stock subject to an Award of Restricted Stock Units until the shares of Common Stock are actually issued thereunder.

 

7.4.
Awards to Participants Outside the United States. The Committee may modify the terms of any Award under the Plan if the applicable Participant is, at the time of grant or award of such Award to such Participant or, if such Award is not initially granted or awarded to such Participant, at the time such Participant first acquires rights or any interest in such Award or at any time during the term of such Award, resident or primarily employed outside of the United States in any manner deemed by the Committee to be necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in which such Participant is then resident or primarily employed, or so that the value and other benefits of such Award to such Participant, as affected by foreign tax laws and other restrictions applicable as a result of such Participant’s residence or employment abroad, shall be comparable to the value of such an Award to a Participant who is resident or primarily employed in the United States. An Award may be modified under this Section 7.4 in a manner that is inconsistent with the express terms of the Plan, so long as such modifications will not contravene any applicable law or regulation. The Committee may establish supplements to, or amendments, restatements, or alternative versions of the Plan for the purpose of granting and administrating any such modified Award. No such modification, supplement, amendment, restatement or alternative version may increase the share limit of Section 4.

 

8.
Adjustment Provisions

 

8.1.
Adjustment for Corporate Actions. Subject to the provisions of Section 8.2, if at any time or from time to time after the date on which the Board has adopted this Plan, the outstanding shares of Common Stock (or any other securities covered by the Plan by reason of the prior application of this Section 8.1) are increased, decreased, or exchanged for a different number or kind of shares or other securities, or if additional shares or new or different shares or other securities are distributed with respect to such shares of Common Stock or other securities, through merger, consolidation, sale of all or substantially all the property of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, spin-off transaction, extraordinary distribution or other similar distribution with respect to such shares of Common Stock, or other securities, or if the value of the outstanding shares of Common Stock is substantially reduced by reason of a spinoff transaction or extraordinary distribution, the Committee shall have the discretion to make adjustments as the Committee may deem appropriate in (i) the maximum numbers and kinds of shares provided in Section 4, (ii) the numbers and kinds of shares or other securities subject to the then outstanding Awards, (iii) the exercise price for each share or other unit of any other securities subject to then outstanding Options (without change in the aggregate purchase price as to which such Options remain exercisable), and (iv) the repurchase price of each share of Restricted Stock then subject to a Risk of Forfeiture in the form of a Company repurchase right.

 

8.2.
Change of Control. Subject to the applicable provisions of the Award Agreement, in the event of a Change of Control, the Committee shall have the discretion, exercisable in advance of, at the time of, or (except to the extent otherwise provided below) at any time after, the Change of Control, to provide for any or all of the following (subject to and upon such terms as the Committee may deem appropriate): (A) the Acceleration, in whole or in part, of any or all outstanding Options (including such Awards that are assumed or replaced pursuant to clause (C) below) that are not exercisable in full at the time the Change of Control, such Acceleration to become effective at the time of the Change of Control, or at such time following the Change of Control that the employment, consulting, officer or Board member relationship of the applicable Optionee or Optionees (or of the Participant that is the then holder of any such Option) with the Company and its Affiliates (including, without limitation, the Acquiring Person or any of its Affiliates) terminates, or at such other time or times as the Committee shall determine; (B) the lapse or termination of the Risk of Forfeiture (including, without limitation, all or any (or any portion) of the Company’s

 


 

repurchase rights) with respect to outstanding Awards of Restricted Stock and Restricted Stock Units, such lapse or termination to become effective at the time of the Change of Control, or at such time following the Change of Control that the employment, consulting, officer or Board member relationship with the Company and its Affiliates (including, without limitation, the Acquiring Person or any of its Affiliates) of the Participant or Participants that hold such Awards of Restricted Stock (or the person to whom such Awards of Restricted Stock were initially made) terminates, or at such other time or times as the Committee shall determine; (C) the assumption of all or any (or any portion of) outstanding Awards, or the substitution of all or any (or any portion of) such outstanding Awards with equivalent awards, by the Acquiring Person or any of its Affiliates; or (D) the termination of all or any (or any portion of) Awards (other than Awards that are assumed or substituted pursuant to clause (C) above) that remain outstanding at the time of the consummation of the Change of Control, provided that, the Committee shall have made the determination to effect such termination prior to the consummation of the Change of Control and there has been or there will be full compliance with any applicable provisions set forth below in this Section 8.2 that may require in certain cases or under certain circumstances the payment of or provision of consideration to holders of Options terminated pursuant to the provisions of this clause (D), and provided, further, that, subject to and without limiting the provisions set forth in the next sentence, if the Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of such terminated Awards on account of such termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined, then the Company shall be required to make such payment or provide such consideration in accordance with the terms and conditions so determined by the Committee; otherwise, except if and to the extent otherwise provided in the next sentence, the Company shall not be required to make any payment or provide any consideration in connection with, or as a result of, the termination of Awards pursuant to the foregoing provisions of this clause (D). Notwithstanding anything express or implied in the foregoing provisions of this Section 8.2 to the contrary, in the event that the Committee elects, in its sole and absolute discretion, to terminate all or any (or any portion of) Options pursuant to the provisions of the foregoing clause (D) and the Committee does not provide to any Participant that is a holder of an Option any portion of which is both exercisable immediately prior to the applicable Change of Control and to be terminated pursuant to the provisions of the foregoing clause (D) (each, a “Terminated Vested Option”) at least five (5) business days prior written notice of such potential termination thereof, then, prior to the consummation of such applicable Change of Control, the Committee shall ensure that adequate provision has been made so that the Company, the Acquiring Person or any of their respective Affiliates is legally obligated to make payment or provide consideration on account of such termination to such holder of such Terminated Vested Option that was not provided such prior written notice of termination, which payment or consideration shall consist of the difference between (x) the cash, stock, securities, other property or other consideration that would have been received in connection with such applicable Change of Control by such holder of such Terminated Vested Option that was not provided such prior written notice of termination if such holder had exercised such Terminated Vested Option immediately prior to such applicable Change of Control (or cash, stock, securities, other property or other consideration having a fair market value (as determined by the Committee in good faith) equal to the cash, stock, securities, other property or other consideration to which such holder of such Terminated Vested Option would otherwise be entitled under this clause (x)) and (y) the aggregate exercise price with respect to such Terminated Vested Option. The Committee shall have the authority to provide that any escrow, holdback, earn-out or similar provisions in the agreement effecting the Change of Control will apply to any cash payment made pursuant to this Section 8.2 to the same extent and in the same manner as such provisions apply to a holder of a share of Common Stock. The provisions of this Section 8.2 shall not be construed as to limit or restrict in any way the Committee’s general authority under Sections 7.1(d), 7.2(d) or 7.3(a) hereof to Accelerate Options in whole or in part at any time or to waive or terminate at any time any Risk of Forfeiture applicable to shares of Restricted Stock and Restricted Stock Units. Each outstanding Award, or portion thereof, that is assumed in connection with a Change of Control, or is otherwise to continue in effect subsequent to a Change of Control, will be appropriately adjusted, immediately after the Change of Control, as to the number and class of securities and, for an Option, the price at which it may be exercised in accordance with Section 8.1.

 

8.3.
Dissolution or Liquidation. Upon dissolution or liquidation of the Company, each outstanding Option shall terminate, but each Participant shall have the right, immediately prior to such dissolution or liquidation, to

 


 

exercise any and all Options held by such Participant to the extent such Options are exercisable on the date of such dissolution or liquidation.

 

8.4.
Related Matters. Any adjustment in Awards made pursuant to this Section 8 shall be determined and made, if at all, by the Committee and shall include any correlative modification of terms, including exercise prices, rates of vesting or exercisability, Risks of Forfeiture and applicable repurchase prices, which the Committee may deem necessary or appropriate so as to ensure that the rights of the Participants in their respective Awards are not substantially diminished nor enlarged as a result of the adjustment and corporate action other than as expressly contemplated in this Section 8. No fraction of a share shall be purchasable or deliverable upon exercise, but in the event any adjustment hereunder of the number of shares covered by an Award shall cause such number to include a fraction of a share, such number of shares shall be adjusted to the nearest smaller whole number of shares. No adjustment of an Option exercise price per share pursuant to this Section 8 shall result in an exercise price that is less than the par value of the Common Stock.

 

8.5.
Substitute Awards. Awards may, in the discretion of the Committee, be granted under the Plan in assumption or substitution for outstanding awards previously granted by an entity acquired by the Company or any Affiliate or with which the Company or any Affiliate merges, amalgamates or combines (such Awards, “Substitute Awards”). The number of Shares underlying any Substitute Awards shall not be counted against the aggregate number of Shares (under Section 4) that may be delivered pursuant to Awards granted under the Plan and the exercise price of any Options granted as Substitute Awards may be less than the Market Value of the Common Stock as of the Grant date.

 

9.
Settlement of Awards

 

9.1.
Violation of Law. Notwithstanding any other provision of the Plan or the relevant Award Agreement, if, at any time, in the reasonable opinion of the Company, the issuance of shares of Common Stock covered by an Award may constitute a violation of law, then the Company may delay such issuance and the delivery of a certificate for such shares until (i) approval shall have been obtained from such governmental agencies, other than the Securities and Exchange Commission, as may be required under any applicable law, rule, or regulation and (ii) in the case where such issuance would constitute a violation of a law administered by or a regulation of the Securities and Exchange Commission, one of the following conditions shall have been satisfied:

 

(a)
the shares are at the time of the issue of such shares effectively registered under the Securities Act; or

 

(b)
the Company shall have determined, on such basis as it deems appropriate (including an opinion of counsel in form and substance satisfactory to the Company) that the sale or issuance of such shares does not require registration under the Securities Act or any applicable state securities laws.

 

9.2.
Corporate Restrictions on Rights in Stock. Any Common Stock to be issued pursuant to Awards shall be subject to all restrictions upon the transfer thereof that may be now or hereafter imposed by the Certificate of Incorporation, the By-laws of the Company and the Ancillary Agreements, each as amended and in effect from time to time. Whenever Common Stock is to be issued pursuant to an Award, unless the Committee otherwise so directs at the time of the grant (or, if such Award is an Option, at any time prior to the exercise thereof), the Company shall be under no obligation, notwithstanding any other provision of the Plan or the relevant Award Agreement to the contrary, to issue such Common Stock until such time, if ever, as the applicable Participant or prospective Participant shall have become a party to and bound by any agreement (including, without limitation, the Ancillary Agreements and any Stockholder Agreement) that the Committee, in its sole discretion, shall require that such Participant or prospective Participant enter into prior to, and as a condition to, the issuance of such Common Stock by the Company to such Participant or prospective Participant.

 

9.3.
Investment Representations. The Company shall be under no obligation to issue any shares covered by an Award unless such have been effectively registered under the Securities Act or the Participant shall have

 


 

made such written representations to the Company (and upon which the Company believes it may reasonably rely) as the Company may deem necessary or appropriate for purposes of confirming that the issuance of such shares will be exempt from the registration requirements of that Act and any applicable state securities laws and otherwise in compliance with all applicable laws, rules and regulations, including but not limited to that the Participant is acquiring shares for his or her own account for the purpose of investment and not with a view to, or for sale in connection with, the distribution of any such shares.

 

9.4.
Registration. If the Company shall deem it necessary or desirable to register under the Securities Act or other applicable statutes any shares of Common Stock issued or to be issued pursuant to Awards, or to qualify any such shares of Common Stock for exemption from the Securities Act or other applicable statutes, then the Company shall take such action at its own expense. The Company may require from each recipient of an Award, or each holder of shares of Common Stock acquired pursuant to the Plan, such information in writing for use in any registration statement, prospectus, preliminary prospectus or offering circular as is reasonably necessary for such purpose and may require reasonable indemnity to the Company and its officers and directors from such holder against all losses, claims, damage and liabilities arising from such use of the information so furnished and caused by any untrue statement of any material fact therein or caused by the omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made.

 

9.5.
Lock-Up. If, in connection with any underwritten public offering of securities of the Company, the Company sends written notice to each Participant stating that the restrictions on transfer set forth in this Section 9.5 are applicable to such underwritten public offering, no Participant shall sell, make any short sale of, loan, grant any option for the purchase of, pledge or otherwise encumber, or otherwise dispose of, any shares of Common Stock or any Awards during the one hundred-eighty (180) day period (and which period may be extended as requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) commencing on the effective date of any registration statement relating to such underwritten public offering, unless the Company has granted its prior written consent to any such sale, short sale, loan, grant of option, pledge, other encumbrance or other disposition. The foregoing restrictions are intended and shall be construed so as to preclude any Participant from engaging in any hedging or other transaction that is designed to or reasonably could be expected to lead to or result in, a sale or disposition of any shares of Common Stock during such period even if such shares of Common Stock are or would be disposed of by someone other than such Participant. Such prohibited hedging or other transactions would include, without limitation, any short sale (whether or not against the box) or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any shares of Common Stock or with respect to any security that includes, relates to, or derives any significant part of its value from any shares of Common Stock. Without limiting the generality and applicability of the foregoing provisions of this Section 9.5, if, in connection with any underwritten public offering of securities of the Company, the managing underwriter of such offering requires that the Company’s then current directors and officers enter into a lock-up agreement, then (a) each Participant (regardless of whether or not such Participant has complied or complies with the provisions of clause (b) below) shall be bound by, and shall be deemed to have agreed to, the same lock-up terms as those to which the Company’s directors and officers are required to adhere; and (b) at the request of the Company or such managing underwriter, each Participant shall execute and deliver a lock-up agreement in form and substance equivalent to that which is required to be executed by the Company’s then current directors and officers.

 

9.6.
Placement of Legends; Stop Orders; etc. Each share of Common Stock to be issued pursuant to Awards may bear a reference to the investment representations made in accordance with Section 9.3 in addition to any other applicable restrictions under the Plan, the terms of the Award and, if applicable, under any Stockholder Agreement or any other agreement between the Company and any Participant, and to the fact that no registration statement has been filed with the Securities and Exchange Commission in respect to such shares of Common Stock. All shares of Common Stock or other securities delivered under the Plan (as well as all certificates representing such shares of Common Stock or other securities) shall be subject to

 


 

such stop-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities law, and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions.

 

9.7.
Tax Withholding. Whenever shares of Common Stock are issued or to be issued pursuant to Awards, the Company shall have the right to require the recipient to remit to the Company an amount sufficient to satisfy federal, state, local or other withholding tax requirements if, when, and to the extent required by law (whether so required to secure for the Company an otherwise available tax deduction or otherwise) prior to the delivery of any certificate or certificates for such shares (or other payment). The obligations of the Company under the Plan shall be conditional on satisfaction of all such withholding obligations and the Company shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the recipient of an Award. However, in such cases Participants may elect, subject to the approval of the Committee, acting in its sole and absolute discretion, to satisfy an applicable withholding requirement, in whole or in part, by having the Company withhold shares otherwise issuable under the Award to satisfy their tax obligations. Participants may only elect to have shares of Common Stock withheld having a Market Value on the date the tax is to be determined equal to the minimum statutory total tax which could be imposed on the transaction (or such other rate as determined by the Committee). All elections shall be irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitations that the Committee deems appropriate.

 

10.
Reservation of Stock

 

The Company shall at all times during the term of the Plan and any outstanding Options granted hereunder reserve or otherwise keep available such number of shares of Common Stock as will be sufficient to satisfy the requirements of the Plan (if then in effect) and such Options and shall pay all fees and expenses necessarily incurred by the Company in connection therewith.

 

11.
No Special Service Rights

 

Nothing contained in the Plan or in any Award Agreement shall confer upon any recipient of an Award any right with respect to the continuation of his or her employment, consulting, officer or Board member relationship or other association with the Company (or any Affiliate), or interfere in any way with the right of the Company (or any Affiliate), subject to the terms of any separate employment, consulting, officer or Board member agreement or provision of law or corporate articles or by-laws to the contrary, at any time to terminate such employment, consulting, officer or Board member agreement or to increase or decrease, or otherwise adjust, the other terms and conditions of the recipient’s employment, consulting or Board member relationship or other association with the Company and its Affiliates.

 

12.
Nonexclusivity of the Plan

 

Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders of the Company shall be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including without limitation, the granting of stock options, restricted stock and stock grants other than under the Plan, and such arrangements may be either applicable generally or only in specific cases.

 

13.
Termination and Amendment of the Plan

 

The Board, which shall include the affirmative vote of at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders, may at any time terminate the Plan or make such amendments or modifications of the Plan as it shall deem advisable. In the event of the termination of the Plan, the terms of the Plan shall survive any such termination with respect to any Award that is outstanding on the date of such termination, unless the holder of such Award agrees in writing to terminate

 


 

such Award or to terminate all or any of the provisions of the Plan that apply to such Award. Unless the Board otherwise expressly provides, any amendment or modification of the Plan shall affect the terms of any Award outstanding on the date of such amendment or modification as well as the terms of any Award made from and after the date of such amendment or modification; provided, however, that except to the extent otherwise provided in the last sentence of this paragraph, (i) no amendment or modification of the Plan shall apply to any Award that is outstanding on the date of such amendment or modification if such amendment or modification would reduce the number of shares subject to such Award, increase the purchase price applicable to shares subject to such Award or materially adversely affect the provisions applicable to such Award that relate to the vesting or exercisability of such Award or of the shares subject to such Award, (ii) no amendment or modification of the Plan shall apply to any Incentive Option that is outstanding on the date of such amendment or modification if such amendment or modification would result in such Incentive Option no longer being treated as an “incentive stock option” within the meaning of Section 422 of the Code and (iii) no amendment or modification of the Plan shall apply to any Award that is outstanding on the date of such amendment or modification unless such amendment or modification of the Plan shall also apply to all other Awards outstanding on the date of such amendment or modification (except for those Awards to whom such amendment or modification is not applicable by virtue of the provisions of the foregoing clause (ii) hereof). In the event of any amendment or modification of the Plan that is described in clause (i), (ii) or (iii) of the foregoing proviso, such amendment or modification of the Plan shall apply to any Award outstanding on the date of such amendment or modification only if the recipient of such Award consents in writing thereto.

 

The Committee, which shall include the affirmative vote of at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders, may amend or modify, prospectively or retroactively, the terms of any outstanding Award without amending or modifying the terms of the Plan itself, provided that as amended or modified such Award is consistent with the terms of the Plan as in effect at the time of the amendment or modification of such Award, but no such amendment or modification of such Award shall, without the written consent of the recipient of such Award, reduce the number of shares subject to such Award, increase the purchase price applicable to shares subject to such Award, adversely affect the provisions applicable to such Award that relate to the vesting or exercisability of such Award or of the shares subject to such Award, or otherwise materially adversely affect the terms of such Award (except for amendments or modifications to the terms of such Award or of the stock subject to such Award that are expressly permitted by the terms of the Plan or that result from any amendment or modification of the Plan in accordance with the provisions of the first paragraph of this Section 13 or that are permitted by the provisions set forth below in this Section 13), or, if such Award is an Incentive Option, result in such Incentive Option no longer being treated as an “incentive stock option” within the meaning of Section 422 of the Code. Notwithstanding any of the foregoing provisions of this paragraph to the contrary, the Committee, which shall include the affirmative vote of at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders, is expressly authorized to amend any or all outstanding Options to effect a repricing thereof by lowering the purchase price applicable to the shares of Common Stock subject to such Option or Options without the approval of the stockholders of the Company or the holder or holders of such Option or Options, and, in connection with such repricing, to amend or modify any of the other terms of the Option or Options so repriced, including, without limitation, for purposes of reducing the number of shares subject to such Option or Options or for purposes of adversely affecting the provisions applicable to such Option or Options that relate to the vesting or exercisability thereof, in each case without the approval of stockholders of the Company or the holder or holders of such Option or Options.

 

In addition, notwithstanding anything express or implied in any of the foregoing provisions of this Section 13 to the contrary, the Committee may amend or modify, prospectively or retroactively, the terms of any outstanding Award to the extent the Committee reasonably determines necessary or appropriate to conform such Award to the requirements of Section 409A of the Code (concerning non-qualified deferred compensation), if applicable.

 

14.
Interpretation of the Plan

 

In the event of any conflict between the provisions of this Plan and the provisions of any Ancillary Agreement, the provisions of the Ancillary Agreement shall control. In the event of any conflict between the provisions of this Plan and the provisions of any applicable Award Agreement, the provisions of this Plan shall control,

 


 

except if and to the extent that the conflicting provision in such Award Agreement was authorized and approved by the Committee, which shall include the affirmative vote of at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders, at the time of the grant of the Award evidenced by such Award Agreement or is ratified by the Committee, which shall include the affirmative vote of at least one Board member designated by the Former Crestovo Holders and one Board member designated by the Former Finch Holders, at any time subsequent to the grant of such Award, in which case the conflicting provision in such Award Agreement shall control. Without limiting the generality of the foregoing provisions of this Section 14, insofar as possible the provisions of the Plan and such Award Agreement shall be construed so as to give full force and effect to all such provisions. In the event of any conflict between the provisions of this Plan and the provisions of any applicable Stockholder Agreement (other than any of the Ancillary Agreements) or other agreement between the Company and the applicable Participant, the provisions of such Stockholder Agreement or other agreement shall control except as required to fulfill the intention that this Plan constitute an incentive stock option plan within the meaning of Section 422 of the Code, but insofar as possible the provisions of the Plan and any such Stockholder Agreement or other agreement shall be construed so as to give full force and effect to all such provisions.

 

15.
Notices and Other Communications

 

Any notice, demand, request or other communication hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person or duly sent by first class mail or overnight courier, postage prepaid, or telecopied with a confirmation copy by first class mail or overnight courier, addressed or telecopied, as the case may be, (i) if to the recipient of an Award, at his or her residence address last filed with the Company and (ii) if to the Company, at its principal place of business, addressed to the attention of its Chief Executive Officer, or to such other address or telecopier number, as the case may be, as the addressee may have designated by notice to the addressor. All such notices, requests, demands and other communications shall be deemed to have been received: (i) in the case of personal delivery, on the date of such delivery; (ii) in the case of mailing, five (5) days after having been sent by first class mail, postage prepaid; (iii) in the case of overnight courier, one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery; and (iv) in the case of facsimile transmission, when sent and confirmed by facsimile machine report, if sent by facsimile transmission during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day.

 

16.
Governing Law

 

The Plan and all Award Agreements and actions taken thereunder shall be governed, interpreted and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof.

 

17.
Adoption of Plan

 

This 2017 Equity Incentive Plan was originally approved and adopted as of September 21, 2017, by the Board of Directors and as of September 21, 2017, by the Stockholders.

 

[The remainder of this page is intentionally left blank.]

 

 

 


 

ATTACHMENT A

TO

2017 EQUITY INCENTIVE PLAN

Provisions Applicable to Award Recipients

Resident in California

 

Until such time as the Company’s Common Stock has been effectively registered under the Securities Act and if required by any applicable law, the following additional terms shall apply to Awards, and Stock issued pursuant to such Awards, granted under the Plan to persons resident in California as of the date of grant of the Award (each such person, a “California Recipient”). Capitalized terms not defined in this Attachment shall have the respective meanings set forth in the Plan.

 

1. No Option or other right to acquire Stock pursuant to an Award issued to any California Recipient, that is otherwise transferable pursuant to the terms of the Plan, shall be transferable other than by gift or domestic relations order to an immediate family member as that term is defined under applicable California and Federal securities law or to a revocable trust (or by will or the laws of descent and distribution).

 

2. No Option may have an exercise period of more than 10 years from the Grant Date of the Option.

 

3. The following limitations shall apply to the early expiration of Options granted California Recipients on account of termination of employment (unless employment is terminated for cause as defined by applicable law):

 

(a) Subject to Section 2(b) below, in the event the employment or other association with the Company and its Affiliates of an Optionee who is a California Resident is terminated, whether voluntary or otherwise and including on account of an entity ceasing to be an Affiliate of the Company, such California Recipient shall have at least thirty (30) days after the date of such termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to exercise such Option to the extent exercisable as of the date of such termination.

 

(b) In the event that the employment or association with the Company and its Affiliates of an Optionee who is a California Resident is terminated as a result of death or disability, such California Recipient shall have at least six (6) months after the date of such termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to exercise such Option to the extent exercisable as of the date of such termination.

 

4. The Plan must be approved by a majority of the outstanding securities entitled to vote within twelve (12) months before or after the later of (i) the date the Plan is adopted by the Company and (ii) the date on which any Option or other Award is granted to a California Recipient.

 

5. Notwithstanding anything to the contrary in Section 8.1 of the Plan, the Committee shall in any event make adjustments to the number of shares and the purchase price of Awards as may be required by Section 25102(o) of the California Corporations Code.

 

 

 


 

FINCH THERAPEUTICS GROUP, INC.

2017 EQUITY INCENTIVE PLAN

EXERCISE NOTICE

Finch Therapeutics Group, Inc.

200 Inner Belt Road

Somerville, MA 02143

 

To:

Finch Therapeutics Groups, Inc.

 

 

Re:

Exercise of the Option(s)

 

1. Exercise of Option. Effective as of today, , , the undersigned (“Participant”) hereby irrevocably elects to exercise Participant’s option (the “Option”) to purchase ________________ shares of the Common Stock (the “Shares”) of Finch Therapeutics Group, Inc. (the “Company”) under and pursuant to the Company’s 2017 Equity Incentive Plan (the “Plan”) and the Stock Option Agreement dated ______________, _ (the “Option Agreement”). Capitalized terms used but not otherwise defined herein shall have the meaning as defined in the Plan.

 

2. Delivery of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option.

 

3. Representations of Participant. Participant acknowledges that Participant has received, read and understood the Plan, the Option Agreement and agrees to abide by and be bound by their terms and conditions. In particular, the Participant acknowledges that: (i) the ability to sell or otherwise transfer the shares of Company Common Stock subject to the Option (the “Option Shares”) is substantially limited; (ii) any Option Shares that are still subject to Risk of Forfeiture shall be forfeited or subject to return to or repurchase by the Company (or its designee) in the event of a termination of any employment, consulting, officership or Board membership with the Company or any of its Affiliates; and (iii) the Option Shares may be subject to call rights and draft along rights of the Company.

 

4. Rights as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement.

 

5. Tax Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax advice.

 

6. Successors and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.

 

7. Interpretation. Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the Committee, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Committee shall be final and binding on all parties.

 

8. Governing Law; Severability. This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of the Commonwealth of Massachusetts. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice shall continue in full force and effect.

 

9. Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement, the Voting Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior

 


 

undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and Participant.

 

 

 

 

Submitted by:

PARTICIPANT

Signature

Print Name

Address:

 

Accepted by:

FINCH THERAPEUTICS GROUP, INC.

By

Print Name

Title

Address:

Date Received

 

 

 


 

img120795611_0.jpg 

FINCH THERAPEUTICS GROUP, INC.

STOCK OPTION AGREEMENT

 

1. Grant of Option. Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), hereby grants to Optionee, as of the Grant Date, an Option to purchase up to the number of Option Shares specified in the Grant Notice. The Option Shares shall be purchasable from time to time during the Option term specified in Paragraph 2 at the Exercise Price.

 

2. Option Term. The Option shall have a term of ten (10) years measured from the Grant Date and shall accordingly expire at the close of business on the Expiration Date, unless sooner terminated in accordance with the Company’s 2017 Equity Incentive Plan (the “Plan”) (including, without limitation, Section 7.1(e) of the Plan pursuant to which, except in certain circumstances specified in such Section 7.1(e), the Option shall cease to be exercisable and terminate [According to Carta] days after Optionee’s service with the Company ends for any reason or no reason).

 

3. Limited Transferability. The Option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s death and may be exercised, during Optionee’s lifetime, only by Optionee.

 

4. Dates of Exercise. The Option shall become exercisable in one or more installments as specified in Grant Notice. As the Option becomes exercisable for such installments, those installments shall accumulate and the Option shall remain exercisable for the accumulated installments until the Expiration Date or sooner termination of the Option term under the Plan.

 

5. Stockholder Rights. The holder of the Option shall not have any stockholder rights with respect to the Option Shares until such person shall have exercised the Option, paid the Exercise Price and become the record holder of the purchased shares.

 

6. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of the Optionee.

 

7. Construction. This Agreement and the Option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan, including, but not limited to, the limitations set forth in Section 9 of the Plan on the Company’s obligation to deliver Option Shares upon exercise of the Option.

 

8. Code 409A Waiver and Release.

 

(a) Optionee hereby agrees and acknowledges that the Board has taken reasonable steps to value the Company’s common stock and to set the Exercise Price at the fair market value per share of common stock on the Grant Date so that the Option will not be treated as an item of deferred compensation subject to Code Section 409A. However, because the common stock is not readily tradable on an established securities market, there can be no assurance that the Exercise Price is at least equal to the fair market value per share of common stock on the Grant Date. Were the Internal Revenue Service to conclude that the Exercise Price is in fact less than such fair market value and that the Option is accordingly subject to Code Section 409A, then Optionee would be subject to the following adverse tax consequences:

 

(i) As the Option vests and becomes exercisable, Optionee would immediately recognize taxable income for federal income tax purposes equal to the amount by which the fair market value of the Option Shares which vest at that time exceeds the Exercise Price payable for those shares. The Company would also have to collect from Optionee the federal income and employment taxes which must be withheld on that income. Taxation would occur in this manner even though the Option remains unexercised.

 

 


 

(ii) Optionee may also be subject to additional income taxation and withholding taxes on any subsequent increases to the fair market value of the Option Shares purchasable under the vested Option until the Option is exercised or cancelled as to those Option Shares.

 

(iii) In addition to normal income taxes payable as the Option vests, Optionee would also be subject to an additional tax penalty equal to 20% of the amount of income Optionee recognizes under Code Section 409A when the Option vests and may also be subject to such penalty as the underlying Option Shares subsequently increase in fair market value over the period the Option continues to remain outstanding.

 

(iv) There will also be interest penalties if the resulting taxes are not paid on a timely basis.

 

(b) Optionee hereby further agrees and acknowledges that Optionee may incur the same or similar tax consequences, including (without limitation) a second penalty tax, under state income tax laws. Optionee accepts the risk of any unfavorable tax consequences under applicable state laws to options granted with an Exercise Price less than the fair market value of the Option Shares on the Grant Date.

 

(c) Optionee hereby agrees to bear the entire risk of such adverse federal and state tax consequences in the event the Option is deemed to be subject to Code Section 409A and hereby knowingly and voluntarily, in consideration for the grant of the Option, waives and releases any and all claims or causes of action that Optionee might otherwise have against the Company and/or its Board, officers, employees or stockholders arising from or relating to the tax treatment of the Option under Code Section 409A and the corresponding provisions of any applicable state income tax laws and shall not seek any indemnification or other recovery of damages against the Company and/or its Board, officers, employees or stockholders with respect to any adverse federal and state tax consequences or other related costs and expenses Optionee may in fact incur under Code Section 409A (or the corresponding provisions of state income tax laws) as a result of the Option.

 

9. Definitions. The following definitions shall be in effect under the Agreement; any term not defined hereunder shall have the meaning assigned to such term in the Grant Notice or the Plan.

 

(a) Agreement shall mean this Stock Option Agreement.

 

(b) Code shall mean the Internal Revenue Code of 1986, as amended.

 

(c) Exercise Price shall mean the exercise price payable per Option Share as specified in the Grant Notice.

 

(d) Expiration Date shall mean the date on which the Option expires as specified in the Grant Notice.

 

(e) Grant Date shall mean the date of grant of the Option as specified in the Grant Notice.

 

(f) Grant Notice shall mean the Notice of Grant of Stock Option accompanying the Agreement, pursuant to which Optionee has been informed of the basic terms of the Option evidenced hereby.

 

(g) Option Shares shall mean the number of shares of common stock subject to the Option.

 

(h) Optionee shall mean the person to whom the Option is granted as specified in the Grant Notice.

 

10. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of you. Capitalized terms used but not defined herein shall have the meaning assigned under the Plan. This Agreement may be executed in one or more counterparts all of which together shall constitute but one instrument.

 

IN WITNESS WHEREOF, the parties have executed this Agreement as a sealed instrument as of the date first above written.

 


 

 

FINCH THERAPEUTICS GROUP, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Print Name of Optionee

 

 

 

 

By:

 

 

 

 

 

 

Name:

 

 

 

Signature of Optionee

Title:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Optionee’s Address:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Optionee’s Email:

 

 

 

 

 

 

 

 

 

 

 

 

 


EX-10.6 4 fnch-ex10_6.htm EX-10.6 EX-10.6

EXHIBIT 10.6

FINCH THERAPEUTICS GROUP, INC.

2021 EQUITY INCENTIVE PLAN

ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021

APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021

IPO DATE: MARCH 18, 2021

AMENDED AND RESTATED AS OF: JUNE 8, 2023

 

1.
GENERAL.

 

(a)
Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.

 

(b)
Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock Options; (iii) SARs; (iv) Restricted Stock Awards; (v) RSU Awards; (vi) Performance Awards; and (vii) Other Awards.

 

(c)
Adoption Date; Effective Date. The Plan came into existence on the Adoption Date, but no Award was granted prior to the Effective Date.

 

2.
SHARES SUBJECT TO THE PLAN.

 

(a)
Share Reserve. Subject to adjustment in accordance with Section 2(c) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 176,381 shares, which number is the sum of: (i) 156,666 new shares, plus (ii) a number of shares of Common Stock equal to the number of Returning Shares, if any, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5.0% of the total number of shares of Common Stock outstanding on December 31 of the preceding year; provided, however, that the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock.

 

(b)
Aggregate Incentive Stock Option Limit. Notwithstanding anything to the contrary in Section 2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 470,000 shares.

 


(c)
Share Reserve Operation.

 

(i)
Limit Applies to Common Stock Issued Pursuant to Awards. For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.

 

(ii)
Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve. The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued, (2) the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than Common Stock), (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award.

 

(iii)
Reversion of Previously Issued Shares of Common Stock to Share Reserve. The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2) any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award.

 

3.
ELIGIBILITY AND LIMITATIONS.

 

(a)
Eligible Award Recipients. Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.

 

(b)
Specific Award Limitations.

 

(i)
Limitations on Incentive Stock Option Recipients. Incentive Stock Options may be granted only to Employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and (f) of the Code).

 

(ii)
Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with

such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).

 

(iii)
Limitations on Incentive Stock Options Granted to Ten Percent Stockholders. A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i) the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (ii) the Option is not exercisable after the expiration of five years from the date of grant of such Option.

 

(iv)
Limitations on Nonstatutory Stock Options and SARs. Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company (as such term is defined in Rule 405) unless the stock underlying such Awards is treated as “service recipient stock” under Section 409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section 409A.

 

(c)
Aggregate Incentive Stock Option Limit. The aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section 2(b).

 

(d)
Non-Employee Director Compensation Limit. The aggregate value of all compensation granted or paid, as applicable, in each case following the IPO Date, to any individual for service as a Non-Employee Director with respect to any fiscal year, including Awards granted and cash fees paid by the Company to such Non-Employee Director for his or her service as a Non-Employee Director, will not exceed (i) $750,000 in total value or (ii) in the event such Non-Employee Director is first appointed or elected to the Board during such fiscal year, $1,000,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes.

 

4.
OPTIONS AND STOCK APPRECIATION RIGHTS.

 

Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated, or if such Nonstatutory Stock Option fails to qualify as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:

 

(a)
Term. Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.

 

(b)
Exercise or Strike Price. Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price

lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.

 

(c)
Exercise Procedure and Payment of Exercise Price for Options. In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:

 

(i)
by cash or check, bank draft or money order payable to the Company;

 

(ii)
pursuant to a “cashless exercise” program developed under Regulation T as promulgated by the U.S. Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;

 

(iii)
by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;

 

(iv)
if the Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or

 

(v)
in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.

 

(d)
Exercise Procedure and Payment of Appreciation Distribution for SARs. In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR. Such appreciation distribution may

be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.

 

(e)
Transferability. Options and SARs may not be transferred to third party financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer:

 

(i)
Restrictions on Transfer. An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant’s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable U.S. state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.

 

(ii)
Domestic Relations Orders. Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order.

 

(f)
Vesting. The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company, vesting of Options and SARs will cease upon termination of the Participant’s Continuous Service.

 

(g)
Termination of Continuous Service for Cause. Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company, if a Participant’s Continuous Service is terminated for Cause, the Participant’s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.

 

(h)
Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause. Subject to Section 4(i), if a Participant’s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):

 

(i)
three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant’s Disability or death);

 


(ii)
12 months following the date of such termination if such termination is due to the Participant’s Disability;

 

(iii)
18 months following the date of such termination if such termination is due to the Participant’s death; or

 

(iv)
18 months following the date of the Participant’s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).

 

Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.

 

(i)
Restrictions on Exercise; Extension of Exercisability. A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company, if a Participant’s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i) the exercise of the Participant’s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company’s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).

 

(j)
Non-Exempt Employees. No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant’s death or Disability, (ii) a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant’s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company’s then current employment policies and guidelines). This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.

 

(k)
Whole Shares. Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.

 

5.
AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS.

 

(a)
Restricted Stock Awards and RSU Awards. Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:

 

(i)
Form of Award.

 

(1)
RSAs: To the extent consistent with the Company’s Bylaws, at the Board’s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company’s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award.

 

(2)
RSUs: An RSU Award represents a Participant’s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company’s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).

 

(ii)
Consideration.

 

(1)
RSA: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration as the Board may determine and permissible under Applicable Law.

 

(2)
RSU: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the Participant’s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant’s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.

 

(iii)
Vesting. The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant’s Continuous Service.

 

(iv)
Termination of Continuous Service. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company, if a Participant’s Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (ii) any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.

 

(v)
Dividends and Dividend Equivalents. Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement).

 

(vi)
Settlement of RSU Awards. An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.

 

(b)
Performance Awards. With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board.

 

(c)
Other Awards. Other Awards may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.

6.
ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

 

(a)
Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section 2(a), (ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 2(b), and (iii) the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this Section.

 


(b)
Dissolution or Liquidation. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.

 

(c)
Corporate Transaction. The following provisions will apply to Awards in the event of a Corporate Transaction, and unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.

 

(i)
Awards May Be Assumed. In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor’s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board.

 

(ii)
Awards Held by Current Participants. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the “Current Participants”), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction. With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction.

 

(iii)
Awards Held by Persons other than Current Participants. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or

continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction or such later date as required to comply with Section 409A of the Code.

 

(iv)
Payment for Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection with such exercise.

 

(d)
Appointment of Stockholder Representative. As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant’s behalf with respect to any escrow, indemnities and any contingent consideration.

 

(e)
No Restriction on Right to Undertake Transactions. The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.

 

7.
ADMINISTRATION.

 

(a)
Administration by Board. The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in subsection (c) below.

 

(b)
Powers of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

 

(i)
To determine from time to time: (1) which of the persons eligible under the Plan will be granted Awards; (2) when and how each Award will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award that is not valued in whole or in part by reference to, or

otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment.

 

(ii)
To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.

(iii)
To settle all controversies regarding the Plan and Awards granted under it.

 

(iv)
To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.

 

(v)
To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.

 

(vi)
To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.

 

(vii)
To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.

 

(viii)
To submit any amendment to the Plan for stockholder approval.

 

(ix)
To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that, a Participant’s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.

 

(x)
Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.

 


(xi)
To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are non-U.S. nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant non-U.S. jurisdiction).

 

(xii)
To effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1) the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2) the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A) a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B) cash and/or (C) other valuable consideration (as determined by the Board); or (3) any other action that is treated as a repricing under generally accepted accounting principles.

 

(c)
Delegation to Committee.

 

(i)
General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated.

 

(ii)
Rule 16b-3 Compliance. To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available.

 

(d)
Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

 

(e)
Delegation to an Officer. The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award

Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.

 

8.
TAX WITHHOLDING.

 

(a)
Withholding Authorization. As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy any U.S. and/or non-U.S. federal, state, or local tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.

 

(b)
Satisfaction of Withholding Obligation. To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. and/or non-U.S. federal, state, or local tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a “cashless exercise” pursuant to a program developed under Regulation T as promulgated by the U.S. Federal Reserve Board, or (vi) by such other method as may be set forth in the Award Agreement.

 

(c)
No Obligation to Notify or Minimize Taxes; No Liability to Claims. Except as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the “fair market value” of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the U.S. Internal Revenue Service asserts that such exercise price or strike price is less than the “fair market value” of the Common Stock on the date of grant as subsequently determined by the U.S. Internal Revenue Service.

 

(d)
Withholding Indemnification. As a condition to accepting an Award under the Plan, in the event that the amount of the Company’s and/or its Affiliate’s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to

indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.

 

9.
MISCELLANEOUS.

 

(a)
Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.

 

(b)
Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.

 

(c)
Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.

(d)
Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.

 

(e)
No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or non-U.S. jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.

 

(f)
Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)

make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.

 

(g)
Execution of Additional Documents. As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator’s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator’s request.

 

(h)
Electronic Delivery and Participation. Any reference herein or in an Award Agreement to a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.

 

(i)
Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant’s right to voluntarily terminate employment upon a “resignation for good reason,” or for a “constructive termination” or any similar term under any plan of or agreement with the Company.

 

(j)
Securities Law Compliance. A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.

 

(k)
Transfer or Assignment of Awards; Issued Shares. Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.

 

(l)
Effect on Other Employee Benefit Plans. The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant’s benefits under any employee benefit plan sponsored by the

Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

 

(m)
Deferrals. To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section 409A.

 

(n)
Section 409A. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A is a “specified employee” for purposes of Section 409A, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant’s “separation from service” or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.

 

(o)
Choice of Law. This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware.

 

10.
COVENANTS OF THE COMPANY.

 

(a)
Compliance with Law. The Company will seek to obtain from each regulatory commission or agency, as may be deemed necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.

 

11.
ADDITIONAL RULES FOR AWARDS SUBJECT TO SECTION 409A.

 


(a)
Application. Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award.

 

(b)
Non-Exempt Awards Subject to Non-Exempt Severance Arrangements. To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply.

 

(i)
If the Non-Exempt Award vests in the ordinary course during the Participant’s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31st of the calendar year that includes the applicable vesting date, or (ii) the 60th day that follows the applicable vesting date.

 

(ii)
If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant’s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant’s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60th day that follows the date of the Participant’s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to “specified employees,” as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant’s Separation from Service, or, if earlier, the date of the Participant’s death that occurs within such six month period.

 

(iii)
If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant’s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant’s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).

 

(c)
Treatment of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants. The provisions of this subsection (c) shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.

 

(i)
Vested Non-Exempt Awards. The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:

 

(1)
If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award. Upon the Section 409A

Change in Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control.

 

(2)
If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.

 

(ii)
Unvested Non-Exempt Awards. The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to subsection (e) of this Section.

 

(1)
In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.

 

(2)
If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate Transaction.

 

(3)
The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section 409A Change in Control.

 


(d)
Treatment of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors. The following provisions of this subsection (d) shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Corporate Transaction.

 

(i)
If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award. Upon the Section 409A Change in Control the vesting and settlement of any Non-Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control pursuant to the preceding provision.

 

(ii)
If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction.

 

(e)
If the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:

 

(i)
Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.

 

(ii)
The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).

 

(iii)
To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section 409A Change in Control. To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a “separation from service” such Participant is subject to the distribution limitations contained in Section 409A applicable to “specified employees,” as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before

the date that is six months following the date of the Participant’s Separation From Service, or, if earlier, the date of the Participant’s death that occurs within such six month period.

 

(iv)
The provisions in this subsection (e) for delivery of the shares in respect of the settlement of an RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.

 

12.
SEVERABILITY.

 

If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

 

13.
TERMINATION OF THE PLAN.

 

The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i) the Adoption Date, or (ii) the date the Plan is approved by the Company’s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

 

14.
DEFINITIONS. As used in the Plan, the following definitions apply to the capitalized terms indicated below:

 

(a)
Acquiring Entity” means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.

 

(b)
Adoption Date” means March 11, 2021.

 

(c)
Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.

 

(d)
Applicable Law” means shall mean the Code and any applicable U.S. or non-U.S. securities, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).

 


(e)
Award” means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award).

 

(f)
Award Agreement” means a written or electronic agreement between the Company and a Participant evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through electronic means, to a Participant along with the Grant Notice.

 

(g)
Board” means the board of directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants.

 

(h)
Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the date the plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

 

(i)
Cause has the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) the Participant’s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or intentional falsification of any Company or Affiliate documents or records; (ii) the Participant’s material failure to abide by the Company’s Code of Conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct and policies of any Affiliate, as applicable); (iii) the Participant’s unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset or corporate opportunity of the Company or any of its Affiliates (including, without limitation, the Participant’s improper use or disclosure of Company or Affiliate confidential or proprietary information); (iv) any intentional act by the Participant which has a material detrimental effect on the Company’s or its Affiliate’s reputation or business; (v) the Participant’s repeated failure or inability to perform any reasonable assigned duties after written notice from the Company (or its Affiliate, as applicable) of, and a reasonable opportunity to cure, such failure or inability; (vi) any material breach by the Participant of any employment or service agreement between the Participant and the Company (or its Affiliate, as applicable), which breach is not cured pursuant to the terms of such agreement; or (vii) the Participant’s conviction (including any plea of guilty or nolo contendere) of any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs the Participant’s ability to perform his or her duties with the Company (or its Affiliate, as applicable). The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company’s Chief Executive Officer or his or her designee with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.

 


(j)
Change in Control” or “Change of Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

 

(i)
any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;

 

(ii)
there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;

 

(iii)
there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or

 

(iv)
individuals who, on the date the Plan is adopted by the Board, are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.

 

Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event


described in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the payment not to violate Section 409A of the Code.

 

(k)
Code” means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

 

(l)
Committee” means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan.

 

(m)
Common Stock” means the common stock of the Company.

 

(n)
Company” means Finch Therapeutics Group, Inc., a Delaware corporation, and any successor corporation thereto.

 

(o)
Compensation Committee” means the Compensation Committee of the Board.

 

(p)
Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s securities to such person.

 

(q)
Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.

 

Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of “separation from service” as defined


under U.S. Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).

 

(r)
Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

 

(i)
a sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries;

 

(ii)
a sale or other disposition of at least 50% of the outstanding securities of the Company;

 

(iii)
a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

 

(iv)
a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

 

Notwithstanding the foregoing or any other provision of this Plan, (A) the term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Corporate Transaction (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event described in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the payment not to violate Section 409A of the Code.

 

(s)
Director” means a member of the Board.

 

(t)
determine or determined means as determined by the Board or the Committee (or its designee) in its sole discretion.

 

(u)
Disability” means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.

 

(v)
Effective Date” means the IPO Date.

 

(w)
Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

 

(x)
Employer” means the Company or the Affiliate that employs the Participant.

 


(y)
Entity” means a corporation, partnership, limited liability company or other entity.

 

(z)
Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

(aa)
Exchange Act Person means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.

 

(bb)
Fair Market Value” means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows:

 

(i)
If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.

 

(ii)
If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.

 

(iii)
In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.

 

(cc)
Governmental Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) U.S. or non-U.S. federal, state, local, municipal, or other government; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).

 

(dd)
Grant Notice” means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.

 

(ee)
Incentive Stock Option” means an option granted pursuant to Section 4 of the Plan that is intended to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.

 

(ff)
IPO Date” means March 18, 2021.

 

(gg)
Materially Impair means any amendment to the terms of the Award that materially adversely affects the Participant’s rights under the Award. A Participant’s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights. For example, the following

types of amendments to the terms of an Award do not Materially Impair the Participant’s rights under the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option that may be exercised, (ii) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iii) to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iv) to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section 409A; or (v) to comply with other Applicable Laws.

 

(hh)
Non-Employee Director means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.

 

(ii)
Non-Exempt Award means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company or (ii) the terms of any Non-Exempt Severance Agreement.

 

(jj)
Non-Exempt Director Award” means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date.

 

(kk)
Non-Exempt Severance Arrangement” means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant’s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (“Separation from Service”) and such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.

 

(ll)
Nonstatutory Stock Option” means any option granted pursuant to Section 4 of the Plan that does not qualify as an Incentive Stock Option.

 

(mm)
Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.

 

(nn)
Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.

 

(oo)
Option Agreement” means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan.

 

(pp)
Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

 

(qq)
Other Award” means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) that is not an Incentive Stock Options, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award.

 

(rr)
Other Award Agreement means a written or electronic agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.

 

(ss)
Own, Owned, Owner, Ownership means that a person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

 

(tt)
Participant” means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.

 

(uu)
Performance Award” means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.

 

(vv)
Performance Criteria” means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or average stockholder’s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders’ equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; pre-clinical development related compound goals; financing; regulatory milestones, including approval of a compound; stockholder liquidity; corporate governance and compliance; product commercialization; intellectual property; personnel matters; progress of internal research or clinical programs; progress of partnered programs; partner satisfaction; budget management; clinical achievements; completing phases of a clinical study (including the treatment phase); announcing or presenting preliminary or final data from clinical studies; in each case, whether on particular timelines or generally; timely completion of clinical trials; submission of INDs and NDAs and other regulatory achievements; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; research progress, including the development of programs; investor relations, analysts and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable objectives related to process development activities); strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property; establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Company’s products (including with group purchasing organizations, distributors and other vendors); supply chain achievements (including establishing relationships with manufacturers or suppliers of active pharmaceutical ingredients and other component materials and manufacturers of the Company’s products); co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee.

 

(ww)
Performance Goals” means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments,

and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of Common Stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company’s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award.

 

(xx)
Performance Period” means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.

 

(yy)
Plan” means this Finch Therapeutics Group, Inc. 2021 Equity Incentive Plan, as amended from time to time.

 

(zz)
Plan Administrator” means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company’s other equity incentive programs.

 

(aaa)
Post-Termination Exercise Period” means the period following termination of a Participant’s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).

 

(bbb)
Prior Plan” means the Company’s 2017 Equity Incentive Plan.

 

(ccc)
Restricted Stock Award” or “RSA” means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).

 

(ddd)
Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.

 


(eee)
Returning Shares” means shares subject to outstanding stock awards granted under the Prior Plan and that following the Effective Date: (A) are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued; (B) are not issued because such stock award or any portion thereof is settled in cash; (C) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares; (D) are withheld or reacquired to satisfy the exercise, strike or purchase price; or (E) are withheld or reacquired to satisfy a tax withholding obligation.

(fff)
RSU Award” or “RSU means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).

 

(ggg)
RSU Award Agreement means a written or electronic agreement between the Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan.

 

(hhh)
Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

 

(iii)
Rule 405” means Rule 405 promulgated under the Securities Act.

 

(jjj)
Section 409A” means Section 409A of the Code and the regulations and other guidance thereunder.

 

(kkk)
Section 409A Change in Control” means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company’s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).

 

(lll)
Securities Act” means the U.S. Securities Act of 1933, as amended.

 

(mmm)
Share Reserve” means the number of shares available for issuance under the Plan as set forth in Section 2(a).

 

(nnn)
Stock Appreciation Right” or “SAR means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 4.

 

(ooo)
SAR Agreement” means a written or electronic agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan.

 

(ppp)
Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding Common Stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.

 


(qqq)
Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.

 

(rrr)
Trading Policy” means the Company’s policy permitting certain individuals to sell Company shares only during certain “window” periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.

 

(sss)
Unvested Non-Exempt Award” means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction.

 

(ttt)
Vested Non-Exempt Award” means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction.

 

 


FINCH THERAPEUTICS GROUP, INC.

GLOBAL STOCK OPTION GRANT NOTICE

(2021 EQUITY INCENTIVE PLAN)

Finch Therapeutics Group, Inc. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan and the Global Stock Option Agreement, including any additional terms and conditions for your country set forth in the appendix thereto (the “Appendix and, together with the Global Stock Option Agreement, the “Agreement”), all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement, as applicable.

 

 

 

 

 

 

 

 

Optionholder:

 

 

 

 

Date of Grant:

 

 

 

 

Vesting Commencement Date:

 

 

 

 

Number of Shares of Common Stock Subject to Option:

 

 

 

 

Exercise Price (Per Share):

 

 

 

 

Total Exercise Price:

 

 

 

 

Expiration Date:

 

 

 

 

 

 

Type of Grant:

 

[Incentive Stock Option] OR [Nonstatutory Stock Option]

 

 

Exercise and

Vesting Schedule:

 

Subject to the Optionholder’s Continuous Service through each applicable vesting date, the Option will vest as follows:

 

 

 

 

[__________]

Optionholder Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:

 

 

The Option is governed by this Global Stock Option Grant Notice, (the “Grant Notice”) and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the “Option Agreement”) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.

 

 

 

If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option.

 

 

 

You consent to receive this Grant Notice, the Agreement, the Plan, the Prospectus and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 

 

 

You have read and are familiar with the provisions of the Plan, the Agreement, and the Prospectus. In the event of any conflict between the provisions in this Grant Notice, the Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.

 

 

 

The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option.

 

 

 

 

Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other


 

 

 

transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

 

 

 

 

 

 

 

 

 

FINCH THERAPEUTICS GROUP, INC.

 

 

 

OPTIONHOLDER:

 

 

 

 

By:

 

 

 

 

 

 

 

 

Signature

 

 

 

Signature

Title:

 

 

 

 

 

Date:

 

 

 

 

 

 

 

Date:

 

 

 

 

 

 

 

 

 

 

 


FINCH THERAPEUTICS GROUP, INC.

2021 EQUITY INCENTIVE PLAN

GLOBAL STOCK OPTION AGREEMENT

As reflected by your Global Stock Option Grant Notice (“Grant Notice”) Finch Therapeutics Group, Inc. (the “Company”) has granted you an option under its 2021 Equity Incentive Plan (the “Plan”) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the “Option”). The terms of your Option as specified in the Grant Notice and this Global Stock Option Agreement, including any additional terms and conditions for your country set forth in the appendix hereto (the “Appendix” and, together with the Global Stock Option Agreement, the “Agreement”), constitute your Option Agreement. Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable.

The general terms and conditions applicable to your Option are as follows:

1. GOVERNING PLAN DOCUMENT. Your Option is subject to all the provisions of the Plan. Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.

2. EXERCISE.

a. You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission. Please review the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.

b. To the extent permitted by Applicable Law, you may pay your Option exercise price as follows:

1) cash, check, bank draft or money order;

2) subject to Applicable Law and Company and/or Committee consent at the time of exercise, pursuant to a “cashless exercise” program as further described in the Plan if at the time of exercise the Common Stock is publicly traded;

3) subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in the Plan; or

4) subject to Applicable Law and Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a “net exercise” arrangement as further described in the Plan.

3. TERM. You may not exercise your Option before the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires upon the earliest of the following:

a. immediately upon the termination of your Continuous Service for Cause;

b. three months after the termination of your Continuous Service for any reason other than Cause, Disability or death;

c. 12 months after the termination of your Continuous Service due to your Disability;

d. 18 months after your death if you die during your Continuous Service;

e. immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction,

f. the Expiration Date indicated in your Grant Notice; or

g. the day before the 10th anniversary of the Date of Grant.

Notwithstanding the foregoing, if you die during the period provided in Section 3(b) or 3(c) above, the term of your Option shall not expire until the earlier of (i) eighteen months after your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant. Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in the Plan.

To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option and ending on the day three months before the date of your Option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. If the Company provides for the extended exercisability of your Option under certain circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment terminates.

4. RESPONSIBILITY FOR TAXES.


a. Regardless of any action taken by the Company or, if different, the Affiliate to which you provide Continuous Service (the “Service Recipient”) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account, or other tax-related items associated with the grant, vesting or exercise of the Option or sale of the underlying Common Stock or other tax-related items related to your participation in the Plan and legally applicable or deemed applicable to you (the “Tax Liability”), you hereby acknowledge and agree that the Tax Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld by the Company or the Service Recipient. You further acknowledge that the Company and the Service Recipient (i) make no representations or undertakings regarding any Tax Liability in connection with any aspect of this Option, including, but not limited to, the grant, vesting or exercise of the Option, the issuance of Common Stock pursuant to such exercise, the subsequent sale of shares of Common Stock, and the payment of any dividends on the shares; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your Tax Liability or achieve a particular tax result. Further, if you are subject to Tax Liability in more than one jurisdiction, you acknowledge that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax Liability in more than one jurisdiction.

b. Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or the Service Recipient to satisfy all Tax Liability. As further provided in Section 8 of the Plan, you hereby authorize the Company and any applicable Service Recipient to satisfy any applicable withholding obligations with regard to the Tax Liability by one or a combination of the following methods: (i) causing you to pay any portion of the Tax Liability in cash or cash equivalent in a form acceptable to the Company and/or the Service Recipient; (ii) withholding from any compensation otherwise payable to you by the Company or the Service Recipient; (iii) withholding from the proceeds of the sale of shares of Common Stock issued upon exercise of the Option (including by means of a “cashless exercise” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company, or by means of the Company acting as your agent to sell sufficient shares of Common Stock for the proceeds to satisfy such withholding requirements, on your behalf pursuant to this authorization without further consent); (iv) withholding shares of Common Stock otherwise issuable to you upon the exercise of the Option, provided, however, that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Company’s Compensation Committee; and/or (v) any other method determined by the Company to be in compliance with Applicable Law. Furthermore, you agree to pay or reimburse the Company or the Service Recipient any amount the Company or the Service Recipient may be required to withhold, collect or pay as a result of your participation in the Plan or that cannot be satisfied by the means previously described. In the event it is determined that the amount of the Tax Liability was greater than the amount withheld by the Company and/or the Service Recipient (as applicable), you agree to indemnify and hold the Company and/or the Service Recipient (as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold the proper amount.

c. The Company and/or the Service Recipient may withhold or account for your Tax Liability by considering statutory withholding amounts or other withholding rates applicable in your jurisdiction(s), including (i) maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash from the Company or the Service Recipient (with no entitlement to the Common Stock equivalent), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay any Tax Liability directly to the applicable tax authority or to the Company and/or the Service Recipient. If the Tax Liability withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to the exercised portion of the Option, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying such Tax Liability.

d. You acknowledge that you may not be able to exercise your Option even though the Option is vested, and that the Company shall have no obligation to issue or deliver shares of Common Stock until you have fully satisfied any applicable Tax Liability, as determined by the Company. Unless any withholding obligation for the Tax Liability is satisfied, the Company shall have no obligation to issue or deliver to you any Common Stock in respect of the Option.

5. INCENTIVE STOCK OPTION DISPOSITION REQUIREMENT. If your option is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the date of your option grant or within one year after such shares of Common Stock are transferred upon exercise of your option.

6. NATURE OF GRANT. In accepting the Option, you acknowledge, understand and agree that:

a. the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

b. the grant of the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Options, or benefits in lieu of Options, even if Options have been granted in the past;

c. all decisions with respect to future Options or other grants, if any, will be at the sole discretion of the Company;

d. the Option and your participation in the Plan shall not create a right to employment or other service relationship with the Company;


e. the Option and your participation in the Plan shall not be interpreted as forming or amending an employment or service contract with the Company or the Service Recipient, and shall not interfere with the ability of the Company or the Service Recipient, as applicable, to terminate your Continuous Service (if any);

f. you are voluntarily participating in the Plan;

g. the Option and the shares of Common Stock subject to the Option, and the income from and value of same, are not intended to replace any pension rights or compensation;

h. the Option and the shares of Common Stock subject to the Option, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

i. unless otherwise agreed with the Company in writing, the Option and the shares of Common Stock subject to the Option, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate;

j. the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty;

k. if the underlying shares of Common Stock do not increase in value after the grant date, the Option will have no value;

l. if you exercise the Option and acquire shares of Common Stock, the value of such shares of Common Stock may increase or decrease in value, even below the exercise price;

m. no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from the termination of your Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are providing service or the terms of your employment or other service agreement, if any);

n. for purposes of the Option, your Continuous Service will be considered terminated as of the date you are no longer actively providing services to the Company or any Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are providing service or the terms of your employment or other service agreement, if any), and such date will not be extended by any notice period (e.g., your period of Continuous Service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are providing service or the terms of your employment or other service agreement, if any); the Compensation Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of your Option (including whether you may still be considered to be providing services while on a leave of absence); and

o. neither the Company nor the Service Recipient shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to exercise of the Option or the subsequent sale of any shares of Common Stock acquired upon exercise.

7. TRANSFERABILITY. Except as otherwise provided in the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.

8. CORPORATE TRANSACTION. Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.

9. NO LIABILITY FOR TAXES. As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to any Tax Liability arising from the Option and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section 409A only if the exercise price is at least equal to the “fair market value” of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option. Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less than the “fair market value” of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.

10. OBLIGATIONS; RECOUPMENT. You hereby acknowledge that the grant of your Option is additional consideration for any obligations (whether during or after employment) that you have to the Company not to compete, not to solicit its customers, clients or employees, not to disclose or misuse confidential information or similar obligations. Accordingly, if the Company reasonably determines that you breached such obligations, in addition to any other available remedy, the Company may, to the extent permitted by Applicable Law, recoup any income realized by you with respect to the exercise of your Option within two


years of such breach. In addition, to the extent permitted by Applicable Law, this right to recoupment by the Company applies in the event that your employment is terminated for Cause or if the Company reasonably determines that circumstances existed that it could have terminated your employment for Cause.

11. NO ADVICE REGARDING GRANT. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying shares of Common Stock. You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.

12. GOVERNING LAW AND VENUE. The Option and the provisions of this Agreement are governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the conflict of law principles that would result in any application of any law other than the law of the State of Delaware. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement, relating to it, or arising from it, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of the State of Delaware, and no other courts, where this grant is made and/or to be performed.

13. SEVERABILITY. If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

14. INDEBTEDNESS TO THE COMPANY. In the event that you have any loans, draws, advances or any other indebtedness owing to the Company at the time of exercise of all or a portion of the Option, the Company may deduct and not deliver that number of shares of Common Stock with a Fair Market Value subject to the Option equal to such indebtedness to satisfy all or a portion of such indebtedness, to the extent permitted by law and in a manner consistent with Section 409A of the Code, if applicable.

15. COMPLIANCE WITH LAW. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the shares of Common Stock, the Company shall not be required to deliver any shares issuable upon exercise of the Option prior to the completion of any registration or qualification of the shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. You understand that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares. Further, you agree that the Company shall have unilateral authority to amend the Agreement without your consent to the extent necessary to comply with securities or other laws applicable to issuance of shares of Common Stock.

16. LANGUAGE. You acknowledge that you are proficient in the English language, or have consulted with an advisor who is proficient in the English language, so as to enable you to understand the provisions of this Agreement and the Plan. If you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

17. ELECTRONIC DELIVERY AND PARTICIPATION. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

18. SEVERABILITY. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

19. APPENDIX. Notwithstanding any provisions in this Option Agreement, the Option shall be subject to any additional terms and conditions set forth in any Appendix for your country. Moreover, if you relocate to one of the countries included in the Appendix, the additional terms and conditions for such country will apply to you, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Agreement.

20. IMPOSITION OF OTHER REQUIREMENT. The Company reserves the right to impose other requirements on your participation in the Plan, on the Option and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

21. WAIVER. You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other participant.

22. INSIDER TRADING/MARKET ABUSE. You acknowledge that, depending on your or your broker’s country or where the Company shares are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your


ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares (e.g., Options) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company as defined in the laws or regulations in the applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind third parties includes fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. You are responsible for complying with any restrictions and should speak to your personal advisor on this matter.

23. EXCHANGE CONTROL, FOREIGN ASSET/ACCOUNT AND/OR TAX REPORTING. Depending upon the country to which laws you are subject, you may have certain foreign asset/account and/or tax reporting requirements that may affect your ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside your country of residence. Your country may require that you report such accounts, assets or transactions to the applicable authorities in your country. You also may be required to repatriate cash received from participating in the Plan to your country within a certain period of time after receipt. You are responsible for knowledge of and compliance with any such regulations and should speak with your personal tax, legal and financial advisors regarding same.

24. OTHER DOCUMENTS. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company’s Trading Policy.

25. QUESTIONS. If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus.

* * * *

 

 


FINCH THERAPEUTICS GROUP, INC.

2021 EQUITY INCENTIVE PLAN

APPENDIX

TO GLOBAL STOCK OPTION AGREEMENT

TERMS AND CONDITIONS

This Appendix forms part of the Agreement and includes additional terms and conditions that govern the Option granted to you under the Plan if you reside and/or work in one of the jurisdictions listed below. Capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or in the Global Stock Option Agreement.

If you are a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which you are currently residing and/or working, or if you relocate to another country after the grant of the Option, the Company shall, in its discretion, determine to what extent the additional terms and conditions contained herein shall be applicable to you.

NOTIFICATIONS

This Appendix may also include information regarding exchange controls and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, and other laws in effect in the respective countries as of January 2021. Such laws are often complex and change frequently. As a result, you should not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time you vest in or exercise the Option, acquire shares of Common Stock, or sell shares of Common Stock acquired under the Plan.

In addition, the information contained below is general in nature and may not apply to your particular situation. You should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.

If you are a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which you are currently residing and/or working, or if you relocate to another country after the grant of the Option, the notifications herein may not apply to you in the same manner.

 

 


FINCH THERAPEUTICS GROUP, INC.

GLOBAL RSU AWARD GRANT NOTICE

(2021 EQUITY INCENTIVE PLAN)

Finch Therapeutics Group, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2021 Equity Incentive Plan (the “Plan”) and the Global RSU Award Agreement, including any additional terms and conditions for your country set forth in the appendix thereto (the “Appendix” and, together with the Global RSU Award Agreement, the “Agreement”), all of which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement, as applicable.

 

 

 

Participant:

 

 

Date of Grant:

 

 

Vesting Commencement Date:

 

 

Number of Restricted Stock Units:

 

 

 

 

 

 

Vesting Schedule:

 

[__________________________________________________________________]. Notwithstanding the foregoing, except as set forth below, vesting shall terminate upon the Participant’s termination of Continuous Service, as described in Section 6(l) of the Agreement.

 

 

Issuance Schedule:

 

One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section 5 of the Agreement.

Participant Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:

 

 

The RSU Award is governed by this Global RSU Award Grant Notice (the “Grant Notice”), and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the “RSU Award Agreement”) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.

 

 

 

You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus. In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.

 

 

 

The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.

 

 

 

 

 

 

 

 

 

 

 

FINCH THERAPEUTICS GROUP, INC.

 

 

 

PARTICIPANT:

 

 

 

 

By:

 

 

 

 

 

 

 

 

Signature

 

 

 

Signature

 

 

 

 

 

Title:

 

 

 

 

 

Date:

 

 


 

 

 

 

 

Date:

 

 

 

 

 

 

 

 

 

 


FINCH THERAPEUTICS GROUP, INC.

2021 EQUITY INCENTIVE PLAN

GLOBAL RSU AWARD AGREEMENT

As reflected by your Global RSU Award Grant Notice (“Grant Notice”), Finch Therapeutics Group, Inc. (the “Company”) has granted you a RSU Award under its 2021 Equity Incentive Plan (the “Plan”) for the number of restricted stock units as indicated in your Grant Notice (the “RSU Award”). The terms of your RSU Award as specified in this Global RSU Award Agreement for your RSU Award, including any additional terms and conditions for your country set forth in the appendix hereto (the “Appendix” and, together with the Global RSU Award Agreement, the “Agreement”) and the Grant Notice constitute your “RSU Award Agreement”. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.

The general terms applicable to your RSU Award are as follows:

1. GOVERNING PLAN DOCUMENT. Your RSU Award is subject to all the provisions of the Plan. Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.

2. GRANT OF THE RSU AWARD. This RSU Award represents your right to be issued on a future date the number of shares of the Company’s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice subject to your satisfaction of the vesting conditions set forth therein (the “Restricted Stock Units”). Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.

3. DIVIDENDS. You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.

4. RESPONSIBILITY FOR TAXES.

a. Regardless of any action taken by the Company or, if different, the Affiliate to which you provide Continuous Service (the “Service Recipient”) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items associated with the grant or vesting of the RSU Award or sale of the underlying Common Stock or other tax-related items related to your participation in the Plan and legally applicable or deemed applicable to you (the “Tax Liability”), you hereby acknowledge and agree that the Tax Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld by the Company or the Service Recipient. You further acknowledge that the Company and the Service Recipient (i) make no representations or undertakings regarding any Tax Liability in connection with any aspect of this RSU Award, including, but not limited to, the grant or vesting of the RSU Award, the issuance of Common Stock pursuant to such vesting, the subsequent sale of shares of Common Stock, and the payment of any dividends on the shares; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your Tax Liability or achieve a particular tax result. Further, if you are subject to Tax Liability in more than one jurisdiction, you acknowledge that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax Liability in more than one jurisdiction.

b. Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or the Service Recipient to satisfy all Tax Liability. As further provided in Section 8 of the Plan, you hereby authorize the Company and any applicable Service Recipient to satisfy any applicable withholding obligations with regard to the Tax Liability by one or a combination of the following methods: (i) causing you to pay any portion of the Tax Liability in cash or cash equivalent in a form acceptable to the Company and/or the Service Recipient; (ii) withholding from any compensation otherwise payable to you by the Company or the Service Recipient; (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award; provided, however, that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Company’s Compensation Committee; (iv) permitting or requiring you to enter into a “same day sale” commitment, if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”), pursuant to this authorization and without further consent, whereby you irrevocably elect to sell a portion of the shares of Common Stock to be delivered in connection with your Restricted Stock Units to satisfy the Tax Liability and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Tax Liability directly to the Company or the Service Recipient; and/or (v) any other method determined by the Company to be in compliance with Applicable Law. Furthermore, you agree to pay or reimburse the Company or the Service Recipient any amount the Company or the Service Recipient may be required to withhold, collect or pay as a result of your participation in the Plan or that cannot be satisfied by the means previously described. In the event it is determined that the amount of the Tax Liability was greater than the amount withheld by the Company and/or the Service Recipient (as applicable), you agree to indemnify and hold


the Company and/or the Service Recipient (as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold the proper amount.

c. The Company and/or the Service Recipient may withhold or account for your Tax Liability by considering statutory withholding amounts or other withholding rates applicable in your jurisdiction(s), including (i) maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash from the Company or the Service Recipient (with no entitlement to the Common Stock equivalent), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay any Tax Liability directly to the applicable tax authority or to the Company and/or the Service Recipient. If the Tax Liability withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to the vested portion of the RSU Award, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying such Tax Liability.

d. You acknowledge that you may not participate in the Plan and the Company shall have no obligation to issue or deliver shares of Common Stock until you have fully satisfied any applicable Tax Liability, as determined by the Company. Unless any withholding obligation for the Tax Liability is satisfied, the Company shall have no obligation to issue or deliver to you any Common Stock in respect of the RSU Award.

5. DATE OF ISSUANCE.

a. The issuance of shares in respect of the Restricted Stock Units is intended to comply with U.S. Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the Tax Liability withholding obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each vested Restricted Stock Unit on the applicable vesting date. Each issuance date determined by this paragraph is referred to as an “Original Issuance Date.”

b. If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day. In addition, if:

1) the Original Issuance Date does not occur (1) during an “open window period” applicable to you, as determined by the Company in accordance with the Company’s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company’s policies (a “10b5-1 Arrangement)), and

2) either (1) a Tax Liability withholding obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Tax Liability withholding obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this Award, and (B) not to permit you to enter into a “same day sale” commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Tax Liability in cash, then the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Common Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, if and only if permitted in a manner that complies with U.S. Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to a “substantial risk of forfeiture” within the meaning of U.S. Treasury Regulations Section 1.409A-1(d).

6. NATURE OF GRANT. In accepting the RSU Award, you acknowledge, understand and agree that:

a. the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

b. the grant of the RSU Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;

c. all decisions with respect to future RSU Awards or other grants, if any, will be at the sole discretion of the Company;

d. the RSU Award and your participation in the Plan shall not create a right to employment or other service relationship with the Company;

e. the RSU Award and your participation in the Plan shall not be interpreted as forming or amending an employment or service contract with the Company or the Service Recipient, and shall not interfere with the ability of the Company or the Service Recipient, as applicable, to terminate your Continuous Service (if any);


f. you are voluntarily participating in the Plan;

g. the RSU Award and the shares of Common Stock subject to the RSU Award, and the income from and value of same, are not intended to replace any pension rights or compensation;

h. the RSU Award and the shares of Common Stock subject to the RSU Award, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

i. unless otherwise agreed with the Company in writing, the RSU Award and the shares of Common Stock subject to the RSU Award, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate;

 

j. the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty;

k. no claim or entitlement to compensation or damages shall arise from forfeiture of the RSU Award resulting from the termination of your Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are providing service or the terms of your employment or other service agreement, if any);

l. for purposes of the RSU Award, your Continuous Service will be considered terminated as of the date you are no longer actively providing services to the Company or any Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are providing service or the terms of your employment or other service agreement, if any), and such date will not be extended by any notice period (e.g., your period of Continuous Service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are providing service or the terms of your employment or other service agreement, if any); the Compensation Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of your RSU Award (including whether you may still be considered to be providing services while on a leave of absence); and

m. neither the Company nor the Service Recipient shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to you pursuant to the settlement of the RSU Award or the subsequent sale of any shares of Common Stock acquired upon settlement.

7. TRANSFERABILITY. Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution

8. CORPORATE TRANSACTION. Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.

9. NO LIABILITY FOR TAXES. As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to any Tax Liability arising from the RSU Award and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.

10. NO ADVICE REGARDING GRANT. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying shares of Common Stock. You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.

11. GOVERNING LAW AND VENUE. The RSU Award and the provisions of this Agreement are governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the conflict of law principles that would result in any application of any law other than the law of the State of Delaware. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement, relating to it, or arising from it, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of the State of Delaware, and no other courts, where this grant is made and/or to be performed.

12. SEVERABILITY. If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.


13. COMPLIANCE WITH LAW. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the shares of Common Stock, the Company shall not be required to deliver any shares issuable upon settlement of the Restricted Stock Units prior to the completion of any registration or qualification of the shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. You understand that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares. Further, you agree that the Company shall have unilateral authority to amend the Agreement without your consent to the extent necessary to comply with securities or other laws applicable to issuance of shares of Common Stock.

14. LANGUAGE. You acknowledge that you are proficient in the English language, or have consulted with an advisor who is proficient in the English language, so as to enable you to understand the provisions of this Agreement and the Plan. If you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

15. ELECTRONIC DELIVERY AND PARTICIPATION. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

16. SEVERABILITY. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

17. APPENDIX. Notwithstanding any provisions in this Global RSU Award Agreement, the RSU Award shall be subject to any additional terms and conditions set forth in any Appendix for your country. Moreover, if you relocate to one of the countries included in the Appendix, the additional terms and conditions for such country will apply to you, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Agreement.

18. IMPOSITION OF OTHER REQUIREMENT. The Company reserves the right to impose other requirements on your participation in the Plan, on the RSU and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

19. WAIVER. You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other participant.

20. INSIDER TRADING/MARKET ABUSE. You acknowledge that, depending on your or your broker’s country or where the Company shares are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares (e.g., Restricted Stock Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company as defined in the laws or regulations in the applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind third parties includes fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. You are responsible for complying with any restrictions and should speak to your personal advisor on this matter.

21. EXCHANGE CONTROL, FOREIGN ASSET/ACCOUNT AND/OR TAX REPORTING. Depending upon the country to which laws you are subject, you may have certain foreign asset/account and/or tax reporting requirements that may affect your ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside your country of residence. Your country may require that you report such accounts, assets or transactions to the applicable authorities in your country. You also may be required to repatriate cash received from participating in the Plan to your country within a certain period of time after receipt. You are responsible for knowledge of and compliance with any such regulations and should speak with your personal tax, legal and financial advisors regarding same.

22. OTHER DOCUMENTS. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company’s Trading Policy.

23. QUESTIONS. If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.

 


FINCH THERAPEUTICS GROUP, INC.

2021 EQUITY INCENTIVE PLAN

APPENDIX

TO GLOBAL RSU AWARD AGREEMENT

TERMS AND CONDITIONS

This Appendix forms part of the Agreement and includes additional terms and conditions that govern the RSU Award granted to you under the Plan if you reside and/or work in one of the jurisdictions listed below. Capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or in the Global RSU Award Agreement.

If you are a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which you are currently residing and/or working, or if you relocate to another country after the grant of the RSU Award, the Company shall, in its discretion, determine to what extent the additional terms and conditions contained herein shall be applicable to you.

NOTIFICATIONS

This Appendix may also include information regarding exchange controls and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, and other laws in effect in the respective countries as of January 2021. Such laws are often complex and change frequently. As a result, you should not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time you vest in the Restricted Stock Units, acquire shares of Common Stock, or sell shares of Common Stock acquired under the Plan.

In addition, the information contained below is general in nature and may not apply to your particular situation. You should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.

If you are a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which you are currently residing and/or working, or if you relocate to another country after the grant of the RSU Award, the notifications herein may not apply to you in the same manner.


EX-10.7 5 fnch-ex10_7.htm EX-10.7 EX-10.7

 

 

EXHIBIT 10.7

 

 

FINCH THERAPEUTICS GROUP, INC.

2021 EMPLOYEE STOCK PURCHASE PLAN

 

ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021

APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021

IPO DATE: MARCH 18, 2021

AMENDED AND RESTATED AS OF: JUNE 8, 2023

 

1.
General; Purpose.

 

(a)
The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

 

(b)
The Plan includes two components: a 423 Component and a Non-423 Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the 423 Component, accordingly, will be construed in a manner that is consistent with the requirements of Section 423 of the Code. Except as otherwise provided in the Plan or determined by the Board, the Non-423 Component will operate and be administered in the same manner as the 423 Component.

 

(c)
The Company, by means of the Plan, seeks to retain the services of Eligible Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.

 

2.
Administration.

 

(a)
The Board or the Committee will administer the Plan. References herein to the Board shall be deemed to refer to the Committee except where context dictates otherwise.

 

(b)
The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

 

(i)
To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).

 

(ii)
To designate from time to time (A) which Related Corporations will be eligible to participate in the Plan as Designated 423 Corporations, (B) which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated Non-423 Corporations and (C) which Designated Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings).

 

(iii)
To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.

 

(iv)
To settle all controversies regarding the Plan and Purchase Rights granted under the Plan.

 

(v)
To suspend or terminate the Plan at any time as provided in Section 12.

1

 


 

 

(vi)
To amend the Plan at any time as provided in Section 12.

 

(vii)
Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component.

 

(viii)
To adopt such rules, procedures and sub-plans as are necessary or appropriate to permit or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the Board specifically is authorized to adopt rules, procedures, and sub-plans regarding, without limitation, eligibility to participate in the Plan, the definition of eligible “earnings,” handling and making of Contributions, establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of share issuances, any of which may vary according to applicable requirements, and which, if applicable to a Designated Non-423 Corporation, do not have to comply with the requirements of Section 423 of the Code.

 

(c)
The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority under the Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.

 

(d)
All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

 

3.
SHARES OF COMMON STOCK SUBJECT TO THE PLAN.

 

(a)
Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 16,666 shares of Common Stock, plus the number of shares of Common Stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the year in which the IPO Date occurs and ending on (and including) January 1, 2031, in an amount equal to the lesser of (i) 1.0% of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year, and (ii) 46,666 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section 3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to satisfy purchases of Common Stock under the Non-423 Component.

 

2

 


 

(b)
If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan.

 

(c)
The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.

 

4.
GRANT OF PURCHASE RIGHTS; OFFERING.

 

(a)
The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, and, with respect to the 423 Component, will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.

(b)
If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company or a third party designated by the Company (each, a “Company Designee”): (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.

 

(c)
The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.

 

5.
ELIGIBILITY.

 

(a)
Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees of a Related Corporation or an Affiliate. Except as provided in Section 5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation or an Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may (unless prohibited by Applicable Law) provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company, the Related Corporation, or the Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code with respect to the 423 Component. The Board may also exclude from participation in the Plan or any Offering Employees who are “highly compensated employees” (within the meaning of Section 423(b)(4)(D) of the Code) of the Company or a Related Corporation or a subset of such highly compensated employees.

 

3

 


 

(b)
The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:

 

(i)
the date on which such Purchase Right is granted will be the “Offering Date” of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right;

 

(ii)
the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and

 

(iii)
the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering.

 

(c)
No Employee will be eligible for the grant of any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section 5(c), the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.

 

(d)
As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the 423 Component only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated, exceeds US $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.

 

(e)
Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate.

 

(f)
Notwithstanding anything in this Section 5 to the contrary, in the case of an Offering under the Non-423 Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion, that participation of such Eligible Employee(s) is not advisable or practical for any reason.

 

6.
PURCHASE RIGHTS; PURCHASE PRICE.

 

(a)
On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings (as defined by the Board in each Offering) or with a maximum dollar amount, as designated by the Board during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.

 

(b)
The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering.

 

4

 


 

(c)
In connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable.

 

(d)
The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of:

 

(i)
an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or

 

(ii)
an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.

 

7.
PARTICIPATION; WITHDRAWAL; TERMINATION.

 

(a)
An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions by completing and delivering to the Company or a Company Designee, within the time specified in the Offering, an enrollment form provided by the Company or Company Designee. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where Applicable Law requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering, and to the extent permitted by Section 423 of the Code with respect to the 423 Component, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash, check or wire transfer prior to a Purchase Date.

 

(b)
During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant’s Purchase Right in that Offering will immediately terminate and the Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right in that Offering shall thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings.

 

(c)
Unless otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by Applicable Law) or (ii) is otherwise no longer eligible to participate. The Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions.

5

 


 

(d)
Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering under the 423 Component to an Offering under the Non-423 Component, the exercise of the Participant’s Purchase Right will be qualified under the 423 Component only to the extent such exercise complies with Section 423 of the Code. If a Participant transfers from an Offering under the Non-423 Component to an Offering under the 423 Component, the exercise of the Purchase Right will remain non-qualified under the Non-423 Component. The Board may establish different and additional rules governing transfers between separate Offerings within the 423 Component and between Offerings under the 423 Component and Offerings under the Non-423 Component.

 

(e)
During a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10.

 

(f)
Unless otherwise specified in the Offering or as required by Applicable Law, the Company will have no obligation to pay interest on Contributions.

 

8.
EXERCISE OF PURCHASE RIGHTS.

 

(a)
On each Purchase Date, each Participant’s accumulated Contributions will be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering.

 

(b)
Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant’s account after the purchase of shares of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest (unless otherwise required by Applicable Law).

 

(c)
No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and, subject to Section 423 of the Code with respect to the 423 Component, the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all Applicable Laws, as determined by the Company in its sole discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless the payment of interest is otherwise required by Applicable Law).

 

9.
COVENANTS OF THE COMPANY.

 

The Company will seek to obtain from each U.S. federal or state, foreign or other regulatory commission, agency or other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the

6

 


 

Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights.

 

10.
DESIGNATION OF BENEFICIARY.

 

(a)
The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company.

 

(b)
If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

11.
ADJUSTMENTS UPON CHANGES IN COMMON STOCK; CORPORATE TRANSACTIONS.

 

(a)
In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive.

 

(b)
In the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase.

 

12.
AMENDMENT, TERMINATION OR SUSPENSION OF THE PLAN.

 

(a)
The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by Applicable Law.

 

(b)
The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated.

 

Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without

7

 


 

limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section 423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or any Offering Document to the contrary, the Board will be entitled to: (i) establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii) permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the Company’s processing of properly completed Contribution elections; (iii) establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant’s Contributions; (iv) amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section 423 of the Code with respect to the 423 Component; and (v) establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering.

 

13.
TAX QUALIFICATION; TAX WITHHOLDING.

 

(a)
Although the Company may endeavor to (i) qualify a Purchase Right for special tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii) avoid adverse tax treatment, the Company makes no representation to that effect and expressly disavows any covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan. The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants.

 

(b)
Each Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation, to enable the Company or the Related Corporation to fulfill any withholding obligation for Tax-Related Items. Without limitation to the foregoing, in the Company’s sole discretion and subject to Applicable Law, such withholding obligation may be satisfied in whole or in part by (i) withholding from the Participant’s salary or any other cash payment due to the Participant from the Company or a Related Corporation; (ii) withholding from the proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii) any other method deemed acceptable by the Board. The Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied.

 

(c)
The 423 Component is exempt from the application of Section 409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section 409A of the Code. The Non-423 Component is intended to be exempt from the application of Section 409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. In furtherance of the foregoing and notwithstanding any provision in the Plan to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section 409A of the Code or that any provision in the Plan would cause an option under the Plan to be subject to Section 409A, the Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the participant’s consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section 409A of the Code, but only to the extent any such amendments or action by the Committee would not violate Section 409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a participant or any other party if the option under the Plan that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto.

 

14.
EFFECTIVE DATE OF PLAN.

 

8

 


 

The Plan became effective immediately prior to the IPO Date. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is, if required under Section 12(a) above, materially amended by the Board.

 

15.
MISCELLANEOUS PROVISIONS.

 

(a)
Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.

 

(b)
A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent).

 

(c)
The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment or amend a Participant’s employment contract, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant.

 

(d)
The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state’s conflicts of laws rules.

 

(e)
If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted.

 

(f)
If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply with Applicable Law.

 

16.
DEFINITIONS.

 

As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

 

(a)
423 Component” means the part of the Plan, which excludes the Non-423 Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees.

 

(b)
Affiliate” means any entity, other than a Related Corporation, whether now or subsequently established, which is at the time of determination, a “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.

 

(c)
Applicable Law” means shall mean the Code and any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the NASDAQ Stock Market, the New York Stock Exchange or the Financial Industry Regulatory Authority).

 

(d)
Board means the board of directors of the Company.

 

9

 


 

(e)
Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

(f)
Code means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

 

(g)
Committee means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c).

 

(h)
Common Stock” means the common stock of the Company.

 

(i)
Company” means Finch Therapeutics Group, Inc., a Delaware corporation.

 

(j)
Contributions” means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions and, with respect to the 423 Component, to the extent permitted by Section 423 of the Code.

 

(k)
Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

 

(i)
a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries;

 

(ii)
a sale or other disposition of more than 50% of the outstanding securities of the Company;

 

(iii)
a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

 

(iv)
a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

 

(l)
Designated 423 Corporation” means any Related Corporation selected by the Board to participate in the 423 Component.

 

(m)
Designated Company means any Designated Non-423 Corporation or Designated 423 Corporation, provided, however, that at any given time, a Related Corporation participating in the 423 Component shall not be a Related Corporation participating in the Non-423 Component.

 

(n)
Designated Non-423 Corporation” means any Related Corporation or Affiliate selected by the Board to participate in the Non-423 Component.

 

(o)
Director means a member of the Board.

10

 


 

(p)
Eligible Employee means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan.

 

(q)
Employee means any person, including an Officer or Director, who is “employed” for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation, or solely with respect to the Non-423 Component, an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

 

(r)
Employee Stock Purchase Plan means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code.

 

(s)
Exchange Act means the U.S. Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.

 

(t)
Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i)
If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.

 

(ii)
In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Sections 409A of the Code.

 

(iii)
Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company’s initial public offering as specified in the final prospectus for that initial public offering.

 

(u)
Governmental Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the NASDAQ Stock Market, the New York Stock Exchange and the Financial Industry Regulatory Authority).

 

(v)
IPO Date means March 18, 2021.

 

(w)
Non-423 Component” means the part of the Plan, which excludes the 423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees.

 

(x)
Offering means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document” approved by the Board for that Offering.

11

 


 

 

(y)
Offering Date” means a date selected by the Board for an Offering to commence.

 

(z)
Officer means a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.

 

(aa)
Participant means an Eligible Employee who holds an outstanding Purchase Right.

 

(bb)
Plan means this Finch Therapeutics Group, Inc. 2021 Employee Stock Purchase Plan, as amended from time to time, including both the 423 Component and the Non-423 Component.

 

(cc)
Purchase Date means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering.

 

(dd)
Purchase Period” means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods.

 

(ee)
Purchase Right means an option to purchase shares of Common Stock granted pursuant to the Plan.
(ff)
Related Corporation means any “parent corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.

 

(gg)
Securities Act means the U.S. Securities Act of 1933, as amended.

 

(hh)
Tax-Related Items” means any income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items arising out of or in relation to a Participant’s participation in the Plan, including, but not limited to, the exercise of a Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan.

 

(ii)
Trading Day means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, including but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading.

 

12

 


EX-31.1 6 fnch-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew P. Blischak, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 11, 2023

By:

/s/ Matthew P. Blischak

Matthew Blischak

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 


EX-31.2 7 fnch-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lance Thibault, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 11, 2023

By:

/s/ Lance Thibault

Lance Thibault

Chief Financial Officer

 

 

 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 


EX-32.1 8 fnch-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc. (the “Company”) for the quarter ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

 

Date: August 11, 2023

By:

/s/ Matthew P. Blischak

Matthew P. Blischak

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

Date: August 11, 2023

By:

/s/ Lance Thibault

Lance Thibault

Chief Financial Officer

 

 

 

(Principal Financial Officer and Principal Accounting Officer)

 

 


GRAPHIC 9 img120795611_0.jpg GRAPHIC begin 644 img120795611_0.jpg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fnch-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 11 fnch-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 fnch-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Document Transition Report Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Outstanding Money Market Funds [Member] Payments of Stock Issuance Costs Payment of deferred offering costs Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] 2021 Equity incentive plan. Two Thousand Twenty One Equity Incentive Plan [Member] 2021 Equity Incentive Plan Other Current Assets [Member] Other Current Assets Other Liabilities, Noncurrent Other liabilities Other Liabilities, Noncurrent, Total Other Liabilities Noncurrent Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Disclosures [Text Block] Fair Value Measurements Temporary equity, shares authorized Temporary Equity, Shares Authorized Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Short-Term Debt, Type [Axis] Gain (Loss) on Termination of Lease Gain on lease termination Gain on lease termination Subsequent Events [Text Block] Subsequent Events Temporary equity, shares issued Temporary Equity, Shares Issued Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Severance and Related Benefits Employee Severance [Member] Class of Stock [Line Items] Class Of Stock [Line Items] Balance Sheet Location [Axis] Assets, Current Total current assets Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Entity Address, State or Province Entity Address, State or Province 2024 Operating Leases, Future Minimum Payments, Due in Two Years 2022 Property, Plant and Equipment, Other Types [Member] Property Plant And Equipment Other Types Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number SHARES, Outstanding, Ending Balance SHARES, Outstanding, Beginning Balance WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Goodwill and Acquired In-Process Research and Development Goodwill and Intangible Assets, Policy [Policy Text Block] Trading Symbol Trading Symbol Common Stock, Shares, Issued Common stock, shares, issued Common Stock, Shares, Issued, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Net Income (Loss) Attributable to Parent [Abstract] Numerator: Shares, Outstanding Ending Balance, Shares Beginning Balance, Shares Common Stock, Capital Shares Reserved for Future Issuance Shares of common stock for potential conversion Prepaid rent reclassified to right-of-use assets Prepaid rent reclassified to right-of-use assets Prepaid rent reclassified to right-of-use assets Entity Address, City or Town Entity Address, City or Town Present value of future minimum lease payments. Present Value of Future Minimum Lease Payments Present value of future minimum lease payments Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Loan Payable Debt Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, Net Increase (Decrease) in Security Deposits Decrease in security deposit Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number SHARES, Options vested or expected to vest | shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period SHARES, Expired Leases of Lessor Disclosure [Text Block] Leases Gain (Loss) On Lease Termination Gain (Loss) On Lease Termination Gain on lease termination Additional Paid-in Capital [Member] Additional Paid-in Capital Liabilities, Current [Abstract] CURRENT LIABILITIES: Assets, Current [Abstract] CURRENT ASSETS: Preferred Stock, Par or Stated Value Per Share Preferred stock par value Impairment of long-lived assets Impairment of long-lived assets Impairment, Long-Lived Asset, Held-for-Use Impairment, Long-Lived Asset, Held-for-Use, Total Statement of Stockholders' Equity [Abstract] OpenBiome. Open Biome [Member] Open Biome Operating Lease, Liability, Current Operating lease liabilities, current Total Initial amount borrowed Principal amount of loan payable Long-Term Debt Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Class of Stock [Domain] Class of Stock Payment of Terminal Fee Obligation and Prepayment Fee Payment of terminal fee obligation and prepayment fee Payment of loan terminal fee obligation and prepayment fee Restructuring Charges recognized Restructuring Charges, Total Restructuring Charges Restructuring Restructuring Concord Avenue Lease Member Concord Avenue Lease Member Concord Avenue Lease Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value AGGREGATE INTRINSIC VALUE, Options vested or expected to vest | $ Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Schedule of accrued expenses and other current liabilities. Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Plan Name Plan Name [Domain] Restricted Cash, Noncurrent Restricted cash, non-current Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Two thousand seventeen equity incentive plan. Two Thousand Seventeen Equity Incentive Plan [Member] 2017 Equity Incentive Plan Liabilities, Current Total current liabilities Liabilities Current Entity Tax Identification Number Entity Tax Identification Number Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Summary of Future Minimum Lease Payments Under Non-Cancellable Leases Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Loss before income taxes Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Interest portion of operating leases future minimum payments due. Interest Portion of Operating Leases Future Minimum Payments Due Less: amount representing interest Construction in Progress [Member] Construction Work-In-Progress Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan Award Type [Axis] Award Type Error correction impact. Error Correction Impact Error correction impact Plan Name [Axis] Plan Name Lessee, Operating Lease, Term of Contract Lease agreement term Sublease agreement term Assets Total financial assets TOTAL ASSETS Non-cash interest expense Non-cash interest expense. Non-cash operating lease and interest cost Interest income, net Investment Income, Net Investment Income, Net, Total Interest income (expense) Operating Lease, Right-of-Use Asset Operating right-of-use assets Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation expense remaining to be recognized Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities Entity Registrant Name Entity Registrant Name Related Party, Type [Domain] Related Party Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings [Member] Accumulated Deficit Class of Stock [Axis] Class of Stock Gain (Loss) on Disposition of Assets Gain (Loss) on Disposition of Assets, Total Gain (loss) on sale and disposal of fixed assets, net Deferred Income Tax Liabilities, Net Deferred tax liability Deferred Income Tax Liabilities, Net, Total Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under employee stock purchase plan, Shares Minimum [Member] Minimum [Member] Proceeds from exercise of stock options, net Proceeds from Stock Options Exercised Significant Accounting Policies [Text Block] Summary Of Significant Accounting Policies Impairment of IPR&D Impairment of In-Process Research and Development Impairment of In-Process Research and Development. Impairment of in-process research and development Equity Component [Domain] Equity Component Employee Stock Option [Member] Employee Stock Option Member Options to Purchase Common Stock Principal repayments of loan Aggregate payoff amount Repayments of Lines of Credit Repayment of loan Capital Leased Assets [Line Items] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] Measurement Frequency Sublease Income Sublease income Sublease income Debt Disclosure [Abstract] Net loss attributable to common stockholders, diluted Net loss attributable to common stockholders-basic and diluted (Note 16) Net Income (Loss) Available to Common Stockholders, Diluted Net loss attributable to common stockholders-basic and diluted (Note 15) Entity Current Reporting Status Entity Current Reporting Status Common Stock, Shares Authorized Common stock, shares authorized Common shares authorized for issuance Research and Development Expense Research and development Research and Development Expense, Total Research and development Assets [Abstract] ASSETS Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of common stock shares available for future grants Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 1,604,761 and 1,601,717 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Accrued restructuring liability as of December 31, 2022 Restructuring Reserve Restructuring Reserve, Total Accrued restructuring liability as of June 30, 2023 Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from Sale of Property, Plant, and Equipment Proceeds on sale of property and equipment Furniture and Fixtures [Member] Office Furniture and Fixtures Undesignated preferred stock. Undesignated Preferred Stock [Member] Undesignated Preferred Stock Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense, Total Operating Income (Loss) Net loss from operations Net loss from operations Entity Ex Transition Period Entity Ex Transition Period Benefit for deferred income taxes Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit), Total Income tax benefit Income tax benefit Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Research and Development Expense [Member] Research and Development Organization, consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Reduction in accumulated deficit. Reduction in Accumulated Deficit Reduction in accumulated deficit Cash payments Cash payments Payments for Restructuring Share-Based Payment Arrangement, Expense Total stock-based compensation expense Operating cash flows used in operating leases Operating cash flows (used in) from operating leases Increase (Decrease) in Operating Lease Liability Operating lease liabilities Cash paid (received) for amounts included in measurement of lease liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Aggregate purchase of common stock Vesting of restricted stock units, Shares Stock Issued During Period, Shares, Restricted Stock Award, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance 2025 Operating Leases, Future Minimum Payments, Due in Three Years 2023 Lessee Operating Lease Leases Area Lessee Operating Lease Leases Area Office and laboratory space for lease Cherry street lease. Cherry Street Lease [Member] Cherry Street Lease Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Sublease and other income Sublease and other income 2023 Operating Leases, Future Minimum Payments Due, Next 12 Months 2021 Operating Expenses [Abstract] OPERATING EXPENSES: Property, Plant and Equipment [Abstract] Subsequent Events [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Number of shares issuable upon the exercise of outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Commitments and Contingencies Disclosure [Abstract] Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Two thousand seventeen and two thousand twenty one equity incentive plan. Two Thousand Seventeen And Two Thousand Twenty One Equity Incentive Plan [Member] 2017 and 2021 Equity Incentive Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross SHARES, Granted Other Accrued Liabilities, Current Accrued other Equity [Text Block] Stockholders' Equity Depreciation Depreciation, Total Depreciation expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price WEIGHTED AVERAGE EXERCISE PRICE, Options vested or expected to vest Operating Leases, Rent Expense, Total Operating Leases, Rent Expense Rental charges Equity, Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Lease, Cost [Table Text Block] Summary of Components of Lease Cost Loss on disposal of fixed assets, net Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total (Gain) loss on sale and disposal of property and equipment Gain on disposal of fixed assets Line of Credit Facility, Maximum Borrowing Capacity Aggregate maximum borrowing capacity SHARES, Vested and distributed Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value SHARES, Vested and distributed Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Supplemental Cash Flow Information Earnings Per Share [Abstract] Loss Contingencies [Table] Maximum milestone payment required under agreement. Maximum Milestone Payment Required Under Agreement Required to pay certain milestones Accounting Policies [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Stock Options [Member] Equity Option [Member] Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share attributable to common stockholders, basic Net loss per share attributable to common stockholders - basic Collaboration revenue. Collaboration Revenue [Member] Collaboration Revenue COMMITMENTS AND CONTINGENCIES (Note 11) Commitments and Contingencies Accrued research and development. Accrued Research And Development Accrued research and development Income Statement [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, Net Related Party, Type [Axis] Related Party Operating Lease, Cost Operating lease cost Short-Term Lease, Cost Short-term lease cost Retirement Benefits [Abstract] Restructuring Type [Axis] Statistical Measurement [Domain] Statistical Measurement Loss Contingencies [Line Items] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Incentive stock options. Incentive Stock Options [Member] Incentive Stock Options All Award Types Award Type Document Period End Date Document Period End Date Statistical Measurement [Axis] Statistical Measurement Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Percentage of increase in shares of common stock reserved for issuance. Percentage Of Increase In Shares Of Common Stock Reserved For Issuance Percentage of increase in shares of common stock reserved for issuance Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share attributable to common stockholders, diluted Net loss per share attributable to common stockholders - diluted Product and Service [Domain] Product and Service Lease, Cost [Abstract] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number SHARES, Options exercisable Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Fair Value, Recurring [Member] Fair Value, Measurements, Recurring Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Schedule of Estimated future principal payments Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Restructuring and Related Costs [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of common stock options, Shares SHARES, Exercised Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Over-Allotment Option [Member] OverAllotment Option Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Revision of Prior Period, Adjustment [Member] Restatement adjustment Equity [Abstract] Schedule of Short-Term Debt [Table] Revision of Prior Period [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price WEIGHTED AVERAGE EXERCISE PRICE, Exercised Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Equity Components [Axis] Equity Components Increase (Decrease) in Accounts Receivable Accounts receivable Restructuring and Related Activities [Abstract] Operating lease obligations. Operating Lease Obligations [Abstract] Leases balance sheet information table text block. Leases Balance Sheet Information [Table Text Block] Leases Balance Sheet Information Financial Liabilities Fair Value Disclosure, Total Financial Liabilities Fair Value Disclosure Financial liabilities Adjustment To Prior Interim Unaudited Financial Statements Accounting Standards Update and Change in Accounting Principle [Text Block] Local Phone Number Local Phone Number Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Sale of Stock [Axis] Sale of Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price WEIGHTED AVERAGE EXERCISE PRICE, Options exercisable Two Thousand Twenty One Employee Stock Purchase Plan [Member] Two Thousand Twenty One Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Statement of Cash Flows [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating Leases, Future Minimum Payments, Due Thereafter Thereafter Common Stock, Par or Stated Value Per Share Common stock, par value Common stock par value Unvested Restricted Stock Units Unvested Restricted Stock Units [Member] Unvested restricted stock units. Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation expense remaining to be recognized, period Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options vested or expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Maximum number of common stock to be issued Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Maximum [Member] Maximum Temporary Equity, Shares Outstanding Ending Balance, Shares Beginning Balance, Shares Temporary equity, shares outstanding Convertible preferred stock outstanding Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Operations and Basis of Presentation Fair Value, Inputs, Level 3 [Member] Significant Observable Inputs (Level 3) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Short-Term Debt, Type [Domain] NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2027 Operating Leases, Future Minimum Payments, Due in Five Years 2025 General and Administrative Expense [Member] General and Administrative Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period SHARES, Cancelled or forfeited Lease liabilities. Lease Liabilities Total lease liabilities Total lease liabilities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Computation of Diluted Loss per Share Attributable to Common Stockholders City Area Code City Area Code CASH FLOWS USED IN OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Operating Leases, Future Minimum Payments Due Total future minimum lease payments Total future minimum lease payments Total minimum lease payments Letter of Credit [Member] Letter of Credit Hood Park Drive Member Hood Park Drive Member Hood Park Lease Defined Contribution Plan [Text Block] Retirement Plan Common Stock, Voting Rights Common stock voting rights Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance General and Administrative Expense General and administrative General and Administrative Expense, Total General and administrative Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average common stock outstanding, basic Summary of Restructuring Activity Restructuring and Related Costs [Table Text Block] WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Employee Stock [Member] Employee Stock CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Lessee, Operating Lease, Description Lease term description Loss on loan extinguishment Loss on extinguishment Loss on loan extinguishment Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Statement [Table] Statement [Table] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Activity of Stock Options Document Fiscal Period Focus Document Fiscal Period Focus Transfers between fair value levels. Transfers Between Fair Value Levels Transfers between fair value levels Accrued Professional Fees, Current Accrued legal and professional fees Statement [Line Items] Statement [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluding from computation of diluted net loss per share Software and Software Development Costs [Member] Software Total lease cost, net Lease, Cost Warrant [Member] Common Stock Warrants Organization, consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Asset Class [Domain] Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current, Total Common Stock [Member] Common Stock Temporary Equity, Par or Stated Value Per Share Temporary equity, par value Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Loan and Security Agreement Loan and security agreement. Loan And Security Agreement [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Total Stock-Based Compensation Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value AGGREGATE INTRINSIC VALUE, Options exercisable Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Schedule of Loan Payable Schedule of Debt [Table Text Block] Cover [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Sale of Stock [Domain] Sale of Stock Schedule of Capital Leased Assets [Table] Security Exchange Name Security Exchange Name New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Preferred Stock, Shares Authorized Preferred shares authorized for issuance Property, Plant and Equipment, Gross Property and equipment held Total Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating lease liability Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price WEIGHTED AVERAGE EXERCISE PRICE, Cancelled or forfeited Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Accrued Employee Benefits, Current Accrued compensation and benefits Stock Issued During Period, Value, Stock Options Exercised Exercise of common stock options Entity Emerging Growth Company Entity Emerging Growth Company Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value AGGREGATE INTRINSIC VALUE, Exercised Amendment Flag Amendment Flag IPO IPO [Member] Initial Public Offering Restructuring Restructuring and Related Activities Disclosure [Text Block] Proceeds from Lines of Credit, Total Proceeds from Lines of Credit Proceeds from borrowings under loan agreement, net Leases [Abstract] Accrued expenses and other current liabilities. Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Securities Act File Number Entity File Number Inner belt road lease. Inner Belt Road Lease [Member] Inner Belt Road Lease Loan payable, non-current Long-Term Debt, Excluding Current Maturities Long-term Debt, Excluding Current Maturities, Total Short-Term Debt [Line Items] Share-Based Payment Arrangement [Abstract] Dividends, Common Stock, Cash Cash dividends declared or paid 2026 Operating Leases, Future Minimum Payments, Due in Four Years 2024 Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Operating Expenses Total operating expenses Operating Expenses, Total Total operating expenses Entity Address, Address Line Two Entity Address, Address Line Two Amendment Description Preferred Stock, Value, Issued Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2023 and December 31, 2022 Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Schedule of future lease payments table text block. Schedule of Future Lease Payments [Table Text Block] Schedule of Future Lease Payments Computer Equipment [Member] Computer Equipment Earnings Per Share [Text Block] Loss per Share Revenues [Abstract] REVENUE: Entity Address, Address Line One Entity Address, Address Line One Antidilutive Securities [Axis] Antidilutive Securities WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Ending Balance WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Outstanding, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Income Statement Location [Axis] Income Statement Location Variable Lease, Cost Variable lease cost Impairment charge Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Fair Value, Inputs, Level 2 [Member] Significant Observable Inputs (Level 2) Depreciation, Depletion and Amortization Depreciation and amortization expense Depreciation, Depletion and Amortization, Total Product and Service [Axis] Product and Service Title of 12(b) Security Title of 12(b) Security Previously Reported [Member] Previously Reported Summary of common shares reserved for potential conversion of outstanding preferred stock, vesting of restricted stock and exercise of stock options and common stock warrants. Summary Of Common Shares Reserved For Potential Conversion Of Outstanding Preferred Stock Vesting Of Restricted Stock And Exercise Of Stock Options And Common Stock Warrants Table [Text Block] Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants Accounting Changes and Error Corrections [Abstract] Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES: Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Lab equipment. Lab Equipment [Member] Lab Equipment Lease term and discount rate table text block. Lease Term and Discount Rate [Table Text Block] Summary of Weighted Average Remaining Operating Lease Term and Discount Rate Defined Contribution Plan, Employer Discretionary Contribution Amount Company's contribution to plan Impairment charges Goodwill and Intangible Asset Impairment Goodwill and Intangible Asset Impairment, Total Impairment of goodwill Impairment of goodwill Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options exercisable Common Stock, Shares, Outstanding Common stock, shares, outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Financing cash flows used in finance leases Principal payments on capital lease obligation. Principal Payments On Capital Lease Obligation Principal payments on finance lease obligation Income Statement Location [Domain] Income Statement Location WEIGHTED AVERAGE EXERCISE PRICE, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Document Type Document Type Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Document Quarterly Report Document Quarterly Report In-process research and development. In Process Research And Development In-process research and development WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Vested and distributed Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Net loss attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic, Total Net Income (Loss) Available to Common Stockholders, Basic Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Entity Filer Category Entity Filer Category Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price WEIGHTED AVERAGE EXERCISE PRICE, Expired Restricted Cash and Cash Equivalents Restricted cash Restricted Cash and Cash Equivalents, Total Balance Sheet Location [Domain] Increase (Decrease) in Other Noncurrent Assets Other non-current assets Accrued Liabilities, Current [Abstract] Asset Class [Axis] Total other (expense) income, net Nonoperating Income (Expense) Total other income, net Total other income (expense), net Property and equipment in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Property and equipment in accounts payable and accrued liabilities Liabilities Total liabilities Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Options to purchase common stock. Options To Purchase Common Stock [Member] Options to Purchase Common Stock Equity, Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity Stock Issued During Period, Shares, Reverse Stock Splits Stock issued during period shares reverse stock splits Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule of effect of error correction of prior interim unaudited financial statements Net Income (Loss) Net loss Net loss Net loss Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE), NET: OTHER INCOME (EXPENSE), NET: Statement of Financial Position [Abstract] Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average common stock outstanding, diluted Impairment charge Impairment of Long-Lived Assets to be Disposed of Decrease in accounts payable and research and development expenses. Decrease In Accounts Payable And Research And Development Expenses Decrease in accounts payable and research and development expenses Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term Income Tax Disclosure [Text Block] Income Taxes Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Ending Balance WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Beginning Balance Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Basic and Diluted Loss per Share Attributable to Common Stockholders Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Leasehold Improvements [Member] Leasehold Improvements Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Measurement Frequency [Domain] Measurement Frequency Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Type of Restructuring [Domain] Revision of Prior Period [Domain] Redeemable Convertible Preferred Stock [Member] Redeemable Convertible Preferred Stock Initial public offering, net of underwriting discounts, commissions and net of offering costs, Shares Stock Issued During Period, Shares, New Issues Stock issued during period, shares Operating Lease, Expense Lease expense Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Income Tax Disclosure [Abstract] EX-101.CAL 13 fnch-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 14 fnch-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Schedule of Future Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Nature of Operations and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Loan Payable link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Loan Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements - Schedule of effect of error correction of prior interim unaudited financial statements (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Leases - Leases Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Leases - Summary of Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Leases - Summary of Weighted Average Remaining Operating Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Leases - Schedule of Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Loan Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Restructuring - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Restructuring - Summary of Restructuring Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Stock-Based Compensation - Summary of Activity of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Retirement Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink XML 15 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 04, 2023
Cover [Abstract]    
Document Type 10-Q/A  
Document Quarterly Report true  
Document Transition Report false  
Amendment Flag true  
Amendment Description Finch Therapeutics Group, Inc. (the “Company”) filed its Form 10-Q for the quarterly period ended June 30, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission on August 10, 2023. The Company is filing this Amendment No. 1 on Form 10-Q/A (i) to correct the Section 302 and Section 906 Certifications (collectively, the “Certifications”) filed in the Form 10-Q as Exhibits 31.1, 31.2, and 32.1, respectively, which inadvertently set forth incorrect names and signatures on the Certifications and (ii) to correct the filing of an amendment to a material contract that was designated as filed in the Exhibit Index of the Form 10-Q but was inadvertently omitted in the filing. Except as expressly set forth herein, this Form 10-Q/A does not reflect events occurring after the date of the Form 10-Q filing or modify or update any of the other disclosures contained therein in any way other than as required to reflect the amendments discussed above. Other than the changes in exhibits referred to above, all other information in the Form 10-Q remains unchanged.  
Entity Central Index Key 0001733257  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Period End Date Jun. 30, 2023  
Entity File Number 001-40227  
Entity Registrant Name FINCH THERAPEUTICS GROUP, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-3433558  
Entity Address, Address Line One 75 State Street  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02109  
City Area Code 617  
Local Phone Number 229-6499  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Trading Symbol FNCH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,604,761
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:    
Cash and cash equivalents $ 34,051 $ 71,038
Accounts receivable 0 144
Prepaid expenses and other current assets 2,448 3,369
Total current assets 36,499 74,551
Property and equipment, net 732 15,936
Operating right-of-use assets 27,308 32,752
In-process research and development 0 32,900
Restricted cash, non-current 2,318 2,568
Other assets 0 4,232
TOTAL ASSETS 66,857 162,939
CURRENT LIABILITIES:    
Accounts payable 432 1,097
Accrued expenses and other current liabilities 7,487 10,161
Operating lease liabilities, current 1,656 3,431
Total current liabilities 9,575 14,689
Deferred tax liability 0 3,461
Loan payable, non-current 0 14,653
Operating lease liabilities, non-current 29,388 34,255
Other liabilities 0 170
Total liabilities 38,963 67,228
COMMITMENTS AND CONTINGENCIES (Note 11)
Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2023 and December 31, 2022 0 0
STOCKHOLDERS' EQUITY:    
Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 1,604,761 and 1,601,717 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively 2 2
Additional paid-in capital 372,830 371,350
Accumulated deficit (344,938) (275,641)
Total stockholders' equity 27,894 95,711
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 66,857 $ 162,939
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Temporary equity, shares authorized 10,000,000 10,000,000
Temporary equity, shares issued 0 0
Temporary equity, shares outstanding 0 0
Temporary equity, par value $ 0.001 $ 0.001
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares, issued 1,604,761 1,601,717 [1]
Common stock, shares, outstanding 1,604,761 1,601,717 [1]
[1]

* Adjusted for the 1-for-30 reverse stock split

XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
REVENUE:        
Total revenue $ 0 $ 361 $ 107 $ 715
OPERATING EXPENSES:        
Research and development 203 13,923 7,199 29,453
General and administrative 8,877 8,164 18,494 17,568
Impairment of in-process research and development 0 0 32,900 0
Impairment of long-lived assets 0 0 13,141 0
Restructuring 801 903 4,037 903
Operating Expenses, Total 9,881 22,990 75,771 47,924
Net loss from operations (9,881) (22,629) (75,664) (47,209)
OTHER INCOME (EXPENSE), NET:        
Interest income, net 420 (65) 845 (52)
Gain on lease termination 752 0 752 0
Loss on loan extinguishment 0 0 (1,366) 0
Gain (loss) on sale and disposal of fixed assets, net 754 (6) 617 (6)
Sublease and other income 1,005 0 2,058 0
Total other income (expense), net 2,931 (71) 2,906 (58)
Loss before income taxes (6,950) (22,700) (72,758) (47,267)
Income tax benefit 0 0 3,461 0
Net loss (6,950) (22,700) (69,297) (47,267)
Net loss attributable to common stockholders, diluted $ (6,950) $ (22,700) $ (69,297) $ (47,267)
Net loss per share attributable to common stockholders, basic $ (4.33) $ (14.31) $ (43.21) $ (29.82)
Net loss per share attributable to common stockholders, diluted $ (4.33) $ (14.31) $ (43.21) $ (29.82)
Weighted-average common stock outstanding, basic [1] 1,604,795 1,585,978 1,603,811 1,585,093
Weighted-average common stock outstanding, diluted [1] 1,604,795 1,585,978 1,603,811 1,585,093
[1]

* Adjusted for the 1-for-30 reverse stock split

XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning Balance, Shares at Dec. 31, 2021 [1]   1,583,669    
Beginning Balance at Dec. 31, 2021 $ 202,224 $ 2 $ 363,217 $ (160,995)
Exercise of common stock options 14   14  
Exercise of common stock options, Shares [1]   680    
Stock-based compensation 2,120   2,120  
Net loss (24,567)     (24,567)
Ending Balance, Shares at Mar. 31, 2022 [1]   1,584,349    
Ending Balance at Mar. 31, 2022 179,791 $ 2 365,351 (185,562)
Beginning Balance, Shares at Dec. 31, 2021 [1]   1,583,669    
Beginning Balance at Dec. 31, 2021 202,224 $ 2 363,217 (160,995)
Net loss (47,267)      
Ending Balance, Shares at Jun. 30, 2022 [1]   1,589,453    
Ending Balance at Jun. 30, 2022 159,092 $ 2 367,352 (208,262)
Beginning Balance, Shares at Mar. 31, 2022 [1]   1,584,349    
Beginning Balance at Mar. 31, 2022 179,791 $ 2 365,351 (185,562)
Exercise of common stock options 61   61  
Exercise of common stock options, Shares [1]   3,279    
Issuance of common stock under employee stock purchase plan, Shares [1]   1,825    
Issuance of common stock under employee stock purchase plan 110   110  
Stock-based compensation 1,830   1,830  
Net loss (22,700)     (22,700)
Ending Balance, Shares at Jun. 30, 2022 [1]   1,589,453    
Ending Balance at Jun. 30, 2022 159,092 $ 2 367,352 (208,262)
Beginning Balance, Shares at Dec. 31, 2022 [1]   1,601,717    
Beginning Balance at Dec. 31, 2022 95,711 $ 2 371,350 (275,641)
Vesting of restricted stock units, Shares [1]   3,044    
Stock-based compensation 1,180   1,180  
Net loss (62,347)     (62,347)
Ending Balance, Shares at Mar. 31, 2023 [1]   1,604,761    
Ending Balance at Mar. 31, 2023 34,544 $ 2 372,530 (337,988)
Beginning Balance, Shares at Dec. 31, 2022 [1]   1,601,717    
Beginning Balance at Dec. 31, 2022 95,711 $ 2 371,350 (275,641)
Net loss (69,297)      
Ending Balance, Shares at Jun. 30, 2023 [1]   1,604,761    
Ending Balance at Jun. 30, 2023 27,894 $ 2 372,830 (344,938)
Beginning Balance, Shares at Mar. 31, 2023 [1]   1,604,761    
Beginning Balance at Mar. 31, 2023 34,544 $ 2 372,530 (337,988)
Stock-based compensation 300   300  
Net loss (6,950)     (6,950)
Ending Balance, Shares at Jun. 30, 2023 [1]   1,604,761    
Ending Balance at Jun. 30, 2023 $ 27,894 $ 2 $ 372,830 $ (344,938)
[1]

* Adjusted for the 1-for-30 reverse stock split

XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS USED IN OPERATING ACTIVITIES:    
Net loss $ (69,297) $ (47,267)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 1,424 2,694
Stock-based compensation expense 1,480 3,950
Impairment of in-process research and development 32,900 0
Loss on loan extinguishment 1,366 0
Impairment of long-lived assets 13,141 0
Gain on lease termination (752) 0
(Gain) loss on sale and disposal of property and equipment (617) 6
Non-cash operating lease and interest cost 1,939 1,003
Benefit for deferred income taxes (3,461) 0
Changes in operating assets and liabilities:    
Accounts receivable 144 320
Prepaid expenses and other current assets 921 (4,858)
Other non-current assets 4,033 308
Accounts payable (664) (2,431)
Accrued expenses and other current liabilities (2,676) (506)
Other non-current liabilities (50) 50
Operating lease liabilities (2,369) 5,246
Net cash used in operating activities (22,538) (41,485)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:    
Proceeds on sale of property and equipment 1,270 0
Purchases of property and equipment (14) (1,803)
Net cash provided by (used in) investing activities 1,256 (1,803)
CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:    
Proceeds from exercise of stock options, net 0 185
Proceeds from borrowings under loan agreement, net 0 14,738
Repayment of loan (15,000) 0
Payment of loan terminal fee obligation and prepayment fee (1,155) 0
Principal payments on finance lease obligation   (11)
Payment of deferred offering costs 0 (132)
Net cash (used in) provided by financing activities (16,155) 14,780
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (37,437) (28,508)
Cash, cash equivalents and restricted cash at beginning of period 73,805 135,965
Cash, cash equivalents and restricted cash at end of period 36,369 107,457
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Property and equipment in accounts payable and accrued liabilities 0 88
Right-of-use assets obtained in exchange for new operating lease liability 0 37,094
Prepaid rent reclassified to right-of-use assets $ 0 $ 7,736
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2023
Jun. 30, 2022
Statement of Cash Flows [Abstract]    
Cash and cash equivalents $ 34,051 $ 104,673
Restricted cash 2,318 2,784
Total cash, cash equivalents and restricted cash $ 36,369 $ 107,457
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Operations and Basis of Presentation
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Basis of Presentation

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Business

Finch Therapeutics Group, Inc. (the “Company” or “FTG”) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (“Finch”) and Crestovo Holdings LLC (“Crestovo”) in September 2017 (the “Merger”), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (“Finch Holdings”). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.

The Company is a microbiome technology company with a portfolio of intellectual property and microbiome assets. In January 2023, the Company announced the decision to wind down its development efforts and focus on realizing the value of its intellectual property estate and other assets.

Liquidity and Capital Resources

Management believes that the Company’s cash and cash equivalents of $34.1 million as of June 30, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of these condensed consolidated financial statements. However, due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company does not currently expect to progress any product candidate through clinical trials or commercial approval and it does not currently expect to generate any revenue from product sales. The Company may never succeed in realizing the value of its intellectual property estate and other assets and, even if it does, it may never generate revenue that is significant or large enough to achieve profitability.

The Company has significantly scaled back its expenses by winding down its development efforts, including by liquidating certain of its assets, terminating vendor contracts and reducing headcount. The Company may need additional funding to support its operating activities as it seeks to realize value from its intellectual property estate and other assets. Until such time, if ever, that the Company can generate substantial revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If the Company is unable to obtain funding as needed, it may decide to pursue a dissolution and liquidation.

Reverse Stock Split

On June 9, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001, at a ratio of 1-for-30 (the “Reverse Stock Split”). The Reverse Stock Split was reflected on the Nasdaq Global Select Market beginning with the opening of trading on June 12, 2023. Pursuant to the Reverse Stock Split, every 30 shares of the Company's issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. The Reverse Stock Split did not change the total number of shares the Company is authorized to issue. The Reverse Stock Split affected all issued and outstanding shares of the Company's common stock, and the respective numbers of shares of common stock underlying the Company’s outstanding stock options, outstanding restricted stock units (“RSU”) and the Company's equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying financial statements have been retrospectively adjusted to give effect to the Reverse Stock Split for all periods presented.

 

Reclassifications

Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of Article 10 of Regulation S-X of the Securities Act of 1933, as amended, published by the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes the disclosures are adequate. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2023.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary for a fair presentation of the Company’s condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, condensed consolidated statements of stockholders’ equity (deficit) for the three and six months ended June 30, 2023 and 2022, and condensed consolidated cash flows for the six months ended June 30, 2023 and 2022. Such adjustments are of a normal and recurring nature. The results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023. The consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements of the Company but does not include all disclosures required by U.S. GAAP.

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary Of Significant Accounting Policies . SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.

The significant accounting policies and estimates used in preparation of the unaudited interim condensed consolidated financial statements are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2023.

Goodwill and Acquired In-Process Research and Development

Goodwill and in-process research and development (“IPR&D”) are evaluated annually for impairment on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. To conduct impairment tests of goodwill, the fair value of the Company’s single reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value.

 

To conduct impairment tests of IPR&D, the fair value of the IPR&D asset is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&D asset exceeds its fair value. We estimate the fair value for our IPR&D asset using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates.

 

 

In January 2023, the Company made the decision to wind down its development efforts, which management concluded was an impairment indicator requiring the Company to perform an interim impairment test of IPR&D. Management's assessment for the impairment of IPR&D indicated that there are no future cash flow projections associated with its IPR&D asset and the fair value of the IPR&D asset was zero. This resulted in an impairment charge of $32.9 million during the six months ended June 30, 2023.

Recently Issued Accounting Pronouncements

On January 1, 2023, the Company adopted Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the Financial Accounting Standards Board (“FASB”) issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Adjustment To Prior Interim Unaudited Financial Statements
6 Months Ended
Jun. 30, 2023
Accounting Changes and Error Corrections [Abstract]  
Adjustment To Prior Interim Unaudited Financial Statements

3. ADJUSTMENT TO PRIOR INTERIM UNAUDITED FINANCIAL STATEMENTS

During the preparation of the second quarter financial statements of fiscal year 2023, the Company identified an error in the accrual of certain costs for the fiscal quarter ended March 31, 2023, which resulted in an overstatement of accounts payable and research and development expenses for that quarter. The correction of this error impacted the unaudited condensed consolidated financial statements for the first quarter of fiscal year 2023. The Company assessed the applicable guidance issued by the SEC and the FASB and concluded this misstatement was not material, individually or in the aggregate, to its unaudited condensed consolidated financial statements for the aforementioned interim period. In the table below, the Company adjusted its previously issued first quarter unaudited condensed consolidated financial information to correct the error by decreasing accounts payable and research and development expenses by $1.6 million for the quarter ended March 31, 2023. The financial statements will be adjusted in subsequent filings with the Securities and Exchange Commission that include such statements, including when the first quarter Form 10-Q is filed for fiscal year 2024.

Accumulated deficit as of March 31, 2023 in the accompanying statement of stockholders’ equity for the quarter ended June 30, 2023 was made smaller by $1.6 million due to the effects of the decreased expense accruals for the first quarter of fiscal year 2023. The following are selected line items from the financial statements also impacted by the $1.6 million, or $1,592 thousand, illustrating the effect of the error correction for the quarter ended March 31, 2023 (in thousands):

 

 

As Previously Reported

 

 

As Revised

 

Research and development

 

$

8,588

 

 

$

6,996

 

Total operating expenses

 

 

(67,482

)

 

 

(65,890

)

Net loss from operations

 

 

(67,375

)

 

 

(65,783

)

Loss before income taxes

 

 

(67,400

)

 

 

(65,808

)

Net loss

 

 

(63,939

)

 

 

(62,347

)

Net loss per share attributable to common stockholders—basic and diluted

 

$

(39.89

)

 

$

(39.19

)

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements . FAIR VALUE MEASUREMENTS

The Company has no financial liabilities measured at fair value on a recurring basis. The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):

 

DESCRIPTION

 

JUNE 30,
2023

 

 

QUOTED
PRICES
IN ACTIVE
MARKETS FOR
IDENTICAL
ASSETS
(LEVEL 1)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 2)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 3)

 

Money market funds

 

$

5,349

 

 

$

5,349

 

 

$

 

 

$

 

 

DESCRIPTION

 

DECEMBER 31,
2022

 

 

QUOTED
PRICES
IN ACTIVE
MARKETS FOR
IDENTICAL
ASSETS
(LEVEL 1)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 2)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 3)

 

Money market funds

 

$

69,991

 

 

$

69,991

 

 

$

 

 

$

 

 

There were no transfers between fair value levels during the six months ended June 30, 2023 and the year ended December 31, 2022. The carrying values of accounts receivable, prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net . PROPERTY AND EQUIPMENT, NET

Property and equipment, net consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Lab equipment

 

$

 

 

$

4,146

 

Office furniture and fixtures

 

 

869

 

 

 

1,406

 

Leasehold improvements

 

 

 

 

 

13,972

 

Construction work-in-progress

 

 

 

 

 

316

 

Software

 

 

 

 

 

4,883

 

Computer equipment

 

 

109

 

 

 

499

 

Total

 

 

978

 

 

 

25,222

 

Less: Accumulated depreciation

 

 

(246

)

 

 

(9,286

)

Property and equipment, net

 

$

732

 

 

$

15,936

 

 

Depreciation expense was $1.4 million and $2.7 million for the six months ended June 30, 2023 and 2022, respectively. During the quarter ended March 31, 2023, the Company recorded an impairment charge of $13.1 million to its long-lived assets, as it was determined that certain equipment, leasehold improvements, and software associated with program development would no longer be used following the discontinuation of the Company's Phase 3 clinical trial in CP101 and significant reduction in the Company's workforce, as announced in January 2023. In addition, during the quarter ended June 30, 2023, the Company sold its lab equipment, which resulted in a gain of $0.8 million included in other income (expense) on the condensed consolidated statement of operations.

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Leases
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Leases . LEASES

Inner Belt Road Lease

In December 2015, the Company entered into a 10-year lease agreement (the "Inner Belt Road Lease") for approximately 25,785 square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The monthly rental payments under the Inner Belt Road Lease, which include base rent charges of $0.1 million, are subject to periodic rent increases through September 2026.

The Inner Belt Road Lease terminated and the Company’s rent obligations ended on June 30, 2023. The landlord agreed to refund the Company for the full amount of the Company’s security deposit, which is included in prepaid expenses and other current assets on the condensed consolidated balance sheet.

The Company's lease expense under the Inner Belt Road Lease was $0.6 million for each of the six months ended June 30, 2023 and 2022.

Hood Lease

On August 3, 2021, Finch entered into a 10-year lease agreement (the “Hood Lease”) with Hood Park LLC, pursuant to which Finch leased approximately 61,139 square feet of office and laboratory space (the “Premises”). The Hood Lease provides Finch with an option to extend the lease for one additional five-year term. Finch’s annual base rent for the Premises started at approximately $4.5 million, and the lease contains annual rent escalations. Finch commenced business operations in the Premises in the second quarter of 2022, which triggered recognition of the lease for accounting purposes. The Company recorded lease expense related to the Hood Lease of $2.7 million and $0.9 million for the six months ended June 30, 2023 and 2022, respectively.

Finch posted a customary letter of credit in the amount of approximately $2.3 million, subject to decrease on a set schedule, as a security deposit pursuant to the Hood Lease. This is included in restricted cash, non-current on the condensed consolidated balance sheet as of June 30, 2023 and December 31, 2022.

In the third quarter of 2022, Finch entered into a sublease agreement to sublet approximately one third of its leased space under the Hood Lease, which commenced on August 10, 2022, for an initial term of two years, with an option for Finch to extend the sublease for up to one additional year, which Finch exercised in the fourth quarter of 2022. Additionally, in the fourth quarter of 2022, Finch entered into a second sublease agreement to sublet the remainder of its leased space under the Hood Lease for a three-year term, which commenced on December 15, 2022. For the six months ended June 30, 2023, Finch recognized sublease income of $1.9 million, which is presented as other income in the condensed consolidated statements of operations. No sublease income was recognized for the six months ended June 30, 2022, as the subleases had not commenced.

The following table presents the classification of right-of-use assets and operating lease liabilities as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

BALANCE SHEET CLASSIFICATION

 

JUNE 30, 2023

 

 

DECEMBER 31, 2022

 

ASSETS:

 

 

 

 

 

 

 

Operating lease assets

Operating right-of-use assets

 

$

27,308

 

 

$

32,752

 

LIABILITIES:

 

 

 

 

 

 

 

    Operating lease liabilities

 

 

 

 

 

 

 

Current

Operating lease liabilities, current

 

$

1,656

 

 

$

3,431

 

Noncurrent

Operating lease liabilities, non-current

 

 

29,388

 

 

 

34,255

 

Total lease liabilities

 

 

$

31,044

 

 

$

37,686

 

 

 

The following table represents the components of operating lease cost, which are included in general and administrative and research and development expense, and sublease income, which is included in other income on the statement of operations for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

 

 

THREE MONTHS ENDED JUNE 30,

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating lease cost

 

$

1,678

 

 

$

1,311

 

 

$

3,405

 

 

$

1,650

 

Short-term lease cost

 

 

4

 

 

 

31

 

 

 

17

 

 

 

139

 

Variable lease cost

 

 

87

 

 

 

469

 

 

 

532

 

 

 

964

 

Sublease income

 

 

(959

)

 

 

 

 

 

(1,919

)

 

 

 

Total lease cost, net

 

$

810

 

 

$

1,811

 

 

$

2,035

 

 

$

2,753

 

 

The weighted-average remaining operating lease term and discount rate as of June 30, 2023 and December 31, 2022 were as follows (in thousands):

 

 

 

JUNE 30, 2023

 

 

DECEMBER 31, 2022

 

Weighted-average remaining lease term (years)

 

 

8.5

 

 

 

8.5

 

Weighted-average discount rate

 

 

8.5

%

 

 

8.3

%

 

Supplemental disclosure of cash flow information related to operating leases for the six months ended June 30, 2023 and 2022 was as follows (in thousands):

 

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

Cash paid (received) for amounts included in measurement of lease liabilities

 

$

2,369

 

 

$

(5,246

)

The following table represents a summary of the Company’s future operating lease payments required as of June 30, 2023 (in thousands):

 

2023

 

$

1,825

 

2024

 

 

4,795

 

2025

 

 

4,930

 

2026

 

 

5,071

 

2027

 

 

5,215

 

Thereafter

 

 

22,391

 

Total future minimum lease payments

 

 

44,227

 

Less: amount representing interest

 

 

(13,183

)

Present value of future minimum lease payments

 

$

31,044

 

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities
6 Months Ended
Jun. 30, 2023
Accrued Liabilities, Current [Abstract]  
Accrued Expenses and Other Current Liabilities . ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Accrued research and development

 

$

99

 

 

$

1,967

 

Accrued legal and professional fees

 

 

4,945

 

 

 

5,852

 

Accrued compensation and benefits

 

 

1,482

 

 

 

880

 

Accrued other

 

 

961

 

 

 

1,462

 

Total accrued expenses and other current liabilities

 

$

7,487

 

 

$

10,161

 

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Loan Payable
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Loan Payable . LOAN PAYABLE

Hercules Loan and Security Agreement

On May 11, 2022, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., providing for a term loan with aggregate maximum borrowings of up to $55.0 million. Under the Loan Agreement, the Company borrowed an initial amount of $15.0 million, and on January 25, 2023 (the “Payoff Date”), the Company voluntarily paid off all outstanding principal, accrued and unpaid interest, fees, costs and expenses under the Loan Agreement, equal to $16.2 million in the aggregate, recording a loss on extinguishment of $1.4 million. Following the Payoff Date, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement and all other documents entered into in connection with the Loan Agreement were terminated.

 

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring
6 Months Ended
Jun. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring . RESTRUCTURING

 

During the three and six months ended June 30, 2023, the Company recognized restructuring charges of $0.8 million and $4.0 million, respectively, primarily consisting of one-time severance payments, healthcare coverage, outplacement services and related expenses in connection with the Company's January 2023 restructuring action (the “January 2023 Restructuring”). All severance payments will be completed by the second quarter of 2024. The accrued restructuring liability is included in accrued compensation and benefits as of June 30, 2023.

 

The following table summarizes the restructuring accrual activity for the six months ended June 30, 2023 (in thousands):

 

 

 

 

 

Accrued restructuring liability as of December 31, 2022

 

$

201

 

Restructuring charges

 

 

4,037

 

Cash payments

 

 

(2,776

)

Accrued restructuring liability as of June 30, 2023

 

$

1,462

 

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

10. INCOME TAXES

During the six months ended June 30, 2023 and the year ended December 31, 2022, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. There were no material changes in the Company’s tax position in the six months ended June 30, 2023 as compared to the year ended December 31, 2022. The benefit for the six months ended June 30, 2023 reflects the full removal of the deferred tax liability on the IPR&D that was written off during the first quarter of 2023 and treated as a discrete item in the tax provision.

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

11. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

 

On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, “Rebiotix”) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the “Court”). The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the “’309 Patent”); 10,463,702 (the “’702 Patent”); 10,328,107 (the “’107 Patent”); 10,064,899; 10,022,406 (the “’406 Patent”); 9,962,413 (the “’413 Patent”); and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the ’107, ’702, and ’309 Patents. In June 2022, Finch alleged infringement of the ’406 and ’413 Patents by Rebiotix. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota (“UMN”), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012, (collectively, the “UMN Patents”). On April 4, 2022, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the UMN Patents. On May 2, 2022, the Company and UMN responded, denying such counterclaims. The Court set a trial date for a five-day trial beginning on May 20, 2024. On January 23, 2023, the Company filed a second amended answer and counterclaims, in which the Company alleged infringement by Rebiotix of two additional U.S. Patents owned by Finch: U.S. Patent Nos. 11,541,080 (the “’080 Patent”) and 11,491,193 (the “’193 Patent”). On February 7, 2023, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the ’080 and ’193 patents. The Court issued a claim construction order on February 28, 2023. On July 6, 2023, Rebiotix filed a motion to dismiss certain counts of our second amended answer and counterclaims based on the assertion that Finch lacks standing to sue as to ’107 Patent, ’702 Patent, ’309 Patent, ’406 Patent, ’413 Patent, ’193 Patent, and ’080 Patent. Rebiotix specifically alleges that the sole named inventor on these patents, Thomas J. Borody, did not assign his rights in those patents to Finch, and as a result, Finch does not own them and therefore does not have standing to assert them. Briefing on this motion is complete.

 

The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined that there is no probable or estimable loss contingency that is required to be recorded as of June 30, 2023.

License and Royalty Payments

The Company is party to license and other agreements under which it is obligated to make milestone and royalty payments and incur annual maintenance fees. The Company owes a nominal annual maintenance fee under its license agreement with UMN, (the “UMN Agreement”), as well as escalating minimum royalty amounts. The minimum payments continue in perpetuity for the University of Minnesota until the agreement is terminated. On April 12, 2023, the Company amended its agreement with UMN to, among other things, allow the Company to satisfy certain performance milestones through sublicensing agreements.

 

The Company is party to an agreement with OpenBiome requiring the Company to pay certain milestones of up to $26.0 million upon the occurrence of certain R&D events, regulatory approvals, and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholder's Equity
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders' Equity

12. STOCKHOLDERS’ EQUITY

On February 24, 2021, the board of directors of the Company (the “Board”) and the Company’s stockholders approved the Company’s Amended and Restated Certificate of Incorporation. The certificate authorized the issuance of up to 200,000,000 shares of $0.001 par value common stock and up to 10,000,000 shares of $0.001 par value undesignated preferred stock. The Board may designate the rights, preferences, privileges, and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and number of shares constituting any series or the designation of any series. The issuance of preferred stock could have the effect of restricting dividends on the Company's common stock, diluting the voting power of the Company's common stock, impairing the liquidation rights of the Company's common stock, or delaying or preventing a change in control. As of June 30, 2023, no shares of preferred stock were outstanding.

Each share of common stock entitles the holder to one vote, together with the holders of any preferred stock outstanding, on all matters submitted to the stockholders for a vote. Common stockholders are also entitled to receive dividends. As of June 30, 2023, no cash dividends have been declared or paid.

As of June 30, 2023 and December 31, 2022 the Company has reserved the following shares of common stock for the exercise of stock options, common stock warrants, vesting of restricted stock and shares issuable under the employee stock purchase plan:

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Options to purchase common stock

 

 

72,586

 

 

 

109,522

 

Unvested restricted stock units

 

 

 

 

 

9,039

 

Shares issuable under employee stock purchase plan

 

 

 

 

 

3

 

 

 

 

72,586

 

 

 

118,564

 

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

13. STOCK-BASED COMPENSATION

2021 Equity Incentive Plan
 

In March 2021, the Board adopted, and the stockholders approved, the 2021 Equity Incentive Plan (the “2021 Plan”).The 2021 Plan was amended and restated as of June 8, 2023 to reflect the stock split. The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates.

The number of shares of common stock reserved for issuance under the Company's 2021 Plan automatically increases on January 1 of each calendar year through January 1, 2031, in an amount equal to (i) 5.0% of the total number of shares of common stock outstanding on December 31 of the year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the applicable January 1. The maximum number of shares of common stock that may be issued on the exercise of incentive stock options under the 2021 Plan is 470,000 shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under the 2021 Plan.

 

On January 1, 2023, the number of shares of common stock reserved and available for issuance under the 2021 Plan automatically increased by 80,089 shares and as of June 30, 2023, there were 72,586 shares of common stock issuable upon the exercise of outstanding options and there were 263,753 shares available for future issuance under the 2021 Plan.

 

2021 Employee Stock Purchase Plan

In March 2021, the Board adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The 2021 ESPP was amended and restated as of June 8, 2023 to reflect the stock split. The 2021 ESPP is administered by the Board or by a committee appointed by the Board. The 2021 ESPP provides participating employees with the opportunity to purchase shares of common stock. The occurrence and duration of offering periods under the 2021 ESPP are subject to the determinations of the compensation committee of the Board. Annually the common stock reserved and available for issuance under the 2021 ESPP automatically increases and on January 1, 2023, increased by 16,018. As of June 30, 2023, 3,354 shares have been issued under the 2021 ESPP and 45,167 shares are available for future issuance.

Stock Options

The following table summarizes the activity of the Company’s stock options under the 2017 Plan and 2021 Plan for the six months ended June 30, 2023:

 

 

SHARES

 

 

WEIGHTED-
AVERAGE
EXERCISE
PRICE

 

 

WEIGHTED-
AVERAGE
REMAINING
CONTRACTUAL
TERM (in years)

 

 

AGGREGATE
INTRINSIC
VALUE
(in thousands)

 

Outstanding as of December 31, 2022

 

 

109,522

 

 

$

293.81

 

 

 

6.9

 

 

$

 

Granted

 

 

34,094

 

 

$

8.15

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(48,146

)

 

$

327.08

 

 

 

 

 

 

 

Expired

 

 

(22,884

)

 

$

291.79

 

 

 

 

 

 

 

Outstanding as of June 30, 2023

 

 

72,586

 

 

$

138.21

 

 

 

6.0

 

 

$

13

 

Options exercisable as of June 30, 2023

 

 

36,785

 

 

$

249.63

 

 

 

2.6

 

 

$

 

Options vested or expected to vest as of June 30, 2023

 

 

72,586

 

 

$

138.21

 

 

 

6.0

 

 

$

13

 

 

As of June 30, 2023, there was approximately $0.3 million of unrecognized compensation expense related to the stock-based compensation arrangements granted under the 2021 Plan remaining to be recognized. The Company expects to recognize this cost over a weighted average period of 3.7 years.

 

Restricted Stock Unit Awards

In June 2022, the Company issued RSU awards with time-based vesting conditions to employees. The fair value of an RSU award is equal to the fair market value of the Company's ordinary shares on the date of grant and the expense is recognized on a straight-line basis over the requisite service period. The RSUs primarily vest over one year from the grant date.

The following table summarizes the activity of the Company’s RSUs under the 2021 Plan for the six months ended June 30, 2023:

 

 

 

RSUs

 

 

WEIGHTED-
AVERAGE
GRANT DATE FAIR VALUE

 

 

AGGREGATE
INTRINSIC
VALUE
(in thousands)

 

Outstanding as of December 31, 2022

 

 

9,039

 

 

$

83.88

 

 

$

131

 

Vested and distributed

 

 

(3,317

)

 

$

83.80

 

 

 

 

Forfeited

 

 

(5,722

)

 

$

83.93

 

 

 

 

Unvested as of June 30, 2023

 

 

 

 

$

 

 

$

 

 

Stock-Based Compensation Expense

Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the periods presented is as follows (in thousands):

 

 

THREE MONTHS ENDED JUNE 30,

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

 

 

$

760

 

 

$

231

 

 

$

1,769

 

General and administrative

 

 

300

 

 

 

1,070

 

 

 

1,249

 

 

 

2,181

 

Total

 

$

300

 

 

$

1,830

 

 

$

1,480

 

 

$

3,950

 

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Retirement Plan
6 Months Ended
Jun. 30, 2023
Retirement Benefits [Abstract]  
Retirement Plan

14. RETIREMENT PLAN

The Company has adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. All employees are eligible to become participants of the plan at their hire date. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right to make additional contributions to this plan. The Company made contributions to the plan of $0.1 million and $0.4 million in the six months ended June 30, 2023 and 2022, respectively.

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Loss per Share

15. LOSS PER SHARE

Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):

 

 

 

FOR THE THREE MONTHS
ENDED JUNE 30,

 

 

FOR THE SIX MONTHS
ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(6,950

)

 

$

(22,700

)

 

$

(69,297

)

 

$

(47,267

)

Net loss attributable to
   common stockholders—basic and diluted

 

 

(6,950

)

 

 

(22,700

)

 

 

(69,297

)

 

 

(47,267

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common
   stock outstanding—basic and diluted

 

 

1,604,795

 

 

 

1,585,978

 

 

 

1,603,811

 

 

 

1,585,093

 

Net loss per share attributable
   to common stockholders—basic and diluted

 

$

(4.33

)

 

$

(14.31

)

 

$

(43.21

)

 

$

(29.82

)

 

The Company’s potentially dilutive securities, which include stock options, warrants, RSU awards and shares issuable under the employee stock purchase plan have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at June 30, 2023 and 2022 because including them would have had an anti-dilutive effect:

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

 

2022

 

Options to purchase common stock

 

 

72,586

 

 

 

 

109,522

 

Unvested restricted stock units

 

 

 

 

 

 

9,039

 

Shares issuable under employee stock purchase plan

 

 

 

 

 

 

3

 

 

 

 

72,586

 

 

 

 

118,564

 

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

16. SUBSEQUENT EVENTS

Except as discussed in Note 11, there have no subsequent events through the date of these financial statements.

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Goodwill and Acquired In-Process Research and Development

Goodwill and Acquired In-Process Research and Development

Goodwill and in-process research and development (“IPR&D”) are evaluated annually for impairment on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. To conduct impairment tests of goodwill, the fair value of the Company’s single reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value.

 

To conduct impairment tests of IPR&D, the fair value of the IPR&D asset is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&D asset exceeds its fair value. We estimate the fair value for our IPR&D asset using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates.

 

 

In January 2023, the Company made the decision to wind down its development efforts, which management concluded was an impairment indicator requiring the Company to perform an interim impairment test of IPR&D. Management's assessment for the impairment of IPR&D indicated that there are no future cash flow projections associated with its IPR&D asset and the fair value of the IPR&D asset was zero. This resulted in an impairment charge of $32.9 million during the six months ended June 30, 2023.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

On January 1, 2023, the Company adopted Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the Financial Accounting Standards Board (“FASB”) issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Adjustment To Prior Interim Unaudited Financial Statements (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Changes and Error Corrections [Abstract]  
Schedule of effect of error correction of prior interim unaudited financial statements The following are selected line items from the financial statements also impacted by the $1.6 million, or $1,592 thousand, illustrating the effect of the error correction for the quarter ended March 31, 2023 (in thousands):

 

 

As Previously Reported

 

 

As Revised

 

Research and development

 

$

8,588

 

 

$

6,996

 

Total operating expenses

 

 

(67,482

)

 

 

(65,890

)

Net loss from operations

 

 

(67,375

)

 

 

(65,783

)

Loss before income taxes

 

 

(67,400

)

 

 

(65,808

)

Net loss

 

 

(63,939

)

 

 

(62,347

)

Net loss per share attributable to common stockholders—basic and diluted

 

$

(39.89

)

 

$

(39.19

)

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):

 

DESCRIPTION

 

JUNE 30,
2023

 

 

QUOTED
PRICES
IN ACTIVE
MARKETS FOR
IDENTICAL
ASSETS
(LEVEL 1)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 2)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 3)

 

Money market funds

 

$

5,349

 

 

$

5,349

 

 

$

 

 

$

 

 

DESCRIPTION

 

DECEMBER 31,
2022

 

 

QUOTED
PRICES
IN ACTIVE
MARKETS FOR
IDENTICAL
ASSETS
(LEVEL 1)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 2)

 

 

SIGNIFICANT
OBSERVABLE
INPUTS
(LEVEL 3)

 

Money market funds

 

$

69,991

 

 

$

69,991

 

 

$

 

 

$

 

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Lab equipment

 

$

 

 

$

4,146

 

Office furniture and fixtures

 

 

869

 

 

 

1,406

 

Leasehold improvements

 

 

 

 

 

13,972

 

Construction work-in-progress

 

 

 

 

 

316

 

Software

 

 

 

 

 

4,883

 

Computer equipment

 

 

109

 

 

 

499

 

Total

 

 

978

 

 

 

25,222

 

Less: Accumulated depreciation

 

 

(246

)

 

 

(9,286

)

Property and equipment, net

 

$

732

 

 

$

15,936

 

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Tables)
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Leases Balance Sheet Information

The following table presents the classification of right-of-use assets and operating lease liabilities as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

BALANCE SHEET CLASSIFICATION

 

JUNE 30, 2023

 

 

DECEMBER 31, 2022

 

ASSETS:

 

 

 

 

 

 

 

Operating lease assets

Operating right-of-use assets

 

$

27,308

 

 

$

32,752

 

LIABILITIES:

 

 

 

 

 

 

 

    Operating lease liabilities

 

 

 

 

 

 

 

Current

Operating lease liabilities, current

 

$

1,656

 

 

$

3,431

 

Noncurrent

Operating lease liabilities, non-current

 

 

29,388

 

 

 

34,255

 

Total lease liabilities

 

 

$

31,044

 

 

$

37,686

 

Summary of Components of Lease Cost

The following table represents the components of operating lease cost, which are included in general and administrative and research and development expense, and sublease income, which is included in other income on the statement of operations for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

 

 

THREE MONTHS ENDED JUNE 30,

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating lease cost

 

$

1,678

 

 

$

1,311

 

 

$

3,405

 

 

$

1,650

 

Short-term lease cost

 

 

4

 

 

 

31

 

 

 

17

 

 

 

139

 

Variable lease cost

 

 

87

 

 

 

469

 

 

 

532

 

 

 

964

 

Sublease income

 

 

(959

)

 

 

 

 

 

(1,919

)

 

 

 

Total lease cost, net

 

$

810

 

 

$

1,811

 

 

$

2,035

 

 

$

2,753

 

Summary of Weighted Average Remaining Operating Lease Term and Discount Rate

The weighted-average remaining operating lease term and discount rate as of June 30, 2023 and December 31, 2022 were as follows (in thousands):

 

 

 

JUNE 30, 2023

 

 

DECEMBER 31, 2022

 

Weighted-average remaining lease term (years)

 

 

8.5

 

 

 

8.5

 

Weighted-average discount rate

 

 

8.5

%

 

 

8.3

%

Schedule of Supplemental Cash Flow Information

Supplemental disclosure of cash flow information related to operating leases for the six months ended June 30, 2023 and 2022 was as follows (in thousands):

 

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

Cash paid (received) for amounts included in measurement of lease liabilities

 

$

2,369

 

 

$

(5,246

)

Schedule of Future Lease Payments

The following table represents a summary of the Company’s future operating lease payments required as of June 30, 2023 (in thousands):

 

2023

 

$

1,825

 

2024

 

 

4,795

 

2025

 

 

4,930

 

2026

 

 

5,071

 

2027

 

 

5,215

 

Thereafter

 

 

22,391

 

Total future minimum lease payments

 

 

44,227

 

Less: amount representing interest

 

 

(13,183

)

Present value of future minimum lease payments

 

$

31,044

 

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands):

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Accrued research and development

 

$

99

 

 

$

1,967

 

Accrued legal and professional fees

 

 

4,945

 

 

 

5,852

 

Accrued compensation and benefits

 

 

1,482

 

 

 

880

 

Accrued other

 

 

961

 

 

 

1,462

 

Total accrued expenses and other current liabilities

 

$

7,487

 

 

$

10,161

 

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring (Tables)
6 Months Ended
Jun. 30, 2023
Restructuring and Related Activities [Abstract]  
Summary of Restructuring Activity

The following table summarizes the restructuring accrual activity for the six months ended June 30, 2023 (in thousands):

 

 

 

 

 

Accrued restructuring liability as of December 31, 2022

 

$

201

 

Restructuring charges

 

 

4,037

 

Cash payments

 

 

(2,776

)

Accrued restructuring liability as of June 30, 2023

 

$

1,462

 

XML 45 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants

As of June 30, 2023 and December 31, 2022 the Company has reserved the following shares of common stock for the exercise of stock options, common stock warrants, vesting of restricted stock and shares issuable under the employee stock purchase plan:

 

 

 

JUNE 30,
2023

 

 

DECEMBER 31,
2022

 

Options to purchase common stock

 

 

72,586

 

 

 

109,522

 

Unvested restricted stock units

 

 

 

 

 

9,039

 

Shares issuable under employee stock purchase plan

 

 

 

 

 

3

 

 

 

 

72,586

 

 

 

118,564

 

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Total Stock-Based Compensation Expense

Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the periods presented is as follows (in thousands):

 

 

THREE MONTHS ENDED JUNE 30,

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

 

 

$

760

 

 

$

231

 

 

$

1,769

 

General and administrative

 

 

300

 

 

 

1,070

 

 

 

1,249

 

 

 

2,181

 

Total

 

$

300

 

 

$

1,830

 

 

$

1,480

 

 

$

3,950

 

Restricted Stock Units (RSUs) [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Activity of Stock Options

The following table summarizes the activity of the Company’s RSUs under the 2021 Plan for the six months ended June 30, 2023:

 

 

 

RSUs

 

 

WEIGHTED-
AVERAGE
GRANT DATE FAIR VALUE

 

 

AGGREGATE
INTRINSIC
VALUE
(in thousands)

 

Outstanding as of December 31, 2022

 

 

9,039

 

 

$

83.88

 

 

$

131

 

Vested and distributed

 

 

(3,317

)

 

$

83.80

 

 

 

 

Forfeited

 

 

(5,722

)

 

$

83.93

 

 

 

 

Unvested as of June 30, 2023

 

 

 

 

$

 

 

$

 

 

Stock Options [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Activity of Stock Options

The following table summarizes the activity of the Company’s stock options under the 2017 Plan and 2021 Plan for the six months ended June 30, 2023:

 

 

SHARES

 

 

WEIGHTED-
AVERAGE
EXERCISE
PRICE

 

 

WEIGHTED-
AVERAGE
REMAINING
CONTRACTUAL
TERM (in years)

 

 

AGGREGATE
INTRINSIC
VALUE
(in thousands)

 

Outstanding as of December 31, 2022

 

 

109,522

 

 

$

293.81

 

 

 

6.9

 

 

$

 

Granted

 

 

34,094

 

 

$

8.15

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(48,146

)

 

$

327.08

 

 

 

 

 

 

 

Expired

 

 

(22,884

)

 

$

291.79

 

 

 

 

 

 

 

Outstanding as of June 30, 2023

 

 

72,586

 

 

$

138.21

 

 

 

6.0

 

 

$

13

 

Options exercisable as of June 30, 2023

 

 

36,785

 

 

$

249.63

 

 

 

2.6

 

 

$

 

Options vested or expected to vest as of June 30, 2023

 

 

72,586

 

 

$

138.21

 

 

 

6.0

 

 

$

13

 

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share (Tables)
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Basic and Diluted Loss per Share Attributable to Common Stockholders

Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):

 

 

 

FOR THE THREE MONTHS
ENDED JUNE 30,

 

 

FOR THE SIX MONTHS
ENDED JUNE 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(6,950

)

 

$

(22,700

)

 

$

(69,297

)

 

$

(47,267

)

Net loss attributable to
   common stockholders—basic and diluted

 

 

(6,950

)

 

 

(22,700

)

 

 

(69,297

)

 

 

(47,267

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common
   stock outstanding—basic and diluted

 

 

1,604,795

 

 

 

1,585,978

 

 

 

1,603,811

 

 

 

1,585,093

 

Net loss per share attributable
   to common stockholders—basic and diluted

 

$

(4.33

)

 

$

(14.31

)

 

$

(43.21

)

 

$

(29.82

)

Computation of Diluted Loss per Share Attributable to Common Stockholders The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at June 30, 2023 and 2022 because including them would have had an anti-dilutive effect:

 

 

SIX MONTHS ENDED JUNE 30,

 

 

 

2023

 

 

 

2022

 

Options to purchase common stock

 

 

72,586

 

 

 

 

109,522

 

Unvested restricted stock units

 

 

 

 

 

 

9,039

 

Shares issuable under employee stock purchase plan

 

 

 

 

 

 

3

 

 

 

 

72,586

 

 

 

 

118,564

 

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Feb. 18, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Cash and cash equivalents $ 34,051 $ 71,038 $ 104,673  
Common stock, par value $ 0.001 $ 0.001    
Stock issued during period shares reverse stock splits 30      
Common Stock        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Common stock, par value       $ 0.001
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Summary Of Significant Accounting Policies - Additional Information (Details)
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Summary Of Significant Accounting Policies [Table]  
Impairment charges $ 32.9
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Adjustment To Prior Interim Unaudited Financial Statements - Additional Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Accounting Changes and Error Corrections [Abstract]  
Decrease in accounts payable and research and development expenses $ 1,600
Reduction in accumulated deficit 1,600
Error correction impact $ 1,592
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Adjustment To Prior Interim Unaudited Financial Statements - Schedule of effect of error correction of prior interim unaudited financial statements (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Research and development $ 203   $ 13,923   $ 7,199 $ 29,453
Total operating expenses 9,881   22,990   75,771 47,924
Net loss from operations (9,881)   (22,629)   (75,664) (47,209)
Loss before income taxes (6,950)   (22,700)   (72,758) (47,267)
Net loss $ (6,950) $ (62,347) $ (22,700) $ (24,567) $ (69,297) $ (47,267)
Net loss per share attributable to common stockholders - basic $ (4.33)   $ (14.31)   $ (43.21) $ (29.82)
Net loss per share attributable to common stockholders - diluted $ (4.33)   $ (14.31)   $ (43.21) $ (29.82)
Previously Reported            
Research and development $ 8,588          
Total operating expenses (67,482)          
Net loss from operations (67,375)          
Loss before income taxes (67,400)          
Net loss $ (63,939)          
Net loss per share attributable to common stockholders - basic $ (39.89)          
Net loss per share attributable to common stockholders - diluted $ (39.89)          
Restatement adjustment            
Research and development $ 6,996          
Total operating expenses (65,890)          
Net loss from operations (65,783)          
Loss before income taxes (65,808)          
Net loss $ (62,347)          
Net loss per share attributable to common stockholders - basic $ (39.19)          
Net loss per share attributable to common stockholders - diluted $ (39.19)          
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
ASSETS    
Total financial assets $ 66,857 $ 162,939
Fair Value, Measurements, Recurring | Money Market Funds [Member]    
ASSETS    
Total financial assets 5,349 69,991
Fair Value, Measurements, Recurring | Money Market Funds [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1)    
ASSETS    
Total financial assets $ 5,349 $ 69,991
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Additional Information (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Transfers between fair value levels $ 0 $ 0
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial liabilities $ 0  
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total $ 978 $ 25,222
Less: Accumulated depreciation (246) (9,286)
Property and equipment, net 732 15,936
Lab Equipment    
Property, Plant and Equipment [Line Items]    
Total 0 4,146
Office Furniture and Fixtures    
Property, Plant and Equipment [Line Items]    
Total 869 1,406
Leasehold Improvements    
Property, Plant and Equipment [Line Items]    
Total 0 13,972
Construction Work-In-Progress    
Property, Plant and Equipment [Line Items]    
Total 0 316
Software    
Property, Plant and Equipment [Line Items]    
Total 0 4,883
Computer Equipment    
Property, Plant and Equipment [Line Items]    
Total $ 109 $ 499
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Property, Plant and Equipment [Line Items]        
Depreciation expense     $ 1,400 $ 2,700
Impairment charge   $ 13,100    
Gain on disposal of fixed assets $ 800   $ 617 $ (6)
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 03, 2021
USD ($)
ft²
Dec. 31, 2015
USD ($)
ft²
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
Sep. 30, 2022
Capital Leased Assets [Line Items]                
Office and laboratory space for lease | ft²   25,785            
Sublease income     $ 959,000 $ 0 $ 1,919,000 $ 0    
Inner Belt Road Lease                
Capital Leased Assets [Line Items]                
Sublease agreement term   10 years            
Rental charges   $ 100,000            
Lease expense         600,000 600,000    
Hood Park Lease                
Capital Leased Assets [Line Items]                
Sublease agreement term 10 years           3 years 2 years
Office and laboratory space for lease | ft² 61,139              
Rental charges $ 4,500,000              
Lease expense         2,700,000 900,000    
Sublease income         $ 1,900,000 $ 0    
Lease term description         The Hood Lease provides Finch with an option to extend the lease for one additional five-year term      
Letter of Credit                
Capital Leased Assets [Line Items]                
Decrease in security deposit $ 2,300,000              
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Leases Balance Sheet Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Operating right-of-use assets $ 27,308 $ 32,752
Operating lease liabilities, current 1,656 3,431
Operating lease liabilities, non-current 29,388 34,255
Total lease liabilities $ 31,044 $ 37,686
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Summary of Components of Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Leases [Abstract]        
Operating lease cost $ 1,678 $ 1,311 $ 3,405 $ 1,650
Short-term lease cost 4 31 17 139
Variable lease cost 87 469 532 964
Sublease income (959) 0 (1,919) 0
Total lease cost, net $ 810 $ 1,811 $ 2,035 $ 2,753
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Summary of Weighted Average Remaining Operating Lease Term and Discount Rate (Details)
Jun. 30, 2023
Dec. 31, 2022
Lease, Cost [Abstract]    
Weighted-average remaining lease term 8 years 6 months 8 years 6 months
Weighted-average discount rate 8.50% 8.30%
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Leases [Abstract]    
Cash paid (received) for amounts included in measurement of lease liabilities $ 2,369 $ (5,246)
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Schedule of Future Lease Payments (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Operating Lease Obligations [Abstract]  
2023 $ 1,825
2024 4,795
2025 4,930
2026 5,071
2027 5,215
Thereafter 22,391
Total future minimum lease payments 44,227
Less: amount representing interest (13,183)
Present value of future minimum lease payments $ 31,044
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accrued Liabilities, Current [Abstract]    
Accrued research and development $ 99 $ 1,967
Accrued legal and professional fees 4,945 5,852
Accrued compensation and benefits 1,482 880
Accrued other 961 1,462
Total accrued expenses and other current liabilities $ 7,487 $ 10,161
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Loan Payable - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jan. 25, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
May 11, 2022
Short-Term Debt [Line Items]            
Aggregate payoff amount       $ 15,000 $ 0  
Loss on extinguishment   $ 0 $ 0 $ (1,366) $ 0  
Loan And Security Agreement [Member]            
Short-Term Debt [Line Items]            
Aggregate maximum borrowing capacity           $ 55,000
Aggregate payoff amount $ 16,200          
Loss on extinguishment $ 1,400          
Initial amount borrowed           $ 15,000
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Restructuring and Related Activities [Abstract]        
Restructuring Charges recognized $ 801 $ 903 $ 4,037 $ 903
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring - Summary of Restructuring Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]        
Restructuring $ 801 $ 903 $ 4,037 $ 903
Severance and Related Benefits        
Restructuring Cost and Reserve [Line Items]        
Accrued restructuring liability as of December 31, 2022     201  
Restructuring     4,037  
Cash payments     (2,776)  
Accrued restructuring liability as of June 30, 2023 $ 1,462   $ 1,462  
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Additional Information (Details)
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Open Biome  
Loss Contingencies [Line Items]  
Maximum Milestone Payment Required Under Agreement $ 26.0
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity - Additional Information (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Feb. 18, 2021
Class Of Stock [Line Items]      
Common shares authorized for issuance 200,000,000 200,000,000  
Common stock par value $ 0.001 $ 0.001  
Preferred stock, shares outstanding 0    
Cash dividends declared or paid $ 0    
Common stock voting rights Each share of common stock entitles the holder to one vote    
Common Stock      
Class Of Stock [Line Items]      
Common stock par value     $ 0.001
Undesignated Preferred Stock      
Class Of Stock [Line Items]      
Preferred stock par value     $ 0.001
Maximum | Common Stock      
Class Of Stock [Line Items]      
Common shares authorized for issuance     200,000,000
Maximum | Undesignated Preferred Stock      
Class Of Stock [Line Items]      
Preferred shares authorized for issuance     10,000,000
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants (Details) - shares
Jun. 30, 2023
Dec. 31, 2022
Class Of Stock [Line Items]    
Shares of common stock for potential conversion 72,586 118,564
Options to Purchase Common Stock    
Class Of Stock [Line Items]    
Shares of common stock for potential conversion 72,586 109,522
Unvested Restricted Stock Units    
Class Of Stock [Line Items]    
Shares of common stock for potential conversion 0 9,039
Employee Stock Option Member    
Class Of Stock [Line Items]    
Shares of common stock for potential conversion 0 3
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2023
Jan. 01, 2023
Dec. 31, 2022
[1]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Common Stock, Shares, Issued 1,604,761   1,601,717
2017 Equity Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Unrecognized compensation expense remaining to be recognized, period 3 years 8 months 12 days    
2021 Equity Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of common stock shares available for future grants 263,753 80,089  
Percentage of increase in shares of common stock reserved for issuance 5.00%    
Number of shares issuable upon the exercise of outstanding options 72,586    
Unrecognized compensation expense remaining to be recognized $ 0.3    
2021 Equity Incentive Plan | Incentive Stock Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Maximum number of common stock to be issued 470,000    
2021 Employee Stock Purchase Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of common stock shares available for future grants 45,167 16,018  
Stock Issued During Period, Shares, New Issues 3,354    
[1]

* Adjusted for the 1-for-30 reverse stock split

XML 70 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Activity of Stock Options (Details) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
2017 and 2021 Equity Incentive Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
SHARES, Outstanding, Beginning Balance 109,522  
SHARES, Granted 34,094  
SHARES, Cancelled or forfeited (48,146)  
SHARES, Expired (22,884)  
SHARES, Outstanding, Ending Balance 72,586 109,522
SHARES, Options exercisable 36,785  
SHARES, Options vested or expected to vest | shares 72,586  
WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Beginning Balance $ 293.81  
WEIGHTED AVERAGE EXERCISE PRICE, Granted 8.15  
WEIGHTED AVERAGE EXERCISE PRICE, Cancelled or forfeited 327.08  
WEIGHTED AVERAGE EXERCISE PRICE, Expired 291.79  
WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Ending Balance 138.21 $ 293.81
WEIGHTED AVERAGE EXERCISE PRICE, Options exercisable 249.63  
WEIGHTED AVERAGE EXERCISE PRICE, Options vested or expected to vest $ 138.21  
WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Outstanding 6 years 6 years 10 months 24 days
WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options exercisable 2 years 7 months 6 days  
WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options vested or expected to vest 6 years  
AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance $ 0  
AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance 13,000 $ 0
AGGREGATE INTRINSIC VALUE, Options exercisable 0  
AGGREGATE INTRINSIC VALUE, Options vested or expected to vest | $ $ 13,000  
2021 Equity Incentive Plan | Restricted Stock Units (RSUs) [Member]    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
SHARES, Outstanding, Beginning Balance 9,039  
SHARES, Vested and distributed $ (3,317)  
SHARES, Cancelled or forfeited (5,722)  
SHARES, Outstanding, Ending Balance 0 9,039
WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Outstanding, Beginning Balance $ 83.88  
WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Vested and distributed 83.8  
WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Forfeited 83.93  
WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Ending Balance $ 0 $ 83.88
AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance $ 131,000  
AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance $ 0 $ 131,000
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense $ 300 $ 1,830 $ 1,480 $ 3,950
Research and Development        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense 0 760 231 1,769
General and Administrative        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense $ 300 $ 1,070 $ 1,249 $ 2,181
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Retirement Plan - Additional Information (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Retirement Benefits [Abstract]    
Company's contribution to plan $ 0.1 $ 0.4
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Numerator:            
Net loss $ (6,950) $ (62,347) $ (22,700) $ (24,567) $ (69,297) $ (47,267)
Net loss attributable to common stockholders, basic (6,950)   (22,700)   (69,297) (47,267)
Net loss attributable to common stockholders, diluted $ (6,950)   $ (22,700)   $ (69,297) $ (47,267)
Denominator:            
Weighted-average common stock outstanding, basic [1] 1,604,795   1,585,978   1,603,811 1,585,093
Weighted-average common stock outstanding, diluted [1] 1,604,795   1,585,978   1,603,811 1,585,093
Net loss per share attributable to common stockholders, basic $ (4.33)   $ (14.31)   $ (43.21) $ (29.82)
Net loss per share attributable to common stockholders, diluted $ (4.33)   $ (14.31)   $ (43.21) $ (29.82)
[1]

* Adjusted for the 1-for-30 reverse stock split

XML 74 R60.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluding from computation of diluted net loss per share 72,586 118,564
Options to Purchase Common Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluding from computation of diluted net loss per share 72,586 109,522
Restricted Stock Units (RSUs)    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluding from computation of diluted net loss per share 0 9,039
Employee Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluding from computation of diluted net loss per share 0 3
XML 75 fnch-20230630_htm.xml IDEA: XBRL DOCUMENT 0001733257 us-gaap:EmployeeStockOptionMember 2022-12-31 0001733257 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001733257 us-gaap:EmployeeStockOptionMember 2023-06-30 0001733257 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001733257 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001733257 2023-08-04 0001733257 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001733257 2022-01-01 2022-03-31 0001733257 us-gaap:ComputerEquipmentMember 2023-06-30 0001733257 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001733257 fnch:HoodParkDriveMember 2023-01-01 2023-06-30 0001733257 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001733257 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001733257 us-gaap:CommonStockMember 2023-06-30 0001733257 us-gaap:CommonStockMember 2021-02-18 0001733257 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001733257 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001733257 us-gaap:RestrictedStockUnitsRSUMember fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2023-06-30 0001733257 fnch:HoodParkDriveMember 2021-08-03 2021-08-03 0001733257 2022-04-01 2022-06-30 0001733257 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0001733257 2023-06-30 0001733257 us-gaap:CommonStockMember 2022-12-31 0001733257 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001733257 fnch:HoodParkDriveMember 2021-08-03 0001733257 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-06-30 0001733257 fnch:InnerBeltRoadLeaseMember 2023-01-01 2023-06-30 0001733257 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001733257 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001733257 us-gaap:RetainedEarningsMember 2022-12-31 0001733257 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001733257 us-gaap:EmployeeSeveranceMember 2023-06-30 0001733257 fnch:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 0001733257 fnch:IncentiveStockOptionsMember fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2023-06-30 0001733257 fnch:LabEquipmentMember 2023-06-30 0001733257 fnch:InnerBeltRoadLeaseMember 2015-12-01 2015-12-31 0001733257 fnch:LoanAndSecurityAgreementMember 2023-01-25 2023-01-25 0001733257 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0001733257 us-gaap:ConstructionInProgressMember 2022-12-31 0001733257 srt:ScenarioPreviouslyReportedMember 2023-04-01 2023-06-30 0001733257 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001733257 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-06-30 0001733257 2022-03-31 0001733257 fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2023-06-30 0001733257 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001733257 srt:RestatementAdjustmentMember 2023-04-01 2023-06-30 0001733257 fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember 2022-12-31 0001733257 fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2023-01-01 2023-06-30 0001733257 us-gaap:ConstructionInProgressMember 2023-06-30 0001733257 fnch:UnvestedRestrictedStockUnitsMember 2022-12-31 0001733257 us-gaap:ComputerEquipmentMember 2022-12-31 0001733257 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001733257 fnch:HoodParkDriveMember 2022-12-31 0001733257 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001733257 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001733257 fnch:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001733257 us-gaap:RetainedEarningsMember 2021-12-31 0001733257 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001733257 fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember 2023-01-01 2023-06-30 0001733257 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001733257 fnch:LabEquipmentMember 2022-12-31 0001733257 2023-03-31 0001733257 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001733257 srt:MaximumMember us-gaap:CommonStockMember 2021-02-18 0001733257 us-gaap:RetainedEarningsMember 2022-06-30 0001733257 fnch:HoodParkDriveMember 2022-01-01 2022-06-30 0001733257 fnch:UndesignatedPreferredStockMember 2021-02-18 0001733257 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0001733257 us-gaap:RetainedEarningsMember 2023-06-30 0001733257 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001733257 us-gaap:RetainedEarningsMember 2022-03-31 0001733257 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001733257 2015-12-31 0001733257 fnch:OpenBiomeMember 2023-01-01 2023-06-30 0001733257 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001733257 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001733257 us-gaap:EmployeeSeveranceMember 2022-12-31 0001733257 us-gaap:LetterOfCreditMember 2021-08-03 2021-08-03 0001733257 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001733257 fnch:LoanAndSecurityAgreementMember 2022-05-11 0001733257 us-gaap:RestrictedStockUnitsRSUMember fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2023-01-01 2023-06-30 0001733257 fnch:OptionsToPurchaseCommonStockMember 2022-12-31 0001733257 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001733257 2023-04-01 2023-06-30 0001733257 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001733257 2022-06-30 0001733257 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001733257 2021-12-31 0001733257 us-gaap:CommonStockMember 2022-06-30 0001733257 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001733257 us-gaap:CommonStockMember 2021-12-31 0001733257 fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2023-01-01 0001733257 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001733257 fnch:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-06-30 0001733257 2022-12-31 0001733257 2022-01-01 2022-06-30 0001733257 us-gaap:CommonStockMember 2022-03-31 0001733257 us-gaap:CommonStockMember 2023-03-31 0001733257 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001733257 fnch:UnvestedRestrictedStockUnitsMember 2023-06-30 0001733257 fnch:OptionsToPurchaseCommonStockMember 2023-06-30 0001733257 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001733257 fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember 2023-06-30 0001733257 fnch:InnerBeltRoadLeaseMember 2015-12-31 0001733257 2023-01-01 2023-03-31 0001733257 fnch:InnerBeltRoadLeaseMember 2022-01-01 2022-06-30 0001733257 fnch:HoodParkDriveMember 2022-09-30 0001733257 2023-01-01 2023-06-30 0001733257 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001733257 fnch:TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember 2022-01-01 2022-12-31 0001733257 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001733257 fnch:TwoThousandSeventeenEquityIncentivePlanMember 2023-01-01 2023-06-30 0001733257 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001733257 us-gaap:RetainedEarningsMember 2023-03-31 0001733257 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001733257 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001733257 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001733257 us-gaap:RestrictedStockUnitsRSUMember fnch:TwoThousandTwentyOneEquityIncentivePlanMember 2022-12-31 0001733257 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001733257 srt:MaximumMember fnch:UndesignatedPreferredStockMember 2021-02-18 iso4217:USD shares pure utr:sqft shares iso4217:USD 0001733257 --12-31 true Q2 10-Q/A true 2023-06-30 2023 false 001-40227 FINCH THERAPEUTICS GROUP, INC. DE 82-3433558 75 State Street Suite 100 Boston MA 02109 617 229-6499 Common Stock, $0.001 par value per share FNCH NASDAQ Yes Yes Non-accelerated Filer true true false false 1604761 Finch Therapeutics Group, Inc. (the “Company”) filed its Form 10-Q for the quarterly period ended June 30, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission on August 10, 2023. The Company is filing this Amendment No. 1 on Form 10-Q/A (i) to correct the Section 302 and Section 906 Certifications (collectively, the “Certifications”) filed in the Form 10-Q as Exhibits 31.1, 31.2, and 32.1, respectively, which inadvertently set forth incorrect names and signatures on the Certifications and (ii) to correct the filing of an amendment to a material contract that was designated as filed in the Exhibit Index of the Form 10-Q but was inadvertently omitted in the filing. Except as expressly set forth herein, this Form 10-Q/A does not reflect events occurring after the date of the Form 10-Q filing or modify or update any of the other disclosures contained therein in any way other than as required to reflect the amendments discussed above. Other than the changes in exhibits referred to above, all other information in the Form 10-Q remains unchanged. 34051000 71038000 0 144000 2448000 3369000 36499000 74551000 732000 15936000 27308000 32752000 0 32900000 2318000 2568000 0 4232000 66857000 162939000 432000 1097000 7487000 10161000 1656000 3431000 9575000 14689000 0 3461000 0 14653000 29388000 34255000 0 170000 38963000 67228000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 1604761 1604761 1601717 1601717 2000 2000 372830000 371350000 -344938000 -275641000 27894000 95711000 66857000 162939000 0 361000 107000 715000 0 361000 107000 715000 203000 13923000 7199000 29453000 8877000 8164000 18494000 17568000 0 0 32900000 0 0 0 13141000 0 801000 903000 4037000 903000 9881000 22990000 75771000 47924000 -9881000 -22629000 -75664000 -47209000 420000 -65000 845000 -52000 752000 0 752000 0 0 0 -1366000 0 754000 -6000 617000 -6000 1005000 0 2058000 0 2931000 -71000 2906000 -58000 -6950000 -22700000 -72758000 -47267000 0 0 -3461000 0 -6950000 -22700000 -69297000 -47267000 -6950000 -22700000 -69297000 -47267000 -4.33 -4.33 -14.31 -14.31 -43.21 -43.21 -29.82 -29.82 1604795 1604795 1585978 1585978 1603811 1603811 1585093 1585093 1583669 2000 363217000 -160995000 202224000 680 14000 14000 2120000 2120000 -24567000 -24567000 1584349 2000 365351000 -185562000 179791000 3279 61000 61000 1825 110000 110000 1830000 1830000 -22700000 -22700000 1589453 2000 367352000 -208262000 159092000 1601717 2000 371350000 -275641000 95711000 3044 1180000 1180000 -62347000 -62347000 1604761 2000 372530000 -337988000 34544000 300000 300000 -6950000 -6950000 1604761 2000 372830000 -344938000 27894000 -69297000 -47267000 1424000 2694000 1480000 3950000 32900000 0 -1366000 0 13141000 0 752000 0 617000 -6000 1939000 1003000 -3461000 0 -144000 -320000 -921000 4858000 -4033000 -308000 -664000 -2431000 -2676000 -506000 -50000 50000 -2369000 5246000 -22538000 -41485000 1270000 0 14000 1803000 1256000 -1803000 0 185000 0 14738000 15000000 0 1155000 0 11000 0 132000 -16155000 14780000 -37437000 -28508000 73805000 135965000 36369000 107457000 0 88000 0 37094000 0 7736000 34051000 104673000 2318000 2784000 36369000 107457000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finch Therapeutics Group, Inc. (the “Company” or “FTG”) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (“Finch”) and Crestovo Holdings LLC (“Crestovo”) in September 2017 (the “Merger”), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (“Finch Holdings”). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is a microbiome technology company with a portfolio of intellectual property and microbiome assets. In January 2023, the Company announced the decision to wind down its development efforts and focus on realizing the value of its intellectual property estate and other assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management believes that the Company’s cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of June 30, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of these condensed consolidated financial statements. However, due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not currently expect to progress any product candidate through clinical trials or commercial approval and it does not currently expect to generate any revenue from product sales. The Company may never succeed in realizing the value of its intellectual property estate and other assets and, even if it does, it may never generate revenue that is significant or large enough to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has significantly scaled back its expenses by winding down its development efforts, including by liquidating certain of its assets, terminating vendor contracts and reducing headcount. The Company may need additional funding to support its operating activities as it seeks to realize value from its intellectual property estate and other assets. Until such time, if ever, that the Company can generate substantial revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If the Company is unable to obtain funding as needed, it may decide to pursue a dissolution and liquidation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 9, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at a ratio of 1-for-30 (the “Reverse Stock Split”). The Reverse Stock Split was reflected on the Nasdaq Global Select Market beginning with the opening of trading on June 12, 2023. Pursuant to the Reverse Stock Split, every </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. The Reverse Stock Split did not change the total number of shares the Company is authorized to issue. The Reverse Stock Split affected all issued and outstanding shares of the Company's common stock, and the respective numbers of shares of common stock underlying the Company’s outstanding stock options, outstanding restricted stock units (“RSU”) and the Company's equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying financial statements have been retrospectively adjusted to give effect to the Reverse Stock Split for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of Article 10 of Regulation S-X of the Securities Act of 1933, as amended, published by the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes the disclosures are adequate. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary for a fair presentation of the Company’s condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, condensed consolidated statements of stockholders’ equity (deficit) for the three and six months ended June 30, 2023 and 2022, and condensed consolidated cash flows for the six months ended June 30, 2023 and 2022. Such adjustments are of a normal and recurring nature. The results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements of the Company but does not include all disclosures required by U.S. GAAP.</span></p> 34100000 0.001 30 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The significant accounting policies and estimates used in preparation of the unaudited interim condensed</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consolidated financial statements are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2023.</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Acquired In-Process Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill and in-process research and development (“IPR&amp;D”) are evaluated annually for impairment on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. To conduct impairment tests of goodwill, the fair value of the Company’s single reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&amp;D asset exceeds its fair value. We estimate the fair value for our IPR&amp;D asset using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, the Company made the decision to wind down its development efforts, which management concluded was an impairment indicator requiring the Company to perform an interim impairment test of IPR&amp;D. Management's assessment for the impairment of IPR&amp;D indicated that there are no future cash flow projections associated with its IPR&amp;D asset and the fair value of the IPR&amp;D asset was zero. This resulted in an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the six months ended June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2023, the Company adopted Accounting Standards Update No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the Financial Accounting Standards Board (“FASB”)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.</span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Acquired In-Process Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill and in-process research and development (“IPR&amp;D”) are evaluated annually for impairment on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. To conduct impairment tests of goodwill, the fair value of the Company’s single reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&amp;D asset exceeds its fair value. We estimate the fair value for our IPR&amp;D asset using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, the Company made the decision to wind down its development efforts, which management concluded was an impairment indicator requiring the Company to perform an interim impairment test of IPR&amp;D. Management's assessment for the impairment of IPR&amp;D indicated that there are no future cash flow projections associated with its IPR&amp;D asset and the fair value of the IPR&amp;D asset was zero. This resulted in an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the six months ended June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 32900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2023, the Company adopted Accounting Standards Update No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the Financial Accounting Standards Board (“FASB”)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. ADJUSTMENT TO PRIOR INTERIM UNAUDITED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the preparation of the second quarter financial statements of fiscal year 2023, the Company identified an error in the accrual of certain costs for the fiscal quarter ended March 31, 2023, which resulted in an overstatement of accounts payable and research and development expenses for that quarter. The correction of this error impacted the unaudited condensed consolidated financial statements for the first quarter of fiscal year 2023. The Company assessed the applicable guidance issued by the SEC and the FASB and concluded this misstatement was not material, individually or in the aggregate, to its unaudited condensed consolidated financial statements for the aforementioned interim period. In the table below, the Company adjusted its previously issued first quarter unaudited condensed consolidated financial information to correct the error by decreasing accounts payable and research and development expenses by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the quarter ended March 31, 2023. The financial statements will be adjusted in subsequent filings with the Securities and Exchange Commission that include such statements, including when the first quarter Form 10-Q is filed for fiscal year 2024.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit as of March 31, 2023 in the accompanying statement of stockholders’ equity for the quarter ended June 30, 2023 was made smaller by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million due to the effects of the decreased expense accruals for the first quarter of fiscal year 2023. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are selected line items from the financial statements also impacted by the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,592</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, illustrating the effect of the error correction for the quarter ended March 31, 2023 (in thousands):</span></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:61.314%;"></td> <td style="width:1.642%;"></td> <td style="width:1.0%;"></td> <td style="width:15.701%;"></td> <td style="width:1.0%;"></td> <td style="width:1.642%;"></td> <td style="width:1.0%;"></td> <td style="width:15.701%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As Previously Reported</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As Revised</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,588</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,996</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,482</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,890</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss from operations</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,375</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,783</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,400</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,808</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,347</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders—basic and diluted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.89</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.19</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table></div> 1600000 1600000 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are selected line items from the financial statements also impacted by the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,592</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, illustrating the effect of the error correction for the quarter ended March 31, 2023 (in thousands):</span> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:61.314%;"></td> <td style="width:1.642%;"></td> <td style="width:1.0%;"></td> <td style="width:15.701%;"></td> <td style="width:1.0%;"></td> <td style="width:1.642%;"></td> <td style="width:1.0%;"></td> <td style="width:15.701%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As Previously Reported</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As Revised</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,588</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,996</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,482</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,890</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss from operations</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,375</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,783</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,400</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,808</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,347</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders—basic and diluted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.89</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.19</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table> 1600000 1592000 8588000 6996000 -67482000 -65890000 -67375000 -65783000 -67400000 -65808000 -63939000 -62347000 -39.89 -39.89 -39.19 -39.19 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. FAIR VALUE MEASUREMENTS </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial liabilities measured at fair value on a recurring basis.</span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): </span></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.695%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,349</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,349</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.695%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,991</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,991</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers between fair value levels during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 and the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The carrying values of accounts receivable, prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></p> 0 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.695%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,349</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,349</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.695%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.484%;"></td> <td style="width:1.0%;"></td> <td style="width:11.591999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,991</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,991</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 5349000 5349000 69991000 69991000 0 0 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. PROPERTY AND EQUIPMENT, NET </span><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.897%;"></td> <td style="width:1.455%;"></td> <td style="width:1.0%;"></td> <td style="width:14.354%;"></td> <td style="width:1.0%;"></td> <td style="width:1.455%;"></td> <td style="width:1.0%;"></td> <td style="width:14.839%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,146</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">869</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,406</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,972</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction work-in-progress</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">316</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">499</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">978</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,222</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">246</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,286</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">732</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,936</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense was</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 and 2022, respectively. During the quarter ended March 31, 2023, the Company recorded an impairment charge of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to its long-lived assets, as it was determined that certain equipment, leasehold improvements, and software associated with program development would no longer be used following the discontinuation of the Company's Phase 3 clinical trial in CP101 and significant reduction in the Company's workforce, as announced in January 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, during the quarter ended June 30, 2023, the Company sold its lab equipment, which resulted in a gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(43,51,61,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million included in other income (expense) on the condensed consolidated statement of operations.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.897%;"></td> <td style="width:1.455%;"></td> <td style="width:1.0%;"></td> <td style="width:14.354%;"></td> <td style="width:1.0%;"></td> <td style="width:1.455%;"></td> <td style="width:1.0%;"></td> <td style="width:14.839%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,146</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">869</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,406</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,972</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction work-in-progress</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">316</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">499</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">978</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,222</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">246</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,286</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">732</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,936</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 0 4146000 869000 1406000 0 13972000 0 316000 0 4883000 109000 499000 978000 25222000 246000 9286000 732000 15936000 1400000 2700000 13100000 800000 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. LEASES</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inner Belt Road Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2015, the Company entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease agreement (the "Inner Belt Road Lease") for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,785</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The monthly rental payments under the Inner Belt Road Lease, which include base rent charges of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, are subject to periodic rent increases through September 2026.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inner Belt Road Lease terminated and the Company’s rent obligations ended on June 30, 2023. The landlord agreed to refund the Company for the full amount of the Company’s security deposit, which is included in prepaid expenses and other current assets on the condensed consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's lease expense under the Inner Belt Road Lease was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 and 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hood Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2021, Finch entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease agreement (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">“Hood Lease”</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) with Hood Park LLC, pursuant to which Finch leased approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,139</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">“Premises”</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hood Lease provides Finch with an option to extend the lease for one additional five-year term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Finch’s annual base rent for the Premises started at approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and the lease contains annual rent escalations. Finch commenced business operations in the Premises in the second quarter of 2022, which triggered recognition of the lease for accounting purposes. The Company recorded lease expense related to the Hood Lease of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 and 2022, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finch posted a customary letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, subject to decrease on a set schedule, as a security deposit pursuant to the Hood Lease. This is included in restricted cash, non-current on the condensed consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the third quarter of 2022, Finch entered into a sublease agreement to sublet approximately one third of its leased space under the Hood Lease, which commenced on August 10, 2022, for an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with an option for Finch to extend the sublease for up to one additional year, which Finch exercised in the fourth quarter of 2022. Additionally, in the fourth quarter of 2022, Finch entered into a second sublease agreement to sublet the remainder of its leased space under the Hood Lease for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term, which commenced on December 15, 2022. For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023, Finch recognized sublease income of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which is presented as other income in the condensed consolidated statements of operations. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sublease income was recognized for the six months ended June 30, 2022, as the subleases had not commenced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the classification of right-of-use assets and operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:28.749%;"></td> <td style="width:32.853%;"></td> <td style="width:1.702%;"></td> <td style="width:1.0%;"></td> <td style="width:15.497%;"></td> <td style="width:1.0%;"></td> <td style="width:1.702%;"></td> <td style="width:1.0%;"></td> <td style="width:15.497%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BALANCE SHEET CLASSIFICATION</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating right-of-use assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,308</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,752</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    Operating lease liabilities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,656</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,431</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,388</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,255</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,044</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,686</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents the components of operating lease cost, which are included in general and administrative and research and development expense, and sublease income, which is included in other income on the statement of operations for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three and six months ended June 30, 2023 and 2022 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:30.152%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THREE MONTHS ENDED JUNE 30,</span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIX MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,405</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,650</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">469</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">532</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">964</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease income</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">959</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,919</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost, net</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">810</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,811</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,035</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,753</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining operating lease term and discount rate as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.389%;"></td> <td style="width:1.025%;"></td> <td style="width:1.0%;"></td> <td style="width:22.281%;"></td> <td style="width:1.0%;"></td> <td style="width:1.025%;"></td> <td style="width:1.0%;"></td> <td style="width:22.281%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of cash flow information related to operating leases for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 and 2022 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.262%;"></td> <td style="width:1.262%;"></td> <td style="width:1.0%;"></td> <td style="width:17.607%;"></td> <td style="width:1.0%;"></td> <td style="width:1.262%;"></td> <td style="width:1.0%;"></td> <td style="width:17.607%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid (received) for amounts included in measurement of lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,369</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,246</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents a summary of the Company’s future operating lease payments required as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.116%;"></td> <td style="width:1.892%;"></td> <td style="width:1.0%;"></td> <td style="width:17.992%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,795</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,930</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,071</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,215</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,391</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,227</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: amount representing interest</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,183</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,044</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> P10Y 25785 100000 600000 600000 P10Y 61139 The Hood Lease provides Finch with an option to extend the lease for one additional five-year term 4500000 2700000 900000 2300000 P2Y P3Y 1900000 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the classification of right-of-use assets and operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:28.749%;"></td> <td style="width:32.853%;"></td> <td style="width:1.702%;"></td> <td style="width:1.0%;"></td> <td style="width:15.497%;"></td> <td style="width:1.0%;"></td> <td style="width:1.702%;"></td> <td style="width:1.0%;"></td> <td style="width:15.497%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BALANCE SHEET CLASSIFICATION</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating right-of-use assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,308</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,752</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    Operating lease liabilities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,656</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,431</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,388</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,255</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,044</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,686</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 27308000 32752000 1656000 3431000 29388000 34255000 31044000 37686000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents the components of operating lease cost, which are included in general and administrative and research and development expense, and sublease income, which is included in other income on the statement of operations for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three and six months ended June 30, 2023 and 2022 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:30.152%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.183%;"></td> <td style="width:1.0%;"></td> <td style="width:14.277999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THREE MONTHS ENDED JUNE 30,</span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIX MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,405</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,650</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">469</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">532</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">964</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease income</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">959</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,919</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost, net</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">810</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,811</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,035</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,753</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 1678000 1311000 3405000 1650000 4000 31000 17000 139000 87000 469000 532000 964000 959000 0 1919000 0 810000 1811000 2035000 2753000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining operating lease term and discount rate as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.389%;"></td> <td style="width:1.025%;"></td> <td style="width:1.0%;"></td> <td style="width:22.281%;"></td> <td style="width:1.0%;"></td> <td style="width:1.025%;"></td> <td style="width:1.0%;"></td> <td style="width:22.281%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> </tr> </table> P8Y6M P8Y6M 0.085 0.083 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of cash flow information related to operating leases for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 and 2022 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.262%;"></td> <td style="width:1.262%;"></td> <td style="width:1.0%;"></td> <td style="width:17.607%;"></td> <td style="width:1.0%;"></td> <td style="width:1.262%;"></td> <td style="width:1.0%;"></td> <td style="width:17.607%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months Ended June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid (received) for amounts included in measurement of lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,369</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,246</span></p></td> <td style="background-color:rgba(204,236,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table> -2369000 5246000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents a summary of the Company’s future operating lease payments required as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.116%;"></td> <td style="width:1.892%;"></td> <td style="width:1.0%;"></td> <td style="width:17.992%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,795</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,930</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,071</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,215</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,391</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,227</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: amount representing interest</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,183</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,044</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 1825000 4795000 4930000 5071000 5215000 22391000 44227000 -13183000 31044000 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </span><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.011%;"></td> <td style="width:1.597%;"></td> <td style="width:1.0%;"></td> <td style="width:14.215%;"></td> <td style="width:1.0%;"></td> <td style="width:1.597%;"></td> <td style="width:1.0%;"></td> <td style="width:14.579%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,967</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued legal and professional fees</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,945</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,852</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and benefits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,482</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">961</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,462</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,487</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,161</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.011%;"></td> <td style="width:1.597%;"></td> <td style="width:1.0%;"></td> <td style="width:14.215%;"></td> <td style="width:1.0%;"></td> <td style="width:1.597%;"></td> <td style="width:1.0%;"></td> <td style="width:14.579%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,967</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued legal and professional fees</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,945</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,852</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and benefits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,482</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">961</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,462</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,487</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,161</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 99000 1967000 4945000 5852000 1482000 880000 961000 1462000 7487000 10161000 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. LOAN PAYABLE</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hercules Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 11, 2022, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., providing for a term loan with aggregate maximum borrowings of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Under the Loan Agreement, the Company borrowed an initial amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and on January 25, 2023 (the “Payoff Date”), the Company voluntarily paid off all outstanding principal, accrued and unpaid interest, fees, costs and expenses under the Loan Agreement, equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, recording a loss on extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Following the Payoff Date, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement and all other documents entered into in connection with the Loan Agreement were terminated.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 55000000 15000000 16200000 1400000 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. RESTRUCTURING</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three and six months ended June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recognized restructuring charges of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, primarily consisting of one-time severance payments, healthcare coverage, outplacement services and related expenses in connection with the Company's January 2023 restructuring action (the “January 2023 Restructuring”). All severance payments will be completed by the second quarter of 2024. The accrued restructuring liability is included in accrued compensation and benefits as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the restructuring accrual activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;"></td> <td style="width:1.48%;"></td> <td style="width:1.0%;"></td> <td style="width:16.3%;"></td> <td style="width:1.0%;"></td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued restructuring liability as of December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">201</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restructuring charges</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,037</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,776</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued restructuring liability as of June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,462</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> 800000 4000000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the restructuring accrual activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;"></td> <td style="width:1.48%;"></td> <td style="width:1.0%;"></td> <td style="width:16.3%;"></td> <td style="width:1.0%;"></td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued restructuring liability as of December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">201</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restructuring charges</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,037</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,776</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued restructuring liability as of June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,462</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 201000 4037000 2776000 1462000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the six months ended June 30, 2023 and the year ended December 31, 2022, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. There were no material changes in the Company’s tax position in the six months ended June 30, 2023 as compared to the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The benefit for the six months ended June 30, 2023 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reflects the full removal of the deferred tax liability on the IPR&amp;D that was written off during the first quarter of 2023 and treated as a discrete item in the tax provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, “Rebiotix”) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the “Court”). The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the “’309 Patent”); 10,463,702 (the “’702 Patent”); 10,328,107 (the “’107 Patent”); 10,064,899; 10,022,406 (the “’406 Patent”); 9,962,413 (the “’413 Patent”); and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the ’107, ’702, and ’309 Patents. In June 2022, Finch alleged infringement of the ’406 and ’413 Patents by Rebiotix. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota (“UMN”), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012, (collectively, the “UMN Patents”). On April 4, 2022, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the UMN Patents. On May 2, 2022, the Company and UMN responded, denying such counterclaims. The Court set a trial date for a five-day trial beginning on May 20, 2024. On January 23, 2023, the Company filed a second amended answer and counterclaims, in which the Company alleged infringement by Rebiotix of two additional U.S. Patents owned by Finch: U.S. Patent Nos. 11,541,080 (the “’080 Patent”) and 11,491,193 (the “’193 Patent”). On February 7, 2023, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the ’080 and ’193 patents. The Court issued a claim construction order on February 28, 2023. On July 6, 2023, Rebiotix filed a motion to dismiss certain counts of our second amended answer and counterclaims based on the assertion that Finch lacks standing to sue as to ’107 Patent, ’702 Patent, ’309 Patent, ’406 Patent, ’413 Patent, ’193 Patent, and ’080 Patent. Rebiotix specifically alleges that the sole named inventor on these patents, Thomas J. Borody, did not assign his rights in those patents to Finch, and as a result, Finch does not own them and therefore does not have standing to assert them. Briefing on this motion is complete.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined that there is no probable or estimable loss contingency that is required to be recorded as of June 30, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License and Royalty Payments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is party to license and other agreements under which it is obligated to make milestone and royalty payments and incur annual maintenance fees. The Company owes a nominal annual maintenance fee under its license agreement with UMN, (the “UMN Agreement”), as well as escalating minimum royalty amounts. The minimum payments continue in perpetuity for the University of Minnesota until the agreement is terminated. On April 12, 2023, the Company amended its agreement with UMN to, among other things, allow the Company to satisfy certain performance milestones through sublicensing agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is party to an agreement with OpenBiome requiring the Company to pay certain milestones of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the occurrence of certain R&amp;D events, regulatory approvals, and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.</span></p> 26000000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. STOCKHOLDERS’ EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 24, 2021, the board of directors of the Company (the “Board”</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and the Company’s stockholders approved the Company’s Amended and Restated Certificate of Incorporation. The certificate authorized the issuance of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> par value common stock and up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> par value undesignated preferred stock. The Board may designate the rights, preferences, privileges, and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and number of shares constituting any series or the designation of any series. The issuance of preferred stock could have the effect of restricting dividends on the Company's common stock, diluting the voting power of the Company's common stock, impairing the liquidation rights of the Company's common stock, or delaying or preventing a change in control. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock were outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each share of common stock entitles the holder to one vote</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, together with the holders of any preferred stock outstanding, on all matters submitted to the stockholders for a vote. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stockholders are also entitled to receive dividends. As of June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared or paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 the Company has reserved the following shares of common stock for the exercise of stock options, common stock warrants, vesting of restricted stock and shares issuable under the employee stock purchase plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.24%;"></td> <td style="width:1.54%;"></td> <td style="width:1.0%;"></td> <td style="width:16.84%;"></td> <td style="width:1.0%;"></td> <td style="width:1.54%;"></td> <td style="width:1.0%;"></td> <td style="width:16.84%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,039</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable under employee stock purchase plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,564</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> 200000000 0.001 10000000 0.001 0 Each share of common stock entitles the holder to one vote 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and December 31, 2022 the Company has reserved the following shares of common stock for the exercise of stock options, common stock warrants, vesting of restricted stock and shares issuable under the employee stock purchase plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.24%;"></td> <td style="width:1.54%;"></td> <td style="width:1.0%;"></td> <td style="width:16.84%;"></td> <td style="width:1.0%;"></td> <td style="width:1.54%;"></td> <td style="width:1.0%;"></td> <td style="width:16.84%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JUNE 30,<br/>2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DECEMBER 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,039</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable under employee stock purchase plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,564</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 72586 109522 0 9039 0 3 72586 118564 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. STOCK-BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Equity Incentive Plan<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Board adopted, and the stockholders approved, the 2021 Equity Incentive Plan (the “2021 Plan”).The 2021 Plan was amended and restated as of June 8, 2023 to reflect the stock split. The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance under the Company's 2021 Plan automatically increases on January 1 of each calendar year through January 1, 2031, in an amount equal to (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the applicable January 1. The maximum number of shares of common stock that may be issued on the exercise of incentive stock options under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2023, the number of shares of common stock reserved and available for issuance under the 2021 Plan automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,089</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options and there were</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,753</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares available for future issuance under the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Board adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The 2021 ESPP was amended and restated as of June 8, 2023 to reflect the stock split. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 ESPP is administered by the Board or by a committee appointed by the Board. The 2021 ESPP provides participating employees with the opportunity to purchase shares of common stock. The occurrence and duration of offering periods under the 2021 ESPP are subject to the determinations of the compensation committee of the Board. Annually the common stock reserved and available for issuance under the 2021 ESPP automatically increases and on January 1, 2023, increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,018</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,354</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the 2021 ESPP and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,167</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares are available for future issuance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity of the Company’s stock options under the 2017 Plan and 2021 Plan for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.681%;"></td> <td style="width:1.001%;"></td> <td style="width:1.0%;"></td> <td style="width:9.794%;"></td> <td style="width:1.0%;"></td> <td style="width:1.241%;"></td> <td style="width:1.0%;"></td> <td style="width:9.012999999999998%;"></td> <td style="width:1.0%;"></td> <td style="width:1.001%;"></td> <td style="width:1.0%;"></td> <td style="width:9.073%;"></td> <td style="width:1.0%;"></td> <td style="width:1.241%;"></td> <td style="width:1.0%;"></td> <td style="width:8.953%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SHARES</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (in years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE<br/>(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">293.81</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,094</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.15</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled or forfeited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,146</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327.08</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,884</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">291.79</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of June 30, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138.21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable as of June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,785</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249.63</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vested or expected to vest as of June 30, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138.21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized compensation expense related to the stock-based compensation arrangements granted under the 2021 Plan remaining to be recognized. The Company expects to recognize this cost over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Unit Awards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company issued RSU awards with time-based vesting conditions to employees. The fair value of an RSU award is equal to the fair market value of the Company's ordinary shares on the date of grant and the expense is recognized on a straight-line basis over the requisite service period. The RSUs primarily vest over one year from the grant date.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity of the Company’s RSUs under the 2021 Plan for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.709%;"></td> <td style="width:1.001%;"></td> <td style="width:1.0%;"></td> <td style="width:11.296%;"></td> <td style="width:1.0%;"></td> <td style="width:1.402%;"></td> <td style="width:1.0%;"></td> <td style="width:10.774999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.402%;"></td> <td style="width:1.0%;"></td> <td style="width:10.414000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>GRANT DATE FAIR VALUE</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE<br/>(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,039</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.88</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and distributed</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,317</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.80</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,722</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.93</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the periods presented is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.725%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THREE MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIX MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,769</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,070</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,249</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,181</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,830</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,480</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,950</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> 0.05 470000 80089 72586 263753 16018 3354 45167 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity of the Company’s stock options under the 2017 Plan and 2021 Plan for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.681%;"></td> <td style="width:1.001%;"></td> <td style="width:1.0%;"></td> <td style="width:9.794%;"></td> <td style="width:1.0%;"></td> <td style="width:1.241%;"></td> <td style="width:1.0%;"></td> <td style="width:9.012999999999998%;"></td> <td style="width:1.0%;"></td> <td style="width:1.001%;"></td> <td style="width:1.0%;"></td> <td style="width:9.073%;"></td> <td style="width:1.0%;"></td> <td style="width:1.241%;"></td> <td style="width:1.0%;"></td> <td style="width:8.953%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SHARES</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (in years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE<br/>(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">293.81</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,094</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.15</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled or forfeited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,146</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327.08</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,884</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">291.79</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of June 30, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138.21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable as of June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,785</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249.63</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vested or expected to vest as of June 30, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138.21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 109522 293.81 P6Y10M24D 0 34094 8.15 48146 327.08 22884 291.79 72586 138.21 P6Y 13000 36785 249.63 P2Y7M6D 0 72586 138.21 P6Y 13000 300000 P3Y8M12D <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity of the Company’s RSUs under the 2021 Plan for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months ended June 30, 2023:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.709%;"></td> <td style="width:1.001%;"></td> <td style="width:1.0%;"></td> <td style="width:11.296%;"></td> <td style="width:1.0%;"></td> <td style="width:1.402%;"></td> <td style="width:1.0%;"></td> <td style="width:10.774999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.402%;"></td> <td style="width:1.0%;"></td> <td style="width:10.414000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>GRANT DATE FAIR VALUE</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE<br/>(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,039</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.88</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and distributed</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,317</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.80</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,722</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.93</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of June 30, 2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> 9039 83.88 131000 3317 83.8 5722 83.93 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the periods presented is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.725%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> <td style="width:1.163%;"></td> <td style="width:1.0%;"></td> <td style="width:9.905999999999999%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THREE MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIX MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,769</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,070</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,249</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,181</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,830</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,480</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,950</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 0 760000 231000 1769000 300000 1070000 1249000 2181000 300000 1830000 1480000 3950000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. RETIREMENT PLAN</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. All employees are eligible to become participants of the plan at their hire date. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitatio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ns. The Company reserves the right to make additional contributions to this plan. The Company made contributions to the plan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">illion and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million in the six months ended June 30, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p> 100000 400000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. LOSS PER SHARE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.824%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.725%;"></td> <td style="width:1.0%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.765%;"></td> <td style="width:1.0%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.725%;"></td> <td style="width:1.0%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.765%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE THREE MONTHS<br/>ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE SIX MONTHS<br/>ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,950</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,700</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,297</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,267</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to<br/>   common stockholders—basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,950</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,700</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,297</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,267</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common<br/>   stock outstanding—basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,604,795</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585,978</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,603,811</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable<br/>   to common stockholders—basic and diluted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.33</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.31</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.21</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.82</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s potentially dilutive securities, which include stock options, warrants, RSU awards and shares issuable under the employee stock purchase plan have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and 2022 because including them would have had an anti-dilutive effect:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:69.62%;"></td> <td style="width:1.22%;"></td> <td style="width:1.0%;"></td> <td style="width:11.18%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:10.98%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIX MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,039</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable under employee stock purchase plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,564</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.824%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.725%;"></td> <td style="width:1.0%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.765%;"></td> <td style="width:1.0%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.725%;"></td> <td style="width:1.0%;"></td> <td style="width:1.299%;"></td> <td style="width:1.0%;"></td> <td style="width:12.765%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE THREE MONTHS<br/>ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE SIX MONTHS<br/>ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,950</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,700</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,297</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,267</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to<br/>   common stockholders—basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,950</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,700</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,297</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,267</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common<br/>   stock outstanding—basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,604,795</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585,978</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,603,811</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable<br/>   to common stockholders—basic and diluted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.33</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.31</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.21</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.82</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> </table> -6950000 -22700000 -69297000 -47267000 -6950000 -6950000 -22700000 -22700000 -69297000 -69297000 -47267000 -47267000 1604795 1604795 1585978 1585978 1603811 1603811 1585093 1585093 -4.33 -4.33 -14.31 -14.31 -43.21 -43.21 -29.82 -29.82 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023 and 2022 because including them would have had an anti-dilutive effect:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:69.62%;"></td> <td style="width:1.22%;"></td> <td style="width:1.0%;"></td> <td style="width:11.18%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:1.0%;"></td> <td style="width:10.98%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIX MONTHS ENDED JUNE 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,039</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable under employee stock purchase plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,586</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,564</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table> 72586 109522 0 9039 0 3 72586 118564 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. SUBSEQUENT EVENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except as discussed in Note 11, there have no subsequent events through the date of these financial statements.</span></p> * Adjusted for the 1-for-30 reverse stock split * Adjusted for the 1-for-30 reverse stock split * Adjusted for the 1-for-30 reverse stock split EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 79 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 120 241 1 true 37 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 7 false false R8.htm 100080 - Disclosure - Nature of Operations and Basis of Presentation Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation Nature of Operations and Basis of Presentation Notes 8 false false R9.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100100 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatements Adjustment To Prior Interim Unaudited Financial Statements Notes 10 false false R11.htm 100110 - Disclosure - Fair Value Measurements Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100120 - Disclosure - Property and Equipment, Net Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 100130 - Disclosure - Leases Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeases Leases Notes 13 false false R14.htm 100140 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 14 false false R15.htm 100150 - Disclosure - Loan Payable Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayable Loan Payable Notes 15 false false R16.htm 100160 - Disclosure - Restructuring Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuring Restructuring Notes 16 false false R17.htm 100170 - Disclosure - Income Taxes Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 100180 - Disclosure - Commitments and Contingencies Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 100190 - Disclosure - Stockholder's Equity Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquity Stockholder's Equity Notes 19 false false R20.htm 100200 - Disclosure - Stock-Based Compensation Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 100210 - Disclosure - Retirement Plan Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureRetirementPlan Retirement Plan Notes 21 false false R22.htm 100220 - Disclosure - Loss per Share Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShare Loss per Share Notes 22 false false R23.htm 100230 - Disclosure - Subsequent Events Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 23 false false R24.htm 100240 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 100250 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsTables Adjustment To Prior Interim Unaudited Financial Statements (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatements 25 false false R26.htm 100260 - Disclosure - Fair Value Measurements (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements 26 false false R27.htm 100270 - Disclosure - Property and Equipment, Net (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet 27 false false R28.htm 100280 - Disclosure - Leases (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeases 28 false false R29.htm 100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities 29 false false R30.htm 100310 - Disclosure - Restructuring (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringTables Restructuring (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuring 30 false false R31.htm 100330 - Disclosure - Stockholders' Equity (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables 31 false false R32.htm 100340 - Disclosure - Stock-Based Compensation (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation 32 false false R33.htm 100350 - Disclosure - Loss per Share (Tables) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareTables Loss per Share (Tables) Tables http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShare 33 false false R34.htm 100360 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails Nature of Operations and Basis of Presentation - Additional Information (Details) Details 34 false false R35.htm 100370 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary Of Significant Accounting Policies - Additional Information (Details) Details 35 false false R36.htm 100380 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsAdditionalInformationDetails Adjustment To Prior Interim Unaudited Financial Statements - Additional Information (Details) Details 36 false false R37.htm 100390 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements - Schedule of effect of error correction of prior interim unaudited financial statements (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD Adjustment To Prior Interim Unaudited Financial Statements - Schedule of effect of error correction of prior interim unaudited financial statements (Details) Details 37 false false R38.htm 100400 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 38 false false R39.htm 100410 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 39 false false R40.htm 100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 40 false false R41.htm 100430 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 41 false false R42.htm 100440 - Disclosure - Leases - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 42 false false R43.htm 100450 - Disclosure - Leases - Leases Balance Sheet Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails Leases - Leases Balance Sheet Information (Details) Details 43 false false R44.htm 100460 - Disclosure - Leases - Summary of Components of Lease Cost (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails Leases - Summary of Components of Lease Cost (Details) Details 44 false false R45.htm 100470 - Disclosure - Leases - Summary of Weighted Average Remaining Operating Lease Term and Discount Rate (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingOperatingLeaseTermAndDiscountRateDetails Leases - Summary of Weighted Average Remaining Operating Lease Term and Discount Rate (Details) Details 45 false false R46.htm 100480 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails Leases - Schedule of Supplemental Cash Flow Information (Details) Details 46 false false R47.htm 100490 - Disclosure - Leases - Schedule of Future Lease Payments (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails Leases - Schedule of Future Lease Payments (Details) Details 47 false false R48.htm 100500 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 48 false false R49.htm 100510 - Disclosure - Loan Payable - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails Loan Payable - Additional Information (Details) Details 49 false false R50.htm 100520 - Disclosure - Restructuring - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails Restructuring - Additional Information (Details) Details 50 false false R51.htm 100530 - Disclosure - Restructuring - Summary of Restructuring Activity (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails Restructuring - Summary of Restructuring Activity (Details) Details 51 false false R52.htm 100540 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 52 false false R53.htm 100550 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 53 false false R54.htm 100560 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants (Details) Details 54 false false R55.htm 100570 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 55 false false R56.htm 100580 - Disclosure - Stock-Based Compensation - Summary of Activity of Stock Options (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails Stock-Based Compensation - Summary of Activity of Stock Options (Details) Details 56 false false R57.htm 100590 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Details) Details 57 false false R58.htm 100600 - Disclosure - Retirement Plan - Additional Information (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails Retirement Plan - Additional Information (Details) Details 58 false false R59.htm 100610 - Disclosure - Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) Details 59 false false R60.htm 100620 - Disclosure - Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details) Sheet http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details) Details 60 false false All Reports Book All Reports fnch-20230630.htm fnch-20230630.xsd fnch-20230630_cal.xml fnch-20230630_def.xml fnch-20230630_lab.xml fnch-20230630_pre.xml fnch-ex10_1.htm fnch-ex10_5.htm fnch-ex10_6.htm fnch-ex10_7.htm fnch-ex31_1.htm fnch-ex31_2.htm fnch-ex32_1.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fnch-20230630.htm": { "axisCustom": 0, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 517, "http://xbrl.sec.gov/dei/2023": 32 }, "contextCount": 120, "dts": { "calculationLink": { "local": [ "fnch-20230630_cal.xml" ] }, "definitionLink": { "local": [ "fnch-20230630_def.xml" ] }, "inline": { "local": [ "fnch-20230630.htm" ] }, "labelLink": { "local": [ "fnch-20230630_lab.xml" ] }, "presentationLink": { "local": [ "fnch-20230630_pre.xml" ] }, "schema": { "local": [ "fnch-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 397, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 4, "total": 6 }, "keyCustom": 24, "keyStandard": 217, "memberCustom": 13, "memberStandard": 22, "nsprefix": "fnch", "nsuri": "http://finchtherapeutics.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements", "menuCat": "Notes", "order": "10", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatements", "shortName": "Adjustment To Prior Interim Unaudited Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property and Equipment, Net", "menuCat": "Notes", "order": "12", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Leases", "menuCat": "Notes", "order": "13", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "14", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Loan Payable", "menuCat": "Notes", "order": "15", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayable", "shortName": "Loan Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Restructuring", "menuCat": "Notes", "order": "16", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "17", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "18", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Stockholder's Equity", "menuCat": "Notes", "order": "19", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquity", "shortName": "Stockholder's Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "20", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Retirement Plan", "menuCat": "Notes", "order": "21", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureRetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Loss per Share", "menuCat": "Notes", "order": "22", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShare", "shortName": "Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "23", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "24", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements (Tables)", "menuCat": "Tables", "order": "25", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsTables", "shortName": "Adjustment To Prior Interim Unaudited Financial Statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "26", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Property and Equipment, Net (Tables)", "menuCat": "Tables", "order": "27", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "fnch:LeasesBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "28", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "fnch:LeasesBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "29", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Restructuring (Tables)", "menuCat": "Tables", "order": "30", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "31", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "32", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Loss per Share (Tables)", "menuCat": "Tables", "order": "33", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareTables", "shortName": "Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)", "menuCat": "Details", "order": "34", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails", "shortName": "Nature of Operations and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "35", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary Of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_eab8fd03-1460-4114-877b-a398c4eee747", "decimals": "-5", "first": true, "lang": null, "name": "fnch:DecreaseInAccountsPayableAndResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements - Additional Information (Details)", "menuCat": "Details", "order": "36", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsAdditionalInformationDetails", "shortName": "Adjustment To Prior Interim Unaudited Financial Statements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_eab8fd03-1460-4114-877b-a398c4eee747", "decimals": "-5", "first": true, "lang": null, "name": "fnch:DecreaseInAccountsPayableAndResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Adjustment To Prior Interim Unaudited Financial Statements - Schedule of effect of error correction of prior interim unaudited financial statements (Details)", "menuCat": "Details", "order": "37", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "shortName": "Adjustment To Prior Interim Unaudited Financial Statements - Schedule of effect of error correction of prior interim unaudited financial statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_a1199124-1810-41f9-8ecd-417202786010", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "38", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_3055362e-4e8b-47b8-931c-98479a5d6ae8", "decimals": "-3", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "first": true, "lang": null, "name": "fnch:TransfersBetweenFairValueLevels", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Additional Information (Details)", "menuCat": "Details", "order": "39", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "first": true, "lang": null, "name": "fnch:TransfersBetweenFairValueLevels", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "menuCat": "Details", "order": "40", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "menuCat": "Details", "order": "41", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_1437798b-c93d-434d-a6ca-1cb6e6caafe0", "decimals": "0", "first": true, "lang": null, "name": "fnch:LesseeOperatingLeaseLeasesArea", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Leases - Additional Information (Details)", "menuCat": "Details", "order": "42", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_1437798b-c93d-434d-a6ca-1cb6e6caafe0", "decimals": "0", "first": true, "lang": null, "name": "fnch:LesseeOperatingLeaseLeasesArea", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Leases - Leases Balance Sheet Information (Details)", "menuCat": "Details", "order": "43", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails", "shortName": "Leases - Leases Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:LeasesBalanceSheetInformationTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "lang": null, "name": "fnch:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Leases - Summary of Components of Lease Cost (Details)", "menuCat": "Details", "order": "44", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails", "shortName": "Leases - Summary of Components of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:LeaseTermAndDiscountRateTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Leases - Summary of Weighted Average Remaining Operating Lease Term and Discount Rate (Details)", "menuCat": "Details", "order": "45", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingOperatingLeaseTermAndDiscountRateDetails", "shortName": "Leases - Summary of Weighted Average Remaining Operating Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:LeaseTermAndDiscountRateTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)", "menuCat": "Details", "order": "46", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails", "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:ScheduleOfFutureLeasePaymentsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Leases - Schedule of Future Lease Payments (Details)", "menuCat": "Details", "order": "47", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails", "shortName": "Leases - Schedule of Future Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:ScheduleOfFutureLeasePaymentsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "fnch:AccruedResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "48", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "fnch:AccruedResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfLinesOfCredit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Loan Payable - Additional Information (Details)", "menuCat": "Details", "order": "49", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails", "shortName": "Loan Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_e918ce1d-a4ca-4520-8ba7-b0e6036efbcc", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_5e626320-4146-4af3-9167-06be4eec9695", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c84efb27-c9cc-44a4-8482-40d41856a0dc", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Restructuring - Additional Information (Details)", "menuCat": "Details", "order": "50", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "shortName": "Restructuring - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Restructuring - Summary of Restructuring Activity (Details)", "menuCat": "Details", "order": "51", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails", "shortName": "Restructuring - Summary of Restructuring Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c40a9536-9b33-40b1-be0d-1f108e29017b", "decimals": "-3", "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_079056d8-239d-4a28-adf7-934113cc8d5a", "decimals": "-5", "first": true, "lang": null, "name": "fnch:MaximumMilestonePaymentRequiredUnderAgreement", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "52", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_079056d8-239d-4a28-adf7-934113cc8d5a", "decimals": "-5", "first": true, "lang": null, "name": "fnch:MaximumMilestonePaymentRequiredUnderAgreement", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Stockholders' Equity - Additional Information (Details)", "menuCat": "Details", "order": "53", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants (Details)", "menuCat": "Details", "order": "54", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails", "shortName": "Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "55", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_ea0d00b2-a173-4aed-b37c-52a736e4239e", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_dc23eca2-24db-4f4a-8bd2-60986e8765d1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Stock-Based Compensation - Summary of Activity of Stock Options (Details)", "menuCat": "Details", "order": "56", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "shortName": "Stock-Based Compensation - Summary of Activity of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_3cc83e14-def1-45f7-8f2a-5f50bb81d45b", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)", "menuCat": "Details", "order": "57", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Retirement Plan - Additional Information (Details)", "menuCat": "Details", "order": "58", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails", "shortName": "Retirement Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)", "menuCat": "Details", "order": "59", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_939fad84-45e3-4f2f-aae9-14f640d99c5f", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)", "menuCat": "Details", "order": "60", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_c8b521a7-b8ca-4e41-b397-dd05bd0f2b7c", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Nature of Operations and Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation", "shortName": "Nature of Operations and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fnch-20230630.htm", "contextRef": "C_aecfb6a0-1be5-46b0-a5a5-b323b81869b0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 37, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "fnch_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_AccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 0.0, "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development.", "label": "Accrued Research And Development", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopment", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fnch_CherryStreetLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cherry street lease.", "label": "Cherry Street Lease [Member]", "terseLabel": "Cherry Street Lease" } } }, "localname": "CherryStreetLeaseMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration Revenue" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "fnch_ConcordAvenueLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concord Avenue Lease Member", "label": "Concord Avenue Lease Member", "terseLabel": "Concord Avenue Lease" } } }, "localname": "ConcordAvenueLeaseMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_DecreaseInAccountsPayableAndResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in accounts payable and research and development expenses.", "label": "Decrease In Accounts Payable And Research And Development Expenses", "terseLabel": "Decrease in accounts payable and research and development expenses" } } }, "localname": "DecreaseInAccountsPayableAndResearchAndDevelopmentExpenses", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fnch_ErrorCorrectionImpact": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Error correction impact.", "label": "Error Correction Impact", "terseLabel": "Error correction impact" } } }, "localname": "ErrorCorrectionImpact", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fnch_GainLossOnLeaseTermination": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Lease Termination", "label": "Gain (Loss) On Lease Termination", "terseLabel": "Gain on lease termination" } } }, "localname": "GainLossOnLeaseTermination", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_HoodParkDriveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hood Park Drive Member", "label": "Hood Park Drive Member", "terseLabel": "Hood Park Lease" } } }, "localname": "HoodParkDriveMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_ImpairmentOfInProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment of In-Process Research and Development.", "label": "Impairment of In-Process Research and Development", "negatedLabel": "Impairment of IPR&D", "terseLabel": "Impairment of in-process research and development" } } }, "localname": "ImpairmentOfInProcessResearchAndDevelopment", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_InProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "In-process research and development.", "label": "In Process Research And Development", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopment", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_InnerBeltRoadLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inner belt road lease.", "label": "Inner Belt Road Lease [Member]", "terseLabel": "Inner Belt Road Lease" } } }, "localname": "InnerBeltRoadLeaseMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails2": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest portion of operating leases future minimum payments due.", "label": "Interest Portion of Operating Leases Future Minimum Payments Due", "terseLabel": "Less: amount representing interest" } } }, "localname": "InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "fnch_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "Lab Equipment [Member]", "terseLabel": "Lab Equipment" } } }, "localname": "LabEquipmentMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "fnch_LeaseLiabilities": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities.", "label": "Lease Liabilities", "terseLabel": "Total lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "fnch_LeaseTermAndDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease term and discount rate table text block.", "label": "Lease Term and Discount Rate [Table Text Block]", "terseLabel": "Summary of Weighted Average Remaining Operating Lease Term and Discount Rate" } } }, "localname": "LeaseTermAndDiscountRateTableTextBlock", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fnch_LeasesBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases balance sheet information table text block.", "label": "Leases Balance Sheet Information [Table Text Block]", "terseLabel": "Leases Balance Sheet Information" } } }, "localname": "LeasesBalanceSheetInformationTableTextBlock", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fnch_LesseeOperatingLeaseLeasesArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating Lease Leases Area", "label": "Lessee Operating Lease Leases Area", "terseLabel": "Office and laboratory space for lease" } } }, "localname": "LesseeOperatingLeaseLeasesArea", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "fnch_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_MaximumMilestonePaymentRequiredUnderAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payment required under agreement.", "label": "Maximum Milestone Payment Required Under Agreement", "terseLabel": "Required to pay certain milestones" } } }, "localname": "MaximumMilestonePaymentRequiredUnderAgreement", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fnch_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash interest expense.", "label": "Non-cash interest expense", "terseLabel": "Non-cash operating lease and interest cost" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_OpenBiomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OpenBiome.", "label": "Open Biome [Member]", "terseLabel": "Open Biome" } } }, "localname": "OpenBiomeMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_OperatingLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease obligations.", "label": "Operating Lease Obligations [Abstract]" } } }, "localname": "OperatingLeaseObligationsAbstract", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "fnch_OptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock.", "label": "Options To Purchase Common Stock [Member]", "terseLabel": "Options to Purchase Common Stock" } } }, "localname": "OptionsToPurchaseCommonStockMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "fnch_PaymentOfTerminalFeeObligationAndPrepaymentFee": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of terminal fee obligation and prepayment fee", "label": "Payment of Terminal Fee Obligation and Prepayment Fee", "negatedLabel": "Payment of loan terminal fee obligation and prepayment fee" } } }, "localname": "PaymentOfTerminalFeeObligationAndPrepaymentFee", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in shares of common stock reserved for issuance.", "label": "Percentage Of Increase In Shares Of Common Stock Reserved For Issuance", "terseLabel": "Percentage of increase in shares of common stock reserved for issuance" } } }, "localname": "PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fnch_PrepaidRentReclassifiedToRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid rent reclassified to right-of-use assets", "label": "Prepaid rent reclassified to right-of-use assets", "terseLabel": "Prepaid rent reclassified to right-of-use assets" } } }, "localname": "PrepaidRentReclassifiedToRightOfUseAssets", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_PresentValueOfFutureMinimumLeasePayments": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails2": { "order": 0.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of future minimum lease payments.", "label": "Present Value of Future Minimum Lease Payments", "terseLabel": "Present value of future minimum lease payments" } } }, "localname": "PresentValueOfFutureMinimumLeasePayments", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "fnch_PrincipalPaymentsOnCapitalLeaseObligation": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal payments on capital lease obligation.", "label": "Principal Payments On Capital Lease Obligation", "negatedLabel": "Principal payments on finance lease obligation", "verboseLabel": "Financing cash flows used in finance leases" } } }, "localname": "PrincipalPaymentsOnCapitalLeaseObligation", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fnch_ReductionInAccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in accumulated deficit.", "label": "Reduction in Accumulated Deficit", "terseLabel": "Reduction in accumulated deficit" } } }, "localname": "ReductionInAccumulatedDeficit", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued expenses and other current liabilities.", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "fnch_ScheduleOfFutureLeasePaymentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future lease payments table text block.", "label": "Schedule of Future Lease Payments [Table Text Block]", "terseLabel": "Schedule of Future Lease Payments" } } }, "localname": "ScheduleOfFutureLeasePaymentsTableTextBlock", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of common shares reserved for potential conversion of outstanding preferred stock, vesting of restricted stock and exercise of stock options and common stock warrants.", "label": "Summary Of Common Shares Reserved For Potential Conversion Of Outstanding Preferred Stock Vesting Of Restricted Stock And Exercise Of Stock Options And Common Stock Warrants Table [Text Block]", "terseLabel": "Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options and Common Stock Warrants" } } }, "localname": "SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "fnch_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "fnch_TransfersBetweenFairValueLevels": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transfers between fair value levels.", "label": "Transfers Between Fair Value Levels", "terseLabel": "Transfers between fair value levels" } } }, "localname": "TransfersBetweenFairValueLevels", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen and two thousand twenty one equity incentive plan.", "label": "Two Thousand Seventeen And Two Thousand Twenty One Equity Incentive Plan [Member]", "terseLabel": "2017 and 2021 Equity Incentive Plan" } } }, "localname": "TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "fnch_TwoThousandSeventeenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen equity incentive plan.", "label": "Two Thousand Seventeen Equity Incentive Plan [Member]", "terseLabel": "2017 Equity Incentive Plan" } } }, "localname": "TwoThousandSeventeenEquityIncentivePlanMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_TwoThousandTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Equity incentive plan.", "label": "Two Thousand Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyOneEquityIncentivePlanMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "fnch_UndesignatedPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated preferred stock.", "label": "Undesignated Preferred Stock [Member]", "terseLabel": "Undesignated Preferred Stock" } } }, "localname": "UndesignatedPreferredStockMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fnch_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units.", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested Restricted Stock Units" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://finchtherapeutics.com/20230630", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r240", "r241", "r242", "r243", "r297", "r425", "r466", "r500", "r501", "r555", "r556", "r557", "r558", "r559", "r567", "r568", "r574", "r577", "r582", "r590", "r651", "r693", "r694", "r695", "r696", "r697", "r698" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r240", "r241", "r242", "r243", "r297", "r425", "r466", "r500", "r501", "r555", "r556", "r557", "r558", "r559", "r567", "r568", "r574", "r577", "r582", "r590", "r651", "r693", "r694", "r695", "r696", "r697", "r698" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r211", "r426", "r460", "r461", "r462", "r463", "r464", "r465", "r569", "r578", "r589", "r616", "r647", "r648", "r652", "r701" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r211", "r426", "r460", "r461", "r462", "r463", "r464", "r465", "r569", "r578", "r589", "r616", "r647", "r648", "r652", "r701" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r240", "r241", "r242", "r243", "r287", "r297", "r325", "r326", "r327", "r424", "r425", "r466", "r500", "r501", "r555", "r556", "r557", "r558", "r559", "r567", "r568", "r574", "r577", "r582", "r590", "r593", "r642", "r651", "r694", "r695", "r696", "r697", "r698" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r240", "r241", "r242", "r243", "r287", "r297", "r325", "r326", "r327", "r424", "r425", "r466", "r500", "r501", "r555", "r556", "r557", "r558", "r559", "r567", "r568", "r574", "r577", "r582", "r590", "r593", "r642", "r651", "r694", "r695", "r696", "r697", "r698" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r155", "r156", "r157", "r170", "r171", "r194", "r376", "r377", "r610", "r611", "r612", "r613", "r614", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Restatement adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r125", "r155", "r156", "r157", "r160", "r161", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r194", "r220", "r221", "r347", "r374", "r376", "r377", "r378", "r399", "r414", "r415", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r479" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r125", "r155", "r156", "r157", "r160", "r161", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r194", "r220", "r221", "r347", "r374", "r376", "r377", "r378", "r399", "r414", "r415", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r479" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r125", "r155", "r157", "r160", "r161", "r164", "r165", "r173", "r194", "r347", "r374", "r376", "r377", "r399", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r479", "r614", "r617", "r618", "r619", "r635", "r639", "r640", "r683", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r588" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r214", "r215" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued legal and professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r132", "r453" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r69" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r334", "r335", "r336", "r488", "r632", "r633", "r634", "r682", "r703" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r56", "r57", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r329", "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive securities excluding from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r134", "r153", "r198", "r205", "r209", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r360", "r364", "r389", "r445", "r522", "r588", "r601", "r649", "r650", "r691" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total financial assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r128", "r139", "r153", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r360", "r364", "r389", "r588", "r649", "r650", "r691" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r29", "r30", "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "negatedLabel": "Property and equipment in accounts payable and accrued liabilities", "terseLabel": "Property and equipment in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Capital Leased Assets [Line Items]" } } }, "localname": "CapitalLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r28", "r130", "r570" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r28", "r84", "r149" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r84" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r123", "r136", "r137", "r138", "r153", "r180", "r181", "r188", "r190", "r196", "r197", "r216", "r245", "r247", "r248", "r249", "r252", "r253", "r269", "r270", "r273", "r276", "r283", "r389", "r481", "r482", "r483", "r484", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r510", "r531", "r549", "r560", "r561", "r562", "r563", "r564", "r609", "r628", "r636" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r136", "r137", "r138", "r196", "r269", "r270", "r271", "r273", "r276", "r281", "r283", "r481", "r482", "r483", "r484", "r577", "r609", "r628" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r63", "r447", "r509" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r93", "r237", "r238", "r566", "r644" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock for potential conversion" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r632", "r633", "r682", "r702", "r703" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r68", "r510" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common shares authorized for issuance" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares, issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r68", "r510", "r528", "r703", "r704" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r68", "r450", "r588" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 1,604,761 and 1,601,717 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common stock voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction Work-In-Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r94", "r151", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Loan Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r4", "r100", "r118", "r353", "r354", "r631" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Benefit for deferred income taxes", "totalLabel": "Deferred Income Tax Expense (Benefit), Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r340", "r341", "r446" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "totalLabel": "Deferred Income Tax Liabilities, Net, Total" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Company's contribution to plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanTextBlock": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for defined contribution plan.", "label": "Defined Contribution Plan [Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "DefinedContributionPlanTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureRetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r4", "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r4", "r201" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r298", "r302", "r330", "r331", "r333", "r583" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "terseLabel": "Cash dividends declared or paid" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r145", "r164", "r165", "r167", "r168", "r170", "r177", "r180", "r188", "r189", "r190", "r194", "r377", "r378", "r442", "r458", "r571" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net loss per share attributable to common stockholders - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r145", "r164", "r165", "r167", "r168", "r170", "r180", "r188", "r189", "r190", "r194", "r377", "r378", "r442", "r458", "r571" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net loss per share attributable to common stockholders - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r176", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense remaining to be recognized, period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r680" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense remaining to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance and Related Benefits" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option Member", "verboseLabel": "Options to Purchase Common Stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r124", "r142", "r143", "r144", "r155", "r156", "r157", "r161", "r171", "r173", "r195", "r217", "r222", "r284", "r334", "r335", "r336", "r346", "r347", "r366", "r367", "r368", "r369", "r370", "r372", "r376", "r393", "r394", "r395", "r396", "r397", "r398", "r415", "r467", "r468", "r469", "r488", "r549" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r383", "r384", "r387" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r383", "r384", "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r384", "r421", "r422", "r423", "r575", "r576", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r383", "r384", "r385", "r386", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r262", "r288", "r293", "r384", "r421", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r262", "r288", "r293", "r384", "r422", "r575", "r576", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r384", "r423", "r575", "r576", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Observable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r421", "r422", "r423", "r575", "r576", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r382", "r388" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Office Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r626" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "terseLabel": "Gain (loss) on sale and disposal of fixed assets, net", "totalLabel": "Gain (Loss) on Disposition of Assets, Total" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r4" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "(Gain) loss on sale and disposal of property and equipment", "terseLabel": "Gain on disposal of fixed assets", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "verboseLabel": "Loss on disposal of fixed assets, net" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r402" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Gain on lease termination", "terseLabel": "Gain on lease termination" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r4", "r43", "r44" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on loan extinguishment", "terseLabel": "Loss on loan extinguishment", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "verboseLabel": "Loss on extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r77", "r533" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "General and administrative", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "negatedLabel": "Impairment of goodwill", "terseLabel": "Impairment charges", "totalLabel": "Goodwill and Intangible Asset Impairment, Total", "verboseLabel": "Impairment of goodwill" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r7", "r36" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Acquired In-Process Research and Development" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering", "verboseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r626", "r641" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment charge" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r4", "r37", "r92" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "negatedLabel": "Impairment of long-lived assets", "terseLabel": "Impairment of long-lived assets", "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r4", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment charge" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r74", "r106", "r198", "r204", "r208", "r210", "r443", "r455", "r573" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r223", "r228", "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r228", "r534" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r154", "r339", "r343", "r344", "r345", "r351", "r355", "r356", "r357", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r113", "r121", "r172", "r173", "r202", "r342", "r352", "r459" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax benefit", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r3" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r625" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r615", "r625" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "negatedLabel": "Operating cash flows (used in) from operating leases", "negatedTerseLabel": "Cash paid (received) for amounts included in measurement of lease liabilities", "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating cash flows used in operating leases" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r625" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in security deposits.", "label": "Increase (Decrease) in Security Deposits", "terseLabel": "Decrease in security deposit" } } }, "localname": "IncreaseDecreaseInSecurityDeposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r78", "r80" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Interest income (expense)", "totalLabel": "Investment Income, Net, Total", "verboseLabel": "Interest income, net" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rental charges", "totalLabel": "Operating Leases, Rent Expense, Total" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r406", "r587" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost, net" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Components of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.", "label": "Leases of Lessor Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee, Operating Lease, Description", "terseLabel": "Lease term description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease agreement term", "verboseLabel": "Sublease agreement term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r153", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r361", "r364", "r365", "r389", "r508", "r572", "r601", "r649", "r691", "r692" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r73", "r105", "r452", "r588", "r630", "r638", "r684" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r129", "r153", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r361", "r364", "r365", "r389", "r588", "r649", "r691", "r692" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Aggregate maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r104", "r261", "r267", "r575", "r576", "r700" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Principal amount of loan payable", "totalLabel": "Total", "verboseLabel": "Initial amount borrowed" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r135" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Loan payable, non-current", "totalLabel": "Long-term Debt, Excluding Current Maturities, Total" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r239", "r240", "r241", "r244", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r239", "r240", "r241", "r244", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r85", "r86" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS USED IN OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r75", "r86", "r107", "r127", "r140", "r141", "r144", "r153", "r160", "r164", "r165", "r167", "r168", "r172", "r173", "r186", "r198", "r204", "r208", "r210", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r378", "r389", "r457", "r530", "r547", "r548", "r573", "r599", "r649" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r146", "r164", "r165", "r167", "r168", "r177", "r178", "r187", "r190", "r198", "r204", "r208", "r210", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders, basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r146", "r179", "r182", "r183", "r184", "r185", "r187", "r190" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders-basic and diluted (Note 15)", "totalLabel": "Net loss attributable to common stockholders, diluted", "verboseLabel": "Net loss attributable to common stockholders-basic and diluted (Note 16)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r119", "r120", "r122", "r126", "r158", "r159", "r162", "r163", "r174", "r175", "r218", "r219", "r348", "r349", "r350", "r371", "r375", "r379", "r380", "r381", "r390", "r391", "r392", "r400", "r401", "r416", "r427", "r428", "r429", "r471", "r472", "r473", "r474", "r476" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Adjustment To Prior Interim Unaudited Financial Statements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Total other income, net", "totalLabel": "Total other income (expense), net", "verboseLabel": "Total other (expense) income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE), NET:", "verboseLabel": "OTHER INCOME (EXPENSE), NET:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTotalLabel": "Total operating expenses", "terseLabel": "Total operating expenses", "totalLabel": "Operating Expenses, Total" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r198", "r204", "r208", "r210", "r573" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Net loss from operations", "totalLabel": "Net loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r407", "r587" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r685" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r404" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": { "order": 0.0, "parentTag": "fnch_LeaseLiabilities", "weight": 1.0 }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r404" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "fnch_LeaseLiabilities", "weight": 1.0 }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r403" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r413", "r587" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingOperatingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r412", "r587" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingOperatingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Total minimum lease payments", "totalLabel": "Total future minimum lease payments", "verboseLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months", "terseLabel": "2023", "verboseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2027", "verboseLabel": "2025" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2026", "verboseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2025", "verboseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2024", "verboseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r109", "r111" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r65", "r101", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Operations and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r133" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r58", "r60" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total", "verboseLabel": "Other Liabilities Noncurrent" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Sublease and other income", "terseLabel": "Sublease and other income", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "OverAllotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r227", "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash payments", "terseLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r26" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of deferred offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r67", "r269" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r67", "r510" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred shares authorized for issuance" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r67", "r510", "r528", "r703", "r704" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r67", "r449", "r588" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r622" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r25", "r629" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from borrowings under loan agreement, net", "totalLabel": "Proceeds from Lines of Credit, Total" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds on sale of property and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r2", "r12" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options, net" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r127", "r140", "r141", "r147", "r153", "r160", "r172", "r173", "r198", "r204", "r208", "r210", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r359", "r362", "r363", "r378", "r389", "r443", "r456", "r487", "r530", "r547", "r548", "r573", "r585", "r586", "r600", "r623", "r649" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r89", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r91", "r131", "r454" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total", "totalLabel": "Property, Plant and Equipment, Gross, Total", "verboseLabel": "Property and equipment held" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r444", "r454", "r588" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other Types [Member]", "terseLabel": "Property Plant And Equipment Other Types Member" } } }, "localname": "PropertyPlantAndEquipmentOtherTypesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r294", "r417", "r418", "r503", "r504", "r505", "r506", "r507", "r527", "r529", "r554" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r294", "r417", "r418", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r503", "r504", "r505", "r506", "r507", "r527", "r529", "r554", "r690" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r27", "r629" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayment of loan", "terseLabel": "Aggregate payoff amount", "verboseLabel": "Principal repayments of loan" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r64", "r338", "r699" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r28", "r102", "r130", "r149", "r448" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash and Cash Equivalents, Total" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r114", "r621", "r627" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash, non-current" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r227", "r230", "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r4", "r231", "r233", "r643" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring", "terseLabel": "Restructuring Charges recognized", "totalLabel": "Restructuring Charges, Total", "verboseLabel": "Restructuring" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r226", "r227", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [ "r226", "r227", "r228", "r229", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r227", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Accrued restructuring liability as of June 30, 2023", "periodStartLabel": "Accrued restructuring liability as of December 31, 2022", "totalLabel": "Restructuring Reserve, Total" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r70", "r98", "r451", "r471", "r476", "r485", "r511", "r588" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r124", "r155", "r156", "r157", "r161", "r171", "r173", "r217", "r222", "r334", "r335", "r336", "r346", "r347", "r366", "r368", "r369", "r372", "r376", "r467", "r469", "r488", "r703" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r199", "r200", "r203", "r206", "r207", "r211", "r212", "r213", "r285", "r286", "r426" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "totalLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUE:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r411", "r587" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Computation of Diluted Loss per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCapitalLeasedAsssetsTable": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Capital Leased Assets [Table]" } } }, "localname": "ScheduleOfCapitalLeasedAsssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Loan Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Loss per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Total Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r32", "r33", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Schedule of effect of error correction of prior interim unaudited financial statements" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments Under Non-Cancellable Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Estimated future principal payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r226", "r227", "r228", "r229", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r40", "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring Activity" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r299", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r10", "r11", "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Activity of Stock Options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r96", "r97", "r98", "r136", "r137", "r138", "r196", "r269", "r270", "r271", "r273", "r276", "r281", "r283", "r481", "r482", "r483", "r484", "r577", "r609", "r628" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r299", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Maximum number of common stock to be issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of common stock shares available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "SHARES, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "AGGREGATE INTRINSIC VALUE, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "SHARES, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "SHARES, Cancelled or forfeited", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "SHARES, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance", "periodStartLabel": "AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "SHARES, Outstanding, Ending Balance", "periodStartLabel": "SHARES, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Ending Balance", "periodStartLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "SHARES, Options vested or expected to vest | shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Options vested or expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "AGGREGATE INTRINSIC VALUE, Options vested or expected to vest | $" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "terseLabel": "Aggregate purchase of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "All Award Types", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Cancelled or forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "AGGREGATE INTRINSIC VALUE, Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "verboseLabel": "Number of shares issuable upon the exercise of outstanding options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Ending Balance", "periodStartLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Outstanding, Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options vested or expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "negatedLabel": "SHARES, Vested and distributed", "terseLabel": "SHARES, Vested and distributed" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE, Vested and distributed" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r408", "r587" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87", "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary Of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r123", "r136", "r137", "r138", "r153", "r180", "r181", "r188", "r190", "r196", "r197", "r216", "r245", "r247", "r248", "r249", "r252", "r253", "r269", "r270", "r273", "r276", "r283", "r389", "r481", "r482", "r483", "r484", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r510", "r531", "r549", "r560", "r561", "r562", "r563", "r564", "r609", "r628", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r24", "r124", "r142", "r143", "r144", "r155", "r156", "r157", "r161", "r171", "r173", "r195", "r217", "r222", "r284", "r334", "r335", "r336", "r346", "r347", "r366", "r367", "r368", "r369", "r370", "r372", "r376", "r393", "r394", "r395", "r396", "r397", "r398", "r415", "r467", "r468", "r469", "r488", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r155", "r156", "r157", "r195", "r426", "r480", "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r529", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r594" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r155", "r156", "r157", "r195", "r426", "r480", "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r529", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r594" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureAdjustmentToPriorInterimUnauditedFinancialStatementsScheduleOfEffectOfErrorCorrectionOfPriorInterimUnauditedFinancialStatementsD", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r8", "r67", "r68", "r98" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r67", "r68", "r98", "r481", "r549", "r561" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Initial public offering, net of underwriting discounts, commissions and net of offering costs, Shares", "verboseLabel": "Stock issued during period, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r8", "r98" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock units, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Stock issued during period shares reverse stock splits" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r67", "r68", "r98", "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "SHARES, Exercised", "terseLabel": "Exercise of common stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r8", "r67", "r68", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r8", "r24", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r68", "r71", "r72", "r88", "r512", "r528", "r550", "r551", "r588", "r601", "r630", "r638", "r684", "r703" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://finchtherapeutics.com/20230630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r95", "r152", "r268", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r284", "r373", "r552", "r553", "r565" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholderSEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r410", "r587" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r13", "r45" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary equity, par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "verboseLabel": "Temporary equity, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary equity, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "terseLabel": "Temporary equity, shares outstanding", "verboseLabel": "Convertible preferred stock outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLoanPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r226", "r227", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r409", "r587" ], "calculation": { "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r591", "r592", "r595", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Common Stock Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r179", "r190" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common stock outstanding, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r177", "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common stock outstanding, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://finchtherapeutics.com/20230630/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails", "http://finchtherapeutics.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org//840/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org//420/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//715-70/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r603": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r604": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r605": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r606": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r607": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r608": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 82 0000950170-23-041575-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-041575-xbrl.zip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�NW M1J*)4>,B:EXDM\2UJZX:\V=**YD,Q]5I1MC+V8T "5OT',IP()3!D<%&1 :[ M[>?V(F%VJC<[.09RUB,N8*$1 &<]LH8QV#WOX-EMK9BC'/5>^>9E_3CQ5Q6I M1(9F)K$/3P4Z36ADF1M1*,?XLSYVQU+KS!W#0B, SG;'RTN[?6]_;X\9BAG* M289BY<*\P+Q08^72V>TS0SG 4)R1W6B?=N$T;S>BB8ZQ9GTLCJ4&_?C:M+/A M=NYJL$X+INW$Q0]FS[JRY^T^0.[S*>M 9K):,1GKP%7JP ,W2IR8/5W*7W-G M'U?9U73VL2/72V]?NQ%G=8P[ZV/J<)=VN=W#09@ZM$8=R,G^C'7Q#&/?__U.55D( 8:R?Z_YSMM\- ME(<0&"ER4J3E69ME&:WZ^UV#YA% M-TEK'PF3D[??_E\++9L,^8WGC@]_L8=F5VWAKAI:0-J6ADU MC!I�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�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

I=7 M"/^V#^?F+X6\S.&O.14$%4RK*BP=:&[Y1C&%U_-]>YYF+,RK2@!!YMEB?%]J MBKRVP^]*=SE\3@__Q?'39 N927A!'3FMJ;^[:5)5WYSY %*)G3<1C07Q]H,; M\6@R&@V$O$LR<[I(D@>5K[UFTUT+XX-YM4>>$OVT'5:*[CYE>ZBGUX?:\43 V>*S]O M: GSPAV79 9C0T.0J_F'7Q=56@ 5;$)-K7SP%:!7+2/+U!VPZ5HY(3@4K)> ME_U*.GAN=2JCBT)DI6CY13MNNEP,=%5E-8WEV%L/)-NU6'I79ZY[=;2(7=L& M$;2OY MK&YN\P7U>4&%W$&%A(+PJ:F0?>U"JZ7G[V""_P3"K2Q!Z"63H3KK22T,*06L M@@:/Y8H;:7DMQ$%LD\?4_L(4&KC+AG[J7+D-.(#4NY-4PHR3 +3FNC@;O2?I M4Y+I_?']8:X L4D(;,1 -=P+..A5#3,K%2R<@.OY6HS@WGZ; X4A;OH&?1)T M>%*X3T5QV;FY%[J;[#_RW,5:MFBHB#O%-$MW?;7*5I2@DXSHW1B=9M#\;_C@ MTKKU7;?8)V@SCVFR8G68MEI9D6:5#NP,B-6NIVQ;P<9YH^,V?/'I& V8VZ.)KX9G-^G<#Q?HZ#);NNV& M7V]]8[M&=OB\V)QK09*]+R]5#;P&P6P*9M/>=&+3TNE7+9W>U 4)]H9,VC,K M"G680SM\E7YR%E*22V;M[-$2I"![$@U-_=1C#0U<2.B2K$/N9F+/#?I6)CU@ M<]GJ%]G2C8GV\;'M2"&M*O,/"=;&EK*/ ]?0E;H 1UX_W*7D]F[=9F/PLQ0&N_#1-9Y__[;:$C:PG61FK24!MFV*1C\'S3 ?XS%'W7)2ATW; MZ,#+AM@..?8.&87&;CCJLV8K&Z_[#T@8LK>]+XUL<B M7N(T$K$MO_AEU#Z-O\KMO..21F47'7RSI4<_.<.('V*EOG 7^U3M4]99RJI MV, =OG8GNQ0[K?/?)1?B;>+XL#V?[N%Y').I&EH*B3!%=MI&L7?33Z7/BAW/CGM\>BN[DYOND0,]2M%U, *#>[-K5OS9V\'JE?#\J?7S;#Q"::"L*1\W";+^\B* MM+5(B- [A2%HG,+SI_RR-YGP[KQ*P8$,#N2N&%%C!6'U <(H0 +E:IJ^VJE$EC8\8BO44BN1WY[=SX$L[F;M)U_ ME9O6<-#N:#.^'L1+/J;#UH@SZ;JBK9>.R1M!@%ZH:+_T-CO-)C5YTJ)LM!\F MJ*,>HF6U>_KCL5NEI+_UUAC?BV#P!X-_9W3H:#3F?C08_*"C#1X< VS;WY2L M4=2=:.$Z&?O^EC+)!ES3(@MNT["WA#P'X3W-6@.M86D0Z!X0KZFC,O7J$WHK M'O 6_K#\[Q"?0),P+0F%"SPI'5JGP)2PL?4!HNPY5F6*%*^Z$FDM;:?[YK1M ME%I^1JR)J]N$,1\<<6TN76_T*59]RJ+JMC&\SFNP',BZTH-/O+"M5RKL@I(. M,V1'YS'"YDM_-FB'U)DN\?& (6[Q9C!H,'>B@V?@>0*$ M#UE%Y]H[ S8%+&JX=P&;PVB*N#()OM[NQ@NY$NFRMV.@!%697^.X$[G.'$F& M[NUJ7(C/\/PB^IYAVO!*@/HR? MW2$5T+=! J8ZIA)XG2M;U"7"I4KVV-:RP!)Z1EV"GSQ(^8"E%EA/04MJ6BC" MOW-&H,T]Z@+]$4[8!J_]2Q9@GL %B5S E&%D)7((&/RBQ3WQ1Q1/IXL-DE(_ MAP A]4::@ &N*N^A'G>CUZ/=0,*.89\0_)3SCH)9%< FJ13ZGV NT.W X:8E M)J<4[0G_IG-SUWO09N@"T5)P^_@*W],E'R5BU."O-R#L\"/<*U&6DM?4[5JC M,C6VYI.(-68LCZ74-I)N]\5VCT[1P)R0R8GWW(*2@M7Q(%9',#$F8V+H?B7? MAWXEN\$6_/;WTW>GYQ=GQQ>G$^&=#ZS!P1'VETJEC:*05%Z"45S:"XN&14[74RT+FO3( M[4(&N?VCI,[N/D[?AZ3'R .6YM?!9@X">H>$QG@$]#[PCG[ (!&%@"8MF"DG M1*@#G._<2P!Q$1IF172$RF5J<%GF&G5 S%<#36I?!0$;X':[\]*/"&XW#@'[ MV/2!?D/J99&O&2:&N6?X[RM"1W&$UR"C-"8<#NDE17I;V8-6/VH-XGM->"4J MG$:)MLJO(RDL'JQU#?SX.?X8L^/;C68S6"],"P(<"'QM@A;' I*^:#+\SH.Y[1K1TX<+%:3;W;674=L<_Z5P]_02M% #&>'CS_ M)3__9Z&*Z'=1?))5] ]"S#DL?W/$U/GB^UD7P]"IPK68 =P!@N$E7-"4IZ;? M.\7S%]O(I3-0.8:*I%T3[Z$BZ9M*>U<_OV"J6@LJZ7CA1%9JN*2'+JDG=]>:A5"<9S,)XG;#SOC?6,B(^JJ+D>4,$7!0RD M:J)I="&+,;#88L;V420?P=R"15VDJES!)R =66X6\BK_)*.B3C7@L9"7=:I] M_Z7&H31#LUXS*U<[TJA)P#X4'&3@TL6B0)L0K;)$(NX#;*HUF*H:AP&*@%N/ M@,6U-3L9H2H"PX*M)[$20Q1;1HEL9*(D&[V$ M[_&?Q(_@7A:VKN->B;T1">8Q'N,HB.X@ND?'*_+XLINYD @WAI\7"*DO$5\. MHA9$CK& ;Y/CH7@J&(E!TGR!I!E)0?/C"QJ/U\T&$I'SK1F(0Y-LJ8JR:O)( M:(PL79341-_3NM 'O1ID+D7UL)!TWDM$X45&^QGT8,%%U8A\V@&KZMY#594; MT*Y:;D%:!FGY#:7EW@A+$$TKM5!5QWU%&?=>]RHX/SYS(4B_L:$N26'A0^D9 ME2=X=;U!Y])05;8Z569EO5[;]!()4TU+RC47L.28%TKF^F]8=?3?&VDI5^S@ MTC-S71LR;U>&F*$GZ+RK1:V9V!S1$J\SQUS-T\N93O=L=.L&R6VE_8*9=FT# M#XBK.HPX'TX=V6]=:_%.)8@+#U-G[7XNB25WT2QUZLV/4USI2I%,82(G&,]! M'01U\ 7J8'^\]+I$8=QH(^OYY1R^1)/S,#JGGYKPI?EU&[1JR=Q^1[XU)3"N M> HR516V+@X?MX!SJ\.M[.F[<*>) ,#JI-Y8%!G3'*(DJIF-3K[C+TS_0U0$ MNI">TFOT:[B75QBK^3;!')%=O* MPRR:/K^'V."OP!0U."'+2[G4EB:-92U=ESJ=Z[$_7&RQHX9!"?TFK@^C$Y:. M?H6 6.17TI9 #XE8!ZFP5BI%%==F#^&MGCS- &Q#O/"+B] M1DO-4-9[O'.]K9.-9&/*&S8*]5WI/DMQE1<&9MZF9:60*:SAEWA[* M(]DC.ADPF]52P04TIK(!=K*\^#AF[T)M85LN5V=/-\WI%BN@HQ<:,'7O:,5R M%S:K$(+Y&C1,T# [HF'V0\'\(C-9H.PB_NTF$_B&:WNU'M'-_K1,BXFUZ^8H M1@,R"G)WG>NH\ *D'0-Q2>RU^.,:?4Y0QC(S]C)%LCH;J^TOI;58U'*R8N]! MM[]7[#U"9580CY,3CWOCVXLDWU1:(B+K8()4CKKU[>()3#$8OOH< M5?!R5NUV'*Y,=!Z=K#=IOB6NE[<*2PGRHF02F*RLT\JT[M;"-GOR\?#\,.*, MG$CIEY+OD%"7*[+X88@?,W(+SBNBGSFP5C4);M8(S:BT-I;="E%]!"(ZR'@& M!R+!20E+J>F+])XJ!E)7, 4F_/16E/HP*2I=M((\%T=^Q"*5L.9 XH]%^J3_F!F8T!>VT)&[:$L/3\^8RX( M&C$*TC1MX.X&+[/%Q,Q@K?G$J'^AXM8"!:8&J:7/\2P2H VN?;C@W+)^DVI! M)!LM"'Q^_M$!J=\3;$Y_TPIZD;+0D,,_:E5MHPU]W*(HCK&.Q&+M!)-&B A4 M$)$75+>2.,#J_S1CZ!],^J]P]<&;F0;T(3\"1<$:#0^B U$.]4B:O<;G(Z6& M@P7J%A&&>($4/:9@L?$%-G2 @P/CY^E?&B^.8.P;^ET<8U$X_@9^F\78V7VZ M3E%@<@O*[1&9W.)QJ+9'97)[RV22NIN.Y8@,[(_!(-ZA@W@DYO"CR@P= M/9X@ZR-6SQEZW:C,M8&(W2MT7N[+"'JTCXU:=W(T0#Q?2TOY;RO M=>3-8YP[+DO=**3*";.WR',_/QF#]I M=2CXC>&K]GQUCW8[[IEU^7R\IFY4#FZ$[J!2SG5BPY)WW)K9F'N=5BDB*7L< MSL:N'48GR!'GQHI7PTX+'674ZU-MN7MYQFW=*W0B>FBH[? &Y^YXZQ0>%O\D M$P^*?1RNJ$FHTYO6<*6Q$] 5)XAXV=P#>]Y#O?D>KL ^];#U.G_=U+F0RIW& MFP?N#M%]QQP@UM<<@B1E>*YMH*.7!XN9D;Y=D3DZ5S.3K2 M]UZXL#U*F!_&"_NFJ*.PQFPA3 4OBV4Q(ZK'@I-N6TLA8?"!W;EJ$.+-DUU+ M2?%&;>Q098F%"WI[V\P!FB;G>AN)DW>-BMKN4%"*(6JY.W)Z/%'+?>A\?J+[ MF>K^$PZX^U;&Y$1-1C\>@R0V^D!H)]*266K8!$I^S7;)?7'!24ED5V@W?!D0 MM9=YCJ@4]'-\L(:7O41?!0:L<9KFURB+#]0,[EK""XFWM8! #_97>7?/N8 \5AM% MMCO<[OW&J9?SX[.28JCSEE7OVFIT:LGG&M+0[ E2(MKA?K=Q7HKFT-.E,(IF M:'JD5'=IPL'S]#0<^2$= "5_;-=LN!Z?@3@VP$M-/N#)Y(#I<.W-:E@2@51L M':C$O0>D8QGVR;>H4WV!K7![G+XA?8HR:,D'D&QC MZ1O2HS='H30?6:TX8/0Z+ROJ:\0)#1.Y,56B;2G4RM_I&D77AJ1=I^D+.;ZY MB1]Y$LOJI\/H78O:%*1>1?$GAXFL"@P&H417V3S*I-(<>V:4V:V*TID)I-4P MOL=<>CKDIL<>"]@?U)J$9+274$H0!9M(RYP1=B8.-^M1MPU%T^FV-,V^*<$) M&W#"@L*'P^\>4.7]]S>:Q0/+X7]. M83-.+W[]]?UO;T_?_7(O\O"AN-7>ZY40W)NRJND+[HD]".[]$TQ[9,!"T_Q8 MX_.X+]94HGO'Z#W WXFR(4PJR3&=95TI:[-RJ<5 X]"+)>'/S*(1RF$CMD6> MIA2E\0J&J MDB=\:#IXV/PR'RYQO)]!I+&U'+Y'(/VJJ2C801/(:#RRF32:^VAB9@BBT+MBH:@V@B:O)#JH M>7VY\L 7X,7B8##6: KKS%3+E3!=Z;/<6Q.\/?8Q'B20;Y JN1HZ\OGQ(5@R MEO)4_97&,#%OLKHO2#%XCD'#!PU/&GZQ!QK^G*2$L/7(OL9_;R7*9-3]Q7#R MJD6YUR6X\P4Z@;5KSFIYX]S0*-Q$<1PRQ12AXEM MYT)V#WXVQ%,X8"#06M"H6L.B4=,@[(JQW4 1<_P6K[IJ7F1:=.OKMM9X\^+N MSHQK#1'N![?#53=;(=IKRA0%9,N)B$%1\6L<"REZ8X#P%S"K35W @O"E JV_ MRT*LHP3,DC3?./"I[6X;76A:\'6=Y;A< M*'M^5YE:PQ.C"_$9@1SPT]^4X(PU5;RG0JT]:.*.6R:N>\-PCX>F"8(E>^!, M)G5%Z]5T*MMT-?@1-JG05)&&U=Q"_:D:$:%+W&4FD(EB%2Z0[TR&7+D40G#;R MO'K;6I/K#>\T_+4YB[148*,1,= ?-5>D^@/2R^EFY-;.P6_U2%)E# 8:@%L$ M77F89*LPD_)W1U1C:\#>!%B'Y(^7;(Z==LB-UWJ-SQQ9O@ =5( MBP3A@R55).$4*(Y%O[G*4[!*85VH1C5.J1*)$8=E#D<@X//WQ.,HSQ'*T2*Y:[%8$_JA@=02<&HQGIN8E,G;P M$B$;:X9L(%>3LX/[>BEJF%J"MC1\K[%O?51.IXC&S\CPO9)9+6'LQ16.R!9D MX=@P7D>KKM;D+FI9DV!%.EK-\(SF^2K)>Z->9@UGI+W^XN87\BZ+W[>)_'+^ M"6^F-O=Q[2J'J22/8GAE2]""E?^ZM;C/>@X'N4#$1O_PAP+YSNB5J^B-:9^0 M&R<3')O@V.R0L3T>QV8?ZMS\,.HI+/HZLVRYDW%9OLBB[-<:'$YK)0A=<:". MGZ**L@K(?3L0'.VQACTC$4V[2^)H+)QRT<,0&(I#=D:ZLTRM/O H[SOC*8>5 M,:Q, ,?OU L

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end

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ᖌ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